PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
16151054-4	2005	Further studies with JAK inhibitors and STAT6 signaling showed active signaling of the JAK/STAT6 pathway in these primary TBE cultures by IL-13 in the regulation of hCLCA1 expression.	tbe	122-125	interleukin 13	Mus musculus	138-143
16210602-7	2005	We found that morphine significantly promoted IL-4 and IL-13 production but did not alter IL-5 or IFN-gamma.	Morphine	14-22	interleukin 13	Mus musculus	55-60
16332195-3	2005	All of the selected anti- IL-4- and anti-IL-13-specific hybridoma clones (eight and 10, respectively) required the presence of TSS (0.5-2.5%) for their cloning, stable growth in large-scale cultures, and production of monoclonal antibodies (MAbs).	tss	127-130	interleukin 13	Mus musculus	41-46
16210602-9	2005	Additionally, blockade of Fas/FasL interaction by anti-FasL inhibited the morphine-induced production of IL-4 and IL-13 and AICD of CD4(+) T cells.	Morphine	74-82	interleukin 13	Mus musculus	114-119
16148160-4	2005	Interestingly, in the absence of CFA, RTL401 treatment strongly enhanced production of the Th2 cytokine, IL-13, in spleen, blood, and spinal cord tissue, with variable effects on other Th1 and Th2 cytokines, and no significant effect on the Th3 cytokine, TGF-beta1, or on FoxP3 that is expressed by regulatory T cells.	rtl401	38-44	interleukin 13	Mus musculus	105-110
15699166-8	2005	They also demonstrate that IL-13 is a potent stimulator of inflammation, fibrosis, hyaluronic acid accumulation, myofibroblast accumulation, alveolar remodeling, mucus metaplasia, and respiratory failure and death in mice with wild-type IL-11Ralpha loci and that these alterations are ameliorated in the absence of IL-11Ralpha.	Hyaluronic Acid	83-98	interleukin 13	Mus musculus	27-32
15927844-0	2005	Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia.	Hydroxyurea	24-35	interleukin 13	Mus musculus	52-66
15927844-0	2005	Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia.	zileuton	40-48	interleukin 13	Mus musculus	52-66
15927844-4	2005	OBJECTIVE: To determine whether hydroxyurea and zileuton, a hydroxyurea derivative with antiinflammatory properties, affect IL-13 secretion.	Hydroxyurea	32-43	interleukin 13	Mus musculus	124-129
15927844-4	2005	OBJECTIVE: To determine whether hydroxyurea and zileuton, a hydroxyurea derivative with antiinflammatory properties, affect IL-13 secretion.	zileuton	48-56	interleukin 13	Mus musculus	124-129
15608148-8	2005	Together, these data indicate that the increased expression of IL-10 significantly contributed to silica-induced lung fibrosis by exacerbating the Th2 response and the production of the profibrotic cytokines IL-4 and IL-13.	Silicon Dioxide	98-104	interleukin 13	Mus musculus	217-222
15563687-7	2005	IL-13 induced calcium transients in cultured murine ASM cells and augmented the calcium and contractile responses of these cells to leukotriene D4.	Calcium	14-21	interleukin 13	Mus musculus	0-5
15563687-7	2005	IL-13 induced calcium transients in cultured murine ASM cells and augmented the calcium and contractile responses of these cells to leukotriene D4.	Calcium	80-87	interleukin 13	Mus musculus	0-5
15563687-7	2005	IL-13 induced calcium transients in cultured murine ASM cells and augmented the calcium and contractile responses of these cells to leukotriene D4.	Leukotriene D4	132-146	interleukin 13	Mus musculus	0-5
15576672-8	2005	Also, at the site of local allergen stimulation, the draining thoracic lymph nodes, allergen-induced lymphocyte proliferation, and IL-13 secretion were decreased by administration of LpA and Ppg.	Lipid A	183-186	interleukin 13	Mus musculus	131-136
15784120-5	2005	RESULTS: Budesonide administration reduced airway hyper-reactivity and leukocyte infiltration in association with a decrease in production of the Th2 mediators, IL-4, IL-13 and eotaxin-1.	Budesonide	9-19	interleukin 13	Mus musculus	167-172
15683846-4	2005	Intratracheal administration of LY294002 significantly inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-5, IL-13, and eotaxin levels in bronchoalveolar lavage fluid.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	32-40	interleukin 13	Mus musculus	138-143
16012943-7	2005	Exposure of muscle cells to IL-4 or IL-13 increased TGF-beta1 ( P < .01), COX-2 protein, and prostaglandin (PG)E 2 .	Prostaglandins E	96-115	interleukin 13	Mus musculus	36-41
16012943-9	2005	Incubation of tissue with IL-4, IL-13, TGF-beta1, or PGE 2 enhanced carbachol-induced muscle cell contractility ( P < .05).	Carbachol	68-77	interleukin 13	Mus musculus	32-37
15927844-8	2005	In lymphocytes activated by concanavalin A, hydroxyurea and zileuton reduce IL-13 secretion by 24-36% and 50-87%, respectively (p<0.05).	Hydroxyurea	44-55	interleukin 13	Mus musculus	76-81
15927844-8	2005	In lymphocytes activated by concanavalin A, hydroxyurea and zileuton reduce IL-13 secretion by 24-36% and 50-87%, respectively (p<0.05).	zileuton	60-68	interleukin 13	Mus musculus	76-81
15778342-6	2005	In addition, ATP stimulation enhanced the expression of several proinflammatory cytokines, such as IL-4, IL-6, IL-13, and TNF-alpha.	Adenosine Triphosphate	13-16	interleukin 13	Mus musculus	111-116
15650316-9	2005	In DS-Nh mice, IFN-gamma and IL-13 production of splenocytes increased in the mice treated with TNCB.	Picryl Chloride	96-100	interleukin 13	Mus musculus	29-34
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Glutamic Acid	65-78	interleukin 13	Mus musculus	32-37
15585312-4	2005	Injection of soluble NES induces a residual type-2 response (IL-13) even in IL-4-deficient mice, and drives a fully polar Th2 response in IL-5-deficient animals.	TES	21-24	interleukin 13	Mus musculus	61-66
15374841-4	2005	In particular, the treatment of the mice with imatinib significantly attenuated airway hyperreactivity and peribronchial eosinophil accumulation, and significantly reduced Th2 cytokines, interleukin-4 and interleukin-13.	Imatinib Mesylate	46-54	interleukin 13	Mus musculus	205-219
15564778-0	2004	Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.	Bleomycin	69-78	interleukin 13	Mus musculus	16-30
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 13	Mus musculus	42-47
15564778-10	2004	In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure.	Bleomycin	135-144	interleukin 13	Mus musculus	17-22
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	66-71
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	155-160
15242841-6	2004	Compared with the saline control, brief allergen challenge resulted in airway hyperresponsiveness, which was prevented by anti-IL-13 treatment.	Sodium Chloride	18-24	interleukin 13	Mus musculus	127-132
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Glutamic Acid	65-78	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Glutamic Acid	65-78	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Glutamic Acid	65-78	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Glutamic Acid	65-78	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Lysine	145-151	interleukin 13	Mus musculus	32-37
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Lysine	145-151	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Lysine	145-151	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Lysine	145-151	interleukin 13	Mus musculus	45-50
15448012-2	2004	In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13.	Lysine	145-151	interleukin 13	Mus musculus	45-50
14597600-3	2003	In murine tracheal rings, IL-13 (100 ng ml-1, 24 h) significantly increased both the carbachol- and KCl-induced maximal force generation without affecting ASM sensitivity.	Carbachol	85-94	interleukin 13	Mus musculus	26-31
15450130-3	2004	We tested whether the innate stimuli peptidoglycan (Ppg, TLR2 agonist) and lipid A (LpA, TLR4 agonist) differentially affect the secretion of interleukin-13 (IL-13) (Th2) and interferon-gamma (IFN-gamma) (Th1).	Lipid A	75-82	interleukin 13	Mus musculus	142-156
15450130-3	2004	We tested whether the innate stimuli peptidoglycan (Ppg, TLR2 agonist) and lipid A (LpA, TLR4 agonist) differentially affect the secretion of interleukin-13 (IL-13) (Th2) and interferon-gamma (IFN-gamma) (Th1).	Lipid A	75-82	interleukin 13	Mus musculus	158-163
15034018-0	2004	Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts.	Fluorescein-5-isothiocyanate	16-42	interleukin 13	Mus musculus	63-68
15034018-2	2004	In response to FITC, BALB/c mice produce IL-4 and IL-13 in the lung.	Fluorescein-5-isothiocyanate	15-19	interleukin 13	Mus musculus	50-55
15791845-8	2004	Dexamethasone can suppress IL-13-induced eosinophilic infiltration in lung but can not inhibit the mucus overproduction.	Dexamethasone	0-13	interleukin 13	Mus musculus	27-32
15297022-13	2004	As above, ELISA and RNAse protection assays showed that IgE, IL-4, and IL-13 proteins, and IL-4 and IL-13 mRNAs in the phthalate-treated animals were all at levels similar to that of control values.	phthalic acid	119-128	interleukin 13	Mus musculus	100-105
15297022-15	2004	Another control, dinitrochlorobenzene (DNCB), a contact sensitizer, also responded as expected, producing smaller but statistically significant increases in IgE and in mRNA for IL-4 and IL-13 but not in the levels of these cytokines.	Dinitrochlorobenzene	17-37	interleukin 13	Mus musculus	186-191
15297022-15	2004	Another control, dinitrochlorobenzene (DNCB), a contact sensitizer, also responded as expected, producing smaller but statistically significant increases in IgE and in mRNA for IL-4 and IL-13 but not in the levels of these cytokines.	Dinitrochlorobenzene	39-43	interleukin 13	Mus musculus	186-191
15153527-5	2004	Intraperitoneal administration of U0126, a specific MAPK/ERK kinase inhibitor, significantly (p < 0.05) inhibited OVA-induced increases in total cell counts, eosinophil counts, and IL-4, IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	U 0126	34-39	interleukin 13	Mus musculus	196-201
15056815-7	2004	Cytokine mRNA levels in the nasal airway of TMA treated mice also revealed an increase in the mRNA levels of the Th2 cytokines IL-4, IL-5, and IL-13, but no change in the level of the Th1 cytokine IFN-gamma.	trimellitic anhydride	44-47	interleukin 13	Mus musculus	143-148
15135806-3	2004	In this study we show that mast cells stimulated by IL-9 and ionomycin or IL-9 and antigen-specific IgE/antigen express several cytokines at mRNA level, among them are IL-5, IL-4, IL-10, IL-9, IL-13, IL-1beta, IL-1Ra, IL-6 and MIF.	Ionomycin	61-70	interleukin 13	Mus musculus	193-198
15124858-6	2004	Ubi-L also showed inhibitory activity on IL-5 and IL-13 production by D10 cells stimulated with phorbol ester plus dibutyryl cAMP.	ubi-l	0-5	interleukin 13	Mus musculus	50-55
15124858-6	2004	Ubi-L also showed inhibitory activity on IL-5 and IL-13 production by D10 cells stimulated with phorbol ester plus dibutyryl cAMP.	Phorbol Esters	96-109	interleukin 13	Mus musculus	50-55
14597600-3	2003	In murine tracheal rings, IL-13 (100 ng ml-1, 24 h) significantly increased both the carbachol- and KCl-induced maximal force generation without affecting ASM sensitivity.	Potassium Chloride	100-103	interleukin 13	Mus musculus	26-31
12794006-7	2003	AG-1478 inhibited BHR, inflammation, and lung remodeling induced by Ova or by molecules themselves generated by Ova, such as LT, IL-13, and monocyte chemoattractant protein-1, which promote identical effects, suggesting the involvement of the EGFR pathway in the asthma-like syndrome observed.	RTKI cpd	0-7	interleukin 13	Mus musculus	129-134
14568929-4	2003	The addition of arginase inhibitors (in the pretreatment phase) or of arginine (in the stimulation phase) completely blocked the down-regulation of iNOS protein by IL-13.	Arginine	70-78	interleukin 13	Mus musculus	164-169
13679819-9	2003	RESULTS: Early treatment with vitamin D augmented allergen-induced T-cell proliferation along with T(H)2 cytokine (IL-4 and IL-13) and IgE production.	Vitamin D	30-39	interleukin 13	Mus musculus	124-129
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 13	Mus musculus	6-11
12743570-12	2003	Both dexa-methasone and anti-IL-5/anti-eotaxin inhibited the increases in lung IL-13 levels after ovalbumin challenge to a similar extent.	Dexamethasone	5-19	interleukin 13	Mus musculus	79-84
12897202-0	2003	Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway.	Adenosine	0-9	interleukin 13	Mus musculus	19-24
12897202-0	2003	Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway.	Adenosine	0-9	interleukin 13	Mus musculus	93-98
12897202-0	2003	Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway.	Adenosine	99-108	interleukin 13	Mus musculus	93-98
12897202-2	2003	We hypothesized that adenosine accumulation, alterations in adenosine receptors, and adenosine-IL-13 autoinduction are critical events in IL-13-induced pathologies.	Adenosine	21-30	interleukin 13	Mus musculus	138-143
12897202-2	2003	We hypothesized that adenosine accumulation, alterations in adenosine receptors, and adenosine-IL-13 autoinduction are critical events in IL-13-induced pathologies.	Adenosine	60-69	interleukin 13	Mus musculus	138-143
12897202-3	2003	To test this, we characterized the effects of IL-13 overexpression on the levels of adenosine, adenosine deaminase (ADA) activity, and adenosine receptors in the murine lung.	Adenosine	84-93	interleukin 13	Mus musculus	46-51
12897202-4	2003	We also determined whether adenosine induced IL-13 in lungs from ADA-null mice.	Adenosine	27-36	interleukin 13	Mus musculus	45-50
12897202-6	2003	During this response, IL-13 caused a progressive increase in adenosine accumulation, inhibited ADA activity and mRNA accumulation, and augmented the expression of the A1, A2B, and A3 but not the A2A adenosine receptors.	Adenosine	61-70	interleukin 13	Mus musculus	22-27
12897202-7	2003	ADA enzyme therapy diminished the IL-13-induced increase in adenosine, inhibited IL-13-induced inflammation, chemokine elaboration, fibrosis, and alveolar destruction, and prolonged the survival of IL-13-transgenic animals.	Adenosine	60-69	interleukin 13	Mus musculus	34-39
12897202-8	2003	In addition, IL-13 was strongly induced by adenosine in ADA-null mice.	Adenosine	43-52	interleukin 13	Mus musculus	13-18
12897202-9	2003	These findings demonstrate that adenosine and adenosine signaling contribute to and influence the severity of IL-13-induced tissue responses.	Adenosine	32-41	interleukin 13	Mus musculus	110-115
12897202-9	2003	These findings demonstrate that adenosine and adenosine signaling contribute to and influence the severity of IL-13-induced tissue responses.	Adenosine	46-55	interleukin 13	Mus musculus	110-115
12897202-10	2003	They also demonstrate that IL-13 and adenosine stimulate one another in an amplification pathway that may contribute to the nature, severity, progression, and/or chronicity of IL-13 and/or Th2-mediated disorders.	Adenosine	37-46	interleukin 13	Mus musculus	176-181
12789240-9	2003	Moreover, goblet cell metaplasia and airway responsiveness to methacholine could be reduced significantly by the IL-4/IL-13 inhibitor.	Methacholine Chloride	62-74	interleukin 13	Mus musculus	118-123
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	148-157	interleukin 13	Mus musculus	36-41
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	148-157	interleukin 13	Mus musculus	73-77
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	251-260	interleukin 13	Mus musculus	36-41
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	251-260	interleukin 13	Mus musculus	73-77
12928422-6	2003	The intranasal IL13-PE therapy significantly reduced the numbers of IL-4 and IL-13 receptor-positive mononuclear cells and macrophages and the levels of profibrotic cytokine and chemokine in the lungs of bleomycin-challenged mice on day 28.	Bleomycin	204-213	interleukin 13	Mus musculus	15-19
12928422-7	2003	Thus, this study demonstrates that IL-4- and/or IL-13-binding cells are required for the maintenance of pulmonary fibrosis induced by bleomycin and highlights the importance of further investigation of antifibrotic therapeutics that target these cells during pulmonary fibrosis.	Bleomycin	134-143	interleukin 13	Mus musculus	48-53
12847266-8	2003	IL-13, H. polygyrus, and N. brasiliensis, but not IL-4, also increased contractility to acetylcholine by mechanisms that involved Stat6 and enteric nerves.	Acetylcholine	88-101	interleukin 13	Mus musculus	0-5
12813015-1	2003	Microarray analysis of the expression profiles of lung tissue in two murine models of asthma revealed high levels of arginase I and arginase II activity, in association with IL-4 and IL-13 overexpression, suggesting that arginine pathways are critical in the pathogenesis of asthma.	Arginine	221-229	interleukin 13	Mus musculus	183-188
12502476-10	2003	Control of steroid-resistant features induced by IL-13, including AHR and mucus production, may provide new therapeutic modalities for asthma.	Steroids	11-18	interleukin 13	Mus musculus	49-54
12654629-0	2003	Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13.	Leukotrienes	0-12	interleukin 13	Mus musculus	155-169
12654629-4	2003	After the intratracheal instillation of recombinant murine (rm) IL-13, Cys-LT increased in the bronchoalveolar lavage fluid (BALF) at 15 min, followed by lower amounts at 3-6 h. Zileuton inhibited LT production in the BALF, eosinophil and neutrophil sequestration in the lungs, and their passage into the BALF.	Cysteine	71-74	interleukin 13	Mus musculus	64-69
12654629-4	2003	After the intratracheal instillation of recombinant murine (rm) IL-13, Cys-LT increased in the bronchoalveolar lavage fluid (BALF) at 15 min, followed by lower amounts at 3-6 h. Zileuton inhibited LT production in the BALF, eosinophil and neutrophil sequestration in the lungs, and their passage into the BALF.	zileuton	178-186	interleukin 13	Mus musculus	64-69
12654629-6	2003	Airways mucus after recombinant murine IL-13-challenge was reduced by zileuton and by LY171883, MK-571, and PH-163.	zileuton	70-78	interleukin 13	Mus musculus	39-44
12654629-6	2003	Airways mucus after recombinant murine IL-13-challenge was reduced by zileuton and by LY171883, MK-571, and PH-163.	LY 171883	86-94	interleukin 13	Mus musculus	39-44
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Cannabinol	0-10	interleukin 13	Mus musculus	234-239
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	interleukin 13	Mus musculus	234-239
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	interleukin 13	Mus musculus	234-239
12626588-10	2003	Reduced IL-5 and IL-13, and increased IFN-gamma levels were observed only in splenocytes cultures from mAra h 1-3 plus HKLM-treated mice.	hklm	119-123	interleukin 13	Mus musculus	17-22
12628967-5	2003	Last, it was demonstrated that IL-13 induces adenosine accumulation and that adenosine in turn stimulates IL-13 elaboration.	Adenosine	45-54	interleukin 13	Mus musculus	31-36
12628967-5	2003	Last, it was demonstrated that IL-13 induces adenosine accumulation and that adenosine in turn stimulates IL-13 elaboration.	Adenosine	77-86	interleukin 13	Mus musculus	106-111
12594274-9	2003	Generation of contact hypersensitivity to dinitrofluorobenzene, which involves Th1 and CD8(+) effector cells, was also intact in IL-13(-/-) mice.	Dinitrofluorobenzene	42-62	interleukin 13	Mus musculus	129-134
12388339-4	2003	Instilled intratracheally, these chemokines induced BHR and mucus accumulation, which were inhibited by the 5-lipoxygenase inhibitor zileuton and by the cysteinyl-LT receptor antagonist MK-571, suggesting mediation by cysteinyl-LT. Because these chemokines also induced release of LT into the bronchoalveolar lavage fluid and IL-13 into the lungs, we hypothesize that LT- and chemokine-based loops for positive-feedback regulations cooperate to maintain and amplify BHR and lung mucus accumulation after allergic challenge and in situations where IL-13, LT, or chemokines are generated.	zileuton	133-141	interleukin 13	Mus musculus	326-331
12388339-4	2003	Instilled intratracheally, these chemokines induced BHR and mucus accumulation, which were inhibited by the 5-lipoxygenase inhibitor zileuton and by the cysteinyl-LT receptor antagonist MK-571, suggesting mediation by cysteinyl-LT. Because these chemokines also induced release of LT into the bronchoalveolar lavage fluid and IL-13 into the lungs, we hypothesize that LT- and chemokine-based loops for positive-feedback regulations cooperate to maintain and amplify BHR and lung mucus accumulation after allergic challenge and in situations where IL-13, LT, or chemokines are generated.	zileuton	133-141	interleukin 13	Mus musculus	547-552
12540780-9	2003	These observations were associated with increased liver endothelial cell injury in IL-13(-/-) mice, as measured by serum levels of hyaluronic acid.	Hyaluronic Acid	131-146	interleukin 13	Mus musculus	83-88
12540780-10	2003	In vitro, IL-13 protected hepatocytes from H(2)O(2)-induced cytotoxicity.	Hydrogen Peroxide	43-51	interleukin 13	Mus musculus	10-15
12034862-6	2002	In vivo, small U373 MG glioblastoma xenografts in nude mice completely regressed in most animals after five intratumoral injections of 1 microg of DT(390)IL13 q.o.d., but not by the control fusion protein DT(390)IL-2.	Thymidine	147-149	interleukin 13	Mus musculus	154-158
12444164-5	2002	Other profibrotic molecules, such as platelet-derived growth factor, monocyte chemotactic protein-1, and IL-13, were also reduced in thyroids of anti-TGFbeta1- and lisinopril-treated mice compared with those of controls.	Lisinopril	164-174	interleukin 13	Mus musculus	105-110
12433369-0	2002	Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.	Oxazolone	0-9	interleukin 13	Mus musculus	85-90
12433369-4	2002	Finally, we show that NK-T cells are the source of the IL-13, since they produce IL-13 upon stimulation by alpha-galactosylceramide, an NK-T cell-specific antigen.	alpha-galactosylceramide	107-131	interleukin 13	Mus musculus	55-60
12433369-4	2002	Finally, we show that NK-T cells are the source of the IL-13, since they produce IL-13 upon stimulation by alpha-galactosylceramide, an NK-T cell-specific antigen.	alpha-galactosylceramide	107-131	interleukin 13	Mus musculus	81-86
12424743-4	2002	In vitro expression of interleukin 4 (IL-4) and IL-13 mRNA by overnight concanavalin A (ConA)-stimulated draining lymph node cells was enhanced following in vivo treatment with TMA but not with DNCB in the B6C3F1, C57BL/6 and BDF1 mice.	trimellitic anhydride	177-180	interleukin 13	Mus musculus	48-53
12424743-5	2002	In contrast, TMA and DNCB induced similar levels of IL-4 and IL-13 mRNA in the BALB/C mice.	trimellitic anhydride	13-16	interleukin 13	Mus musculus	61-66
12424743-5	2002	In contrast, TMA and DNCB induced similar levels of IL-4 and IL-13 mRNA in the BALB/C mice.	Dinitrochlorobenzene	21-25	interleukin 13	Mus musculus	61-66
12161283-2	2002	We show that formaldehyde induced the long-lasting expression of IL-4 and IFN-gamma mRNAs and the transient expression of IL-13 mRNA in mouse spleen and draining lymph nodes.	Formaldehyde	13-25	interleukin 13	Mus musculus	122-127
12065288-7	2002	17beta-Estradiol also decreased the expression of ICAM-1, IFN-gamma, and IL-13 mRNA levels compared with placebo.	Estradiol	0-16	interleukin 13	Mus musculus	73-78
12003965-0	2002	A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-gamma- and interleukin-13-treated murine peritoneal macrophages.	Amphotericin B	34-48	interleukin 13	Mus musculus	106-120
12003965-9	2002	Amphotericin B associated with IL-13 or IFN-gamma, but not with IL-4, enhanced the yeast growth inhibition activity of macrophages.	Amphotericin B	0-14	interleukin 13	Mus musculus	31-36
12486335-2	2002	The number of HO-1 positive cells was increased in the subepithelium of the bronchi after OVA challenge and HO-1 was localized to alveolar macrophage.Zinc-protoporphyrin (Zn-PP), a competitive inhibitor of hemeoxygenase, by intraperitoneal injection clearly inhibited AHR, pulmonary eosinophilia and IL-5 and IL-13 in the lung tissue.	zinc protoporphyrin	150-169	interleukin 13	Mus musculus	309-314
12370375-3	2002	Binding of IL-4 by either the type 1 or 2 IL-4R, or of IL-13 by the type 2 IL-4R, initiates Jak-dependent tyrosine phosphorylation of the IL-4Ralpha-chain and the transcription factor, STAT6.	Tyrosine	106-114	interleukin 13	Mus musculus	55-60
12370375-7	2002	IL-4C and IL-13 increased mucosal permeability, decreased glucose absorption, and decreased chloride secretion in response to 5-hydroxytryptamine.	Chlorides	92-100	interleukin 13	Mus musculus	10-15
12370375-7	2002	IL-4C and IL-13 increased mucosal permeability, decreased glucose absorption, and decreased chloride secretion in response to 5-hydroxytryptamine.	Serotonin	126-145	interleukin 13	Mus musculus	10-15
12370375-9	2002	Responses to PGE(2) and histamine, which were dependent on mast cells and STAT6, were enhanced by IL-4C, but not by IL-13.	Histamine	24-33	interleukin 13	Mus musculus	116-121
12060560-8	2002	These results indicate that IL-13 is a potent stimulator of surfactant phospholipid and surfactant accumulation in the lung.	Phospholipids	71-83	interleukin 13	Mus musculus	28-33
12003965-10	2002	The ROIs were involved in the additive effect of IFN-gamma with amphotericin B, whereas another mechanism was implicated in the increase of candidastatic activity of macrophages treated with IL-13 in association with amphotericin B.	Amphotericin B	217-231	interleukin 13	Mus musculus	191-196
11956061-4	2002	Ovalbumin-sensitized mice treated with either selective COX-1 inhibitor SC58560 (OVA-COX-1 inhibitor) or selective COX-2 inhibitor SC58236 (OVA-COX-2 inhibitor) had significantly greater airway hyperresponsiveness (p < 0.05) and higher levels of IL-13 (p < 0.05) in lung supernatants than did untreated mice that were ovalbumin sensitized (OVA).	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide	131-138	interleukin 13	Mus musculus	249-254
11884467-5	2002	The ability of IL-13 to increase lung size, alveolar size, and lung compliance, to stimulate pulmonary inflammation, hyaluronic acid accumulation, and tissue fibrosis, and to cause respiratory failure and death were markedly decreased, whereas mucus metaplasia was not altered in CCR2(-/-) mice.	Hyaluronic Acid	117-132	interleukin 13	Mus musculus	15-20
11906244-6	2002	The Th2 cytokines IL4, IL10, and IL13 were significantly increased in response to TMA compared to DNCB, with optimal detection occurring 14 days following initial exposure.	trimellitic anhydride	82-85	interleukin 13	Mus musculus	33-37
11906244-6	2002	The Th2 cytokines IL4, IL10, and IL13 were significantly increased in response to TMA compared to DNCB, with optimal detection occurring 14 days following initial exposure.	Dinitrochlorobenzene	98-102	interleukin 13	Mus musculus	33-37
11804843-7	2002	Incubation of longitudinal muscle-myenteric plexus (LMMP) with IL-4 and IL-13 enhanced Carbachol-induced muscle contraction (R(max) 35.5 +/- 1.9 and 32.4 +/- 2.9%, respectively).	Carbachol	87-96	interleukin 13	Mus musculus	72-77
11826401-4	2002	After APAP treatment, a significant increase was observed in serum levels of interleukin (IL)-4, IL-10, and IL-13, cytokines that regulate inflammatory mediator production and cell-mediated autoimmunity.	Acetaminophen	6-10	interleukin 13	Mus musculus	108-113
11734470-7	2001	IL-13 caused mucous metaplasia, enhanced mucin gene expression, enhanced tissue hyaluronic acid accumulation, and subepithelial fibrosis.	Hyaluronic Acid	80-95	interleukin 13	Mus musculus	0-5
11745342-7	2001	At week 12 post infection, LmAg-stimulated spleen cells from L. mexicana-infected IL-4/IL-13(-/-) produced significantly higher levels of IL-12 and IFN-gamma as compared to those from similarly infected wild-type and IL-13(-/-) mice.	lmag	27-31	interleukin 13	Mus musculus	87-92
11745342-7	2001	At week 12 post infection, LmAg-stimulated spleen cells from L. mexicana-infected IL-4/IL-13(-/-) produced significantly higher levels of IL-12 and IFN-gamma as compared to those from similarly infected wild-type and IL-13(-/-) mice.	lmag	27-31	interleukin 13	Mus musculus	217-222
11606024-0	2001	Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells.	Histamine	34-43	interleukin 13	Mus musculus	14-19
11591766-5	2001	The cell type specificity of the minimal IL-13 promoter is mediated by a functionally critical GATA-3 site that binds endogenous GATA-3 proteins, whereas the induction by PMA/ionomycin is mediated by distinct cis-acting elements.	Tetradecanoylphorbol Acetate	171-174	interleukin 13	Mus musculus	41-46
11606024-3	2001	This study was designed to investigate the mechanisms of regulation of IL-13 by histamine in Th2 cells.	Histamine	80-89	interleukin 13	Mus musculus	71-76
11606024-11	2001	We found that histamine dose-dependently enhanced IL-13 secretion and mRNA levels in Th2 cells via H1 and H2 receptors.	Histamine	14-23	interleukin 13	Mus musculus	50-55
11606024-12	2001	Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13.	Tyrphostins	45-55	interleukin 13	Mus musculus	115-120
11606024-12	2001	Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13.	Histamine	66-75	interleukin 13	Mus musculus	115-120
11606024-13	2001	Likewise, pretreatment of Th2 cells with IL-12 also reversed histamine"s effects on IL-13 secretion from stimulatory to inhibitory.	Histamine	61-70	interleukin 13	Mus musculus	84-89
11606024-14	2001	These observations suggest a role for PKA and the Jak-STAT pathway in histamine-mediated elevation of IL-13 secretion and transcription.	Histamine	70-79	interleukin 13	Mus musculus	102-107
11489954-4	2001	In vivo treatment of T. muris-infected IFN-gamma-deficient mice with rIL-18 demonstrated that the inhibitory effect of IL-18 on IL-13 secretion is independent of IFN-gamma.	ril-18	69-75	interleukin 13	Mus musculus	128-133
11090103-13	2000	injections of either IL-10 or IL-13 (1.5, 7.5 and 15 ng in 100 microl saline) produced a dose-dependent attenuation of the UVB-induced hyperalgesia.	Sodium Chloride	70-76	interleukin 13	Mus musculus	30-35
11466394-5	2001	Attenuation of AHR with PTX treatment was found in the presence of elevated bronchoalveolar lavage fluid levels of the Th2 cytokine IL-13 and decreased levels of the Th1 cytokine IFN-gamma.	Pentoxifylline	24-27	interleukin 13	Mus musculus	132-137
11331286-6	2001	In the CC10-rtTA-IL-13 mice, IL-13, mucus metaplasia, inflammation, alveolar enlargement, and enhanced lung volumes were noted at base line and increased greatly after doxycycline administration.	Doxycycline	168-179	interleukin 13	Mus musculus	17-22
11170055-9	2001	Direct cytokine ELISA measurements of lung supernatant showed the level of IL-13 was significantly decreased in the OVA/RSV group compared to OVA mice, while there was no difference in either IL-4 or IL-5 between these two groups.	ova	116-119	interleukin 13	Mus musculus	75-80
11170055-9	2001	Direct cytokine ELISA measurements of lung supernatant showed the level of IL-13 was significantly decreased in the OVA/RSV group compared to OVA mice, while there was no difference in either IL-4 or IL-5 between these two groups.	ova	142-145	interleukin 13	Mus musculus	75-80
11254693-2	2001	Herein we report that in primary murine bone marrow-derived mast cells activated with ionomycin or IgE-Ag the bacterial endotoxin LPS strongly enhances the expression of IL-9 and IL-13, but not IL-4.	Ionomycin	86-95	interleukin 13	Mus musculus	179-184
11160269-2	2001	We show here that IL-4 and IL-13 regulate NO production through depletion of arginine, the substrate of inducible NO synthase (iNOS).	Arginine	77-85	interleukin 13	Mus musculus	27-32
10882414-8	2000	However, chronically rIL-12-treated mice exhibited increased numbers of non-B/non-T cells that when re-stimulated with specific allergen, produce IL-4 at levels 20-fold higher than did CD4 T cells while IL-13 responses are unaffected.	ril-12	21-27	interleukin 13	Mus musculus	203-208
11080527-10	2000	exerted an inhibitory effect on neutrophil influx and produce a marked inhibition of carrageenan-produced interleukin-13 and interleukin-6 in pleural exudation.	Carrageenan	85-96	interleukin 13	Mus musculus	106-120
10934105-4	2000	We found that ovalbumin-sensitized mice that were treated with indomethacin (OVA-indomethacin mice) had significantly greater AHR (p < 0.05) and higher levels of IL-5 (176 +/- 52 versus 66 +/- 4 pg/ml) and IL-13 (1,226 +/- 279 versus 475 +/- 65 pg/ml) in lung supernatants than mice sensitized with ovalbumin alone (OVA mice), while levels of IL-4 and serum IgE were not different.	Indomethacin	63-75	interleukin 13	Mus musculus	209-214
10934105-4	2000	We found that ovalbumin-sensitized mice that were treated with indomethacin (OVA-indomethacin mice) had significantly greater AHR (p < 0.05) and higher levels of IL-5 (176 +/- 52 versus 66 +/- 4 pg/ml) and IL-13 (1,226 +/- 279 versus 475 +/- 65 pg/ml) in lung supernatants than mice sensitized with ovalbumin alone (OVA mice), while levels of IL-4 and serum IgE were not different.	Indomethacin	81-93	interleukin 13	Mus musculus	209-214
11067915-7	2000	We show that in Th2 cells, cAMP promotes the production of both IL-5 and IL-13, which play distinct but critical roles in asthma pathogenesis.	Cyclic AMP	27-31	interleukin 13	Mus musculus	73-78
10995789-3	2000	IL-13 enhanced survival in 100% O(2).	o(2)	32-36	interleukin 13	Mus musculus	0-5
10861042-2	2000	Sensitization and aeroallergen challenge of both wild-type (WT) and IL-13 gene-targeted (IL-13-/-) mice induced allergic disease that was characterized by pulmonary eosinophilia and AHR to beta-methacholine.	beta-methacholine	189-206	interleukin 13	Mus musculus	68-73
10861042-2	2000	Sensitization and aeroallergen challenge of both wild-type (WT) and IL-13 gene-targeted (IL-13-/-) mice induced allergic disease that was characterized by pulmonary eosinophilia and AHR to beta-methacholine.	beta-methacholine	189-206	interleukin 13	Mus musculus	89-98
11036873-4	2000	IL-4 and IL-13 stimulated 3H-thymidine incorporation in the MC3T3-E1 cells and its proliferation in dose dependent manners.	3h-thymidine	26-38	interleukin 13	Mus musculus	9-14
11036873-6	2000	PTH-stimulated cyclic AMP (cAMP) production was inhibited by pretreatment with IL-4 and IL-13 for 48 hr in dose dependent manners.	Cyclic AMP	15-25	interleukin 13	Mus musculus	88-93
11036873-6	2000	PTH-stimulated cyclic AMP (cAMP) production was inhibited by pretreatment with IL-4 and IL-13 for 48 hr in dose dependent manners.	Cyclic AMP	27-31	interleukin 13	Mus musculus	88-93
11036873-7	2000	Pretreatment with IL-4 and IL-13 for 48 hr caused a decrease in PTH-induced cAMP production at any stimulatory concentration.	Cyclic AMP	76-80	interleukin 13	Mus musculus	27-32
10469236-8	1999	Among Th2-type cytokines, IL-13, but not IL-10, was shown to restore the CH reaction to TNCB in IL-4 KO mice.	Picryl Chloride	88-92	interleukin 13	Mus musculus	26-31
10569763-9	1999	The mechanism of disease worsening was partially IL-4 independent, indicating that increased IL-13 and/or decreased IFN-gamma production may have disrupted nitric oxide-based microbicidal responses.	Nitric Oxide	156-168	interleukin 13	Mus musculus	93-98
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Serine	14-20	interleukin 13	Mus musculus	0-5
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Arachidonic Acid	89-105	interleukin 13	Mus musculus	0-5
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Dinoprostone	110-114	interleukin 13	Mus musculus	0-5
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Zymosan	141-148	interleukin 13	Mus musculus	0-5
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Serine	157-163	interleukin 13	Mus musculus	0-5
10521702-0	1999	IL-13 induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production.	Eicosanoids	193-203	interleukin 13	Mus musculus	0-5
10521702-1	1999	In a recent investigation, we demonstrated that long-term treatment of macrophages with IL-13 enhances cPLA2 expression and modulates zymosan-stimulated AA mobilization.	Zymosan	134-141	interleukin 13	Mus musculus	88-93
10521702-3	1999	We demonstrate that in resting macrophages, IL-13 induces, through a MAP kinase-dependent process, (1) an increase of free AA release within 15 min, followed by increased PGE2 production and (2) a time-dependent serine phosphorylation of cPLA2.	Dinoprostone	171-175	interleukin 13	Mus musculus	44-49
10521702-3	1999	We demonstrate that in resting macrophages, IL-13 induces, through a MAP kinase-dependent process, (1) an increase of free AA release within 15 min, followed by increased PGE2 production and (2) a time-dependent serine phosphorylation of cPLA2.	Serine	212-218	interleukin 13	Mus musculus	44-49
10521702-4	1999	Conversely, in macrophages stimulated by zymosan, IL-13 added 30 min before zymosan inhibited the AA release and the serine phosphorylation of cPLA2 induced by the phagocytic agonist.	Zymosan	41-48	interleukin 13	Mus musculus	50-55
10521702-4	1999	Conversely, in macrophages stimulated by zymosan, IL-13 added 30 min before zymosan inhibited the AA release and the serine phosphorylation of cPLA2 induced by the phagocytic agonist.	Zymosan	76-83	interleukin 13	Mus musculus	50-55
10521702-4	1999	Conversely, in macrophages stimulated by zymosan, IL-13 added 30 min before zymosan inhibited the AA release and the serine phosphorylation of cPLA2 induced by the phagocytic agonist.	Serine	117-123	interleukin 13	Mus musculus	50-55
9886369-1	1999	In this study, we demonstrate that human NK cells, human NK clones, the human NK cell line (NK3.3), and a population of murine NK cells can produce the type 2 cytokine IL-13 in response to IL-2 or phorbol myristate acetate plus ionomycin.	Tetradecanoylphorbol Acetate	197-222	interleukin 13	Mus musculus	168-173
9886369-1	1999	In this study, we demonstrate that human NK cells, human NK clones, the human NK cell line (NK3.3), and a population of murine NK cells can produce the type 2 cytokine IL-13 in response to IL-2 or phorbol myristate acetate plus ionomycin.	Ionomycin	228-237	interleukin 13	Mus musculus	168-173
9748607-0	1998	IL-13 increases the cPLA2 gene and protein expression and the mobilization of arachidonic acid during an inflammatory process in mouse peritoneal macrophages.	Arachidonic Acid	78-94	interleukin 13	Mus musculus	0-5
9748607-1	1998	Pretreatment of mouse peritoneal macrophages with interleukin-13 (IL-13) potentiates the mobilization of arachidonic acid (AA) and the production of HETEs but does not affect the production of cyclooxygenase metabolites triggered by the suboptimal concentration of an inflammatory agonist (opsonized-zymosan).	Arachidonic Acid	105-121	interleukin 13	Mus musculus	50-64
9748607-1	1998	Pretreatment of mouse peritoneal macrophages with interleukin-13 (IL-13) potentiates the mobilization of arachidonic acid (AA) and the production of HETEs but does not affect the production of cyclooxygenase metabolites triggered by the suboptimal concentration of an inflammatory agonist (opsonized-zymosan).	Arachidonic Acid	105-121	interleukin 13	Mus musculus	66-71
9748607-1	1998	Pretreatment of mouse peritoneal macrophages with interleukin-13 (IL-13) potentiates the mobilization of arachidonic acid (AA) and the production of HETEs but does not affect the production of cyclooxygenase metabolites triggered by the suboptimal concentration of an inflammatory agonist (opsonized-zymosan).	Zymosan	300-307	interleukin 13	Mus musculus	50-64
9748607-1	1998	Pretreatment of mouse peritoneal macrophages with interleukin-13 (IL-13) potentiates the mobilization of arachidonic acid (AA) and the production of HETEs but does not affect the production of cyclooxygenase metabolites triggered by the suboptimal concentration of an inflammatory agonist (opsonized-zymosan).	Zymosan	300-307	interleukin 13	Mus musculus	66-71
9748607-2	1998	Cycloheximide suppresses these effects of IL-13 suggesting that de novo protein synthesis is involved.	Cycloheximide	0-13	interleukin 13	Mus musculus	42-47
9379051-0	1997	Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population.	Nitric Oxide	39-51	interleukin 13	Mus musculus	63-68
9486409-7	1998	A significant decreased expression of TNF-alpha transgene, endogenous mouse TNF-alpha and IL-1 mRNA was observed in splenocytes of mice treated for 3 or 4 weeks with CHO/IL-4 and CHO/IL-13, and, to a lesser extent, with CHO/IL-10, compared with controls.	cho	179-182	interleukin 13	Mus musculus	183-188
9379051-2	1997	In the present study we analyzed the mechanisms of suppression of nitric oxide (NO) release by IL-13 in the macrophage cell line J774A.1 and in thioglycolate-elicited mouse peritoneal macrophages.	Nitric Oxide	66-78	interleukin 13	Mus musculus	95-100
9379051-7	1997	Pulse labeling with [35S]methionine revealed that IL-13 caused a 4.7-fold reduction of the de novo synthesis of iNOS protein in these cells.	Sulfur-35	21-24	interleukin 13	Mus musculus	50-55
9379051-7	1997	Pulse labeling with [35S]methionine revealed that IL-13 caused a 4.7-fold reduction of the de novo synthesis of iNOS protein in these cells.	Methionine	25-35	interleukin 13	Mus musculus	50-55
9209514-4	1997	This action might be mediated by multiple modulatory activities of IL-13 on LPS-induced cytokine secretion since, relative to control animals, the mice treated with mIL-13 had eight times lower peak blood levels of TNF.	mil-13	165-171	interleukin 13	Mus musculus	67-72
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	freund"s	26-34	interleukin 13	Mus musculus	195-200
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	freund"s incomplete adjuvant	60-88	interleukin 13	Mus musculus	195-200
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	fia	90-93	interleukin 13	Mus musculus	195-200
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	Aluminum Hydroxide	96-103	interleukin 13	Mus musculus	195-200
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	Quil A	108-113	interleukin 13	Mus musculus	195-200
9305732-0	1997	Effect of IL-4 and IL-13 on IFN-gamma-induced production of nitric oxide in mouse macrophages infected with herpes simplex virus type 2.	Nitric Oxide	60-72	interleukin 13	Mus musculus	19-24
9305732-3	1997	Here we demonstrate that IL-4 and IL-13 totally abrogate IFN-gamma-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) mRNA and protein synthesis in a murine macrophage cell line.	Nitric Oxide	75-87	interleukin 13	Mus musculus	34-39
9058827-5	1997	This effect appeared to be IL-13 specific, since survival was not affected in mice that received heat-inactivated rmIL-13.	rmil-13	114-121	interleukin 13	Mus musculus	27-32
9129994-10	1997	The findings that SDZ 280.636 inhibits polyclonal IgE responses and suppresses IL-4, but not IL-13 mRNA expression point towards differences in the regulatory pathways of IL-4 and IL-13 gene transcription in lymphoid organs.	Sulfadiazine	18-21	interleukin 13	Mus musculus	180-185
8543830-0	1996	IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts.	Prostaglandins	81-94	interleukin 13	Mus musculus	0-5
8977218-0	1997	Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13.	Iron	42-46	interleukin 13	Mus musculus	102-107
8977218-8	1997	Thus, IL-4 and IL-13 regulate the iron metabolism of activated macrophages by at least two different pathways: first, by opposing NO-mediated IRP activation, thereby increasing ferritin translation; and second, by an IRP-independent augmentation of TfR mRNA expression.	Iron	34-38	interleukin 13	Mus musculus	15-20
8977218-9	1997	We suggest that IL-4 and IL-13 may enhance iron uptake and storage in activated macrophages and thereby contribute to down-regulation of macrophage effector functions.	Iron	43-47	interleukin 13	Mus musculus	25-30
8912886-2	1996	In this study, reverse transcription-polymerase chain reaction (RT-PCR) was used to demonstrate the activation of genes encoding for IL-2, IFN-gamma, and IL-10 in the lymph nodes from both CII-immunized and control CFA-immunized DBA/1 mice, at Days 10, 40, and 70 after immunization, in the absence of any IL-5 or IL-13 transcription.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	189-192	interleukin 13	Mus musculus	314-319
8543830-7	1996	Both IL-13 and IL-4 inhibited PGE2 production stimulated by IL-1 alpha in long bone cultures.	Dinoprostone	30-34	interleukin 13	Mus musculus	5-10
8543830-8	1996	Suppression of IL-1 alpha-induced bone resorption by IL-13 and IL-4 was recovered by adding exogenous PGE2 to the long bone cultures.	Dinoprostone	102-106	interleukin 13	Mus musculus	53-58
8543830-12	1996	Both IL-13 and IL-4 dose-dependently suppressed the IL-1 alpha-induced stimulation of both COX-2 mRNA expression and PGE2 synthesis.	Dinoprostone	117-121	interleukin 13	Mus musculus	5-10
8543830-14	1996	These results indicated that IL-13 and IL-4 inhibit bone resorption by suppressing COX-2-dependent PG synthesis in osteoblasts.	Prostaglandins	99-101	interleukin 13	Mus musculus	29-34
7911424-3	1994	IL-13 markedly suppressed nitric oxide release and to a lesser extent secretion of the pro-inflammatory cytokine tumor necrosis factor-alpha.	Nitric Oxide	26-38	interleukin 13	Mus musculus	0-5
7492780-6	1995	IL-13 and IL-4 stimulation of murine L cell fibroblasts, which endogenously express the IL-4 receptor (IL-4R alpha) and lack expression of the IL-2 receptor gamma subunit (IL-2R gamma), resulted in tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1)/4PS.	Tyrosine	198-206	interleukin 13	Mus musculus	0-5
7744881-8	1995	Both IL-13 and IL-4 induced low levels of tyrosine phosphorylation of Tyk-2 and Jak-1.	Tyrosine	42-50	interleukin 13	Mus musculus	5-10
7744881-12	1995	However, both IL-13 and IL-4 induced tyrosine phosphorylation of the IL-4-140 kDa receptor chain, suggesting that this is a component of both receptors in these cells and accounts for the similarities in signaling pathways shared by IL-13 and IL-4.	Tyrosine	37-45	interleukin 13	Mus musculus	14-19
7688562-6	1993	In addition, COS-7/hCD40L induced B cell proliferation, which was further enhanced by IL-4, or IL-13.	cos-7	13-18	interleukin 13	Mus musculus	95-100
7909326-6	1994	In contrast, treatment with exogenous rIL-12 profoundly inhibited primary granuloma formation while increasing IFN-gamma, IL-2, IL-10, and IL-12 pulmonary mRNA levels and suppressing IL-4, IL-5, IL-6, and IL-13 mRNA expression.	ril-12	38-44	interleukin 13	Mus musculus	205-210
7903102-5	1993	In addition, IL-13 decreases the production of nitric oxide by activated macrophages.	Nitric Oxide	47-59	interleukin 13	Mus musculus	13-18
7903102-7	1993	The suppression of nitric oxide by IL-13 leads to a decrease in parasiticidal activity by activated macrophages.	Nitric Oxide	19-31	interleukin 13	Mus musculus	35-40
33971182-15	2021	We demonstrated that DHT treatment potently suppressed the expression of the proinflammatory cytokines Il13 and Csf2 by ILC2s.	Dihydrotestosterone	21-24	interleukin 13	Mus musculus	103-107
34716962-10	2022	The expression levels of IL4, IL-9, and IL-13 mRNA in colonic mucosa were also significantly reduced by lycopene.	Lycopene	104-112	interleukin 13	Mus musculus	40-45
34936206-4	2022	The results showed that Gerberae Piloselloidis Herba could significantly mitigate asthma symptoms, reduce eosinophils counts in the bronchoalveolar lavage fluid, as well as decrease IgE, IL-5 and IL-13 concentration, and inflammatory cellular infiltration in lung tissues.	piloselloidis	33-46	interleukin 13	Mus musculus	196-201
34920650-11	2021	Also, IL-13 and histamine levels, hyperplasia of the goblet cell, and hyper-secretion of the mucus insignificantly decreased in vitamin A-treated asthma and rhinitis groups.	Vitamin A	128-137	interleukin 13	Mus musculus	6-11
34992603-11	2021	The reduced parasite count and pathology in infected lungs were associated with strong Th2 immune responses characterized by the high titers of antigen-specific IgG and its subclasses (IgG1, IgG2a, and IgG3) in the sera and significantly increased IL-4, IL-5, IL-13 levels in lung tissues.	th2	87-90	interleukin 13	Mus musculus	260-265
34871095-8	2021	MALDI MS imaging analysis of clofazimine, pyrazinamide and rifampicin revealed a drug-specific distribution within different lesion types including cellular granulomas, developing in BALB/c wild-type mice, and necrotic granulomas of BALB/c IL-13tg animals, emphasizing the necessity of pre-clinical models reflecting human pathology.	Rifampin	59-69	interleukin 13	Mus musculus	240-245
34557016-11	2021	qPCR and ELISA analysis identified that allergen induced increases in IL-5, IL-13, IL-33, IFN-gamma and IL-1beta cytokines mRNA in whole lungs and the levels of IL-6, IL-1beta and TNF-alpha proteins in BALF were significantly attenuated upon oral SPAB treatment.	spab	247-251	interleukin 13	Mus musculus	76-81
34939384-5	2021	Both DXM and PCF effectively decreased the number of eosinophils, lymphocytes, and neutrophils in BAL as well as the secretion of alpha-SMA and TGF-alpha1, IL-5, IL-13, while increased the expression of TNF-alpha and IFN-gamma.	Dexamethasone	5-8	interleukin 13	Mus musculus	162-167
34939384-5	2021	Both DXM and PCF effectively decreased the number of eosinophils, lymphocytes, and neutrophils in BAL as well as the secretion of alpha-SMA and TGF-alpha1, IL-5, IL-13, while increased the expression of TNF-alpha and IFN-gamma.	PHENYL CHLOROFORMATE	13-16	interleukin 13	Mus musculus	162-167
34726583-12	2021	CONCLUSIONS: SHE exhibits Th2 immune suppression under OVA stimulation via GATA3- and NLRP3-dependent IL-4, IL-5, and IL-13 suppression.	th2	26-29	interleukin 13	Mus musculus	118-123
34304725-8	2021	Celastrol reduced levels of Th2 cytokines including IL-4, IL-5, and IL-13 in atopic dermatitis skin lesions of NC/Nga mice.	celastrol	0-9	interleukin 13	Mus musculus	68-73
34769439-7	2021	In addition, IL-4 and IL-13 stimulate tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1).	Tyrosine	38-46	interleukin 13	Mus musculus	22-27
34769439-8	2021	Prolonged treatment with these cytokines leads to increased IRS-1 abundance, which, in turn, amplifies IL-4- and IL-13-stimulated IRS-1 tyrosine phosphorylation.	Tyrosine	136-144	interleukin 13	Mus musculus	113-118
34769439-9	2021	Through signaling crosstalk between IL-4/IL-13 and insulin, a hormone routinely included in mammary cultures, IRS-1 tyrosine phosphorylation is further enhanced.	Tyrosine	116-124	interleukin 13	Mus musculus	41-46
34391816-9	2021	Consistently, in cultured sensory neurons Pam3CSK4 enhanced IL-13-elicted calcium transients, increased number of responders, and orchestrated chemerin, CCL17 and CCL22 release.	Calcium	74-81	interleukin 13	Mus musculus	60-65
34822493-0	2021	Echinochrome A Treatment Alleviates Atopic Dermatitis-like Skin Lesions in NC/Nga Mice via IL-4 and IL-13 Suppression.	echinochrome A	0-14	interleukin 13	Mus musculus	100-105
34723976-11	2021	In PBMCs, production of IL10, IL13 and PDGFB was reduced due to high salt loading.	Salts	69-73	interleukin 13	Mus musculus	30-34
34691223-8	2021	Salvianolic acid A not only reduced DNCB-induced increase of serum IgE but also lowered levels of the Th2 cytokines (IL-4 and IL-13), Th1 cytokine (interferon-gamma), and Th17 cytokine (IL-17A).	salvianolic acid A	0-18	interleukin 13	Mus musculus	126-131
34650552-0	2021	Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling.	Pravastatin	25-36	interleukin 13	Mus musculus	105-110
34650552-10	2021	We further showed that PA promotes IL-13 release from ILC2s by activating IL-33/ST2 signaling to attenuate intestinal I/R injury.	Pravastatin	23-25	interleukin 13	Mus musculus	35-40
34650552-12	2021	Overall, results indicated that the gut microbial metabolite PA can attenuate intestinal I/R injury by promoting the release of IL-13 from ILC2s via IL-33/ST2 signaling, revealing a novel mechanism of and therapeutic strategy for intestinal I/R injury.	Pravastatin	61-63	interleukin 13	Mus musculus	128-133
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 13	Mus musculus	133-138
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Barium	192-194	interleukin 13	Mus musculus	133-138
34460865-10	2021	By stimulating the release of IL-33, alum induced Th2 immunity via IL-5 and IL-13 production in group 2 innate lymphoid cells (ILC2s) and increased MHC class II expression in antigen-presenting cells (APCs) in the lung.	aluminum sulfate	37-41	interleukin 13	Mus musculus	76-81
34118645-6	2021	In contrast, a significant decrease in the expression of IL-33 after DHL treatment in vitro showed that DHL strongly reduced IL-13 and TGF-beta.	dehydrocostus lactone	69-72	interleukin 13	Mus musculus	125-130
34118645-6	2021	In contrast, a significant decrease in the expression of IL-33 after DHL treatment in vitro showed that DHL strongly reduced IL-13 and TGF-beta.	dehydrocostus lactone	104-107	interleukin 13	Mus musculus	125-130
34118645-7	2021	Regarding the mechanism, BLM-induced phosphorylation of JNK, p38 MAPK, and NF-kappaB were significantly reduced after DHL treatment, which further led to the down-regulation of IL-33 expression, thereby decreasing IL-13 and TGF-beta.	dehydrocostus lactone	118-121	interleukin 13	Mus musculus	214-219
34327818-8	2021	Furthermore, IL-4-induced M2 macrophage polarization and IL-13-induced M2 macrophage polarization were suppressed by PFD treatment in vitro, resulting in reductions in the release of arginase-1 (ARG-1), chitinase 3-like 3 (YM-1) and TGF-beta1.	pirfenidone	117-120	interleukin 13	Mus musculus	57-62
34460865-10	2021	By stimulating the release of IL-33, alum induced Th2 immunity via IL-5 and IL-13 production in group 2 innate lymphoid cells (ILC2s) and increased MHC class II expression in antigen-presenting cells (APCs) in the lung.	th2	50-53	interleukin 13	Mus musculus	76-81
34185704-6	2021	Following anti-IL-13 treatment in infected mice, hyaluronan synthase 1 (Has1) was the most downregulated gene and accumulation of the hyaluronan polysaccharide was decreased in the lung.	Hyaluronic Acid	134-144	interleukin 13	Mus musculus	15-20
34445774-7	2021	In vivo experiments showed that acute (4.5 h) PEI exposure stimulated secretion of Th2 cytokines (IL-5 and IL-13) into bronchoalveolar lavage (BAL) fluid.	Polyethyleneimine	46-49	interleukin 13	Mus musculus	107-112
34185704-6	2021	Following anti-IL-13 treatment in infected mice, hyaluronan synthase 1 (Has1) was the most downregulated gene and accumulation of the hyaluronan polysaccharide was decreased in the lung.	Polysaccharides	145-159	interleukin 13	Mus musculus	15-20
34185704-9	2021	Finally, hyaluronan was directly induced in the lungs of mice by administration of IL-13, indicating a new role for IL-13 in lung disease.	Hyaluronic Acid	9-19	interleukin 13	Mus musculus	83-88
34185704-9	2021	Finally, hyaluronan was directly induced in the lungs of mice by administration of IL-13, indicating a new role for IL-13 in lung disease.	Hyaluronic Acid	9-19	interleukin 13	Mus musculus	116-121
34062412-0	2021	Pingchuan formula attenuates airway mucus hypersecretion via regulation of the PNEC-GABA-IL13-Muc5ac axis in asthmatic mice.	gamma-Aminobutyric Acid	84-88	interleukin 13	Mus musculus	89-93
34062412-4	2021	This study aimed to investigate the effect of PCF on airway mucus secretion in asthmatic mice and to explore changes in the PNEC-GABA-IL13-Muc5ac axis.	gamma-Aminobutyric Acid	129-133	interleukin 13	Mus musculus	134-138
34062412-13	2021	CONCLUSION: These findings suggest that PCF controls asthma attacks by reducing airway inflammation and mucus hypersecretion via the PNEC-GABA-IL13-Muc5ac axis.	gamma-Aminobutyric Acid	138-142	interleukin 13	Mus musculus	143-147
34296788-7	2022	In HDM-induced asthmatic mouse model, hemin-DCEVs inhalation reduced eosinophils infiltration and mucus secretion in the airway, decreased the levels of IL-4, IL-5, and IL-13 in the lung and the number of Th2 cells in mediastinal lymph nodes (MLNs), and increased the number of Treg cells in MLNs.	Hemin	38-43	interleukin 13	Mus musculus	169-174
34374265-13	2021	In vitro experiments, compared with PBS group, PGRN level was decreased (P<0.05), IL-6 level was increased (P<0.01), phosphorylation of p38 was activated in IL-13 treatment group.	Lead	36-39	interleukin 13	Mus musculus	157-162
34335571-8	2021	Indeed, injecting rmIL-33 into mice suffering from acute DSS colitis, strongly abrogated epithelial damage, pro-inflammatory cytokine secretion, and loss of barrier integrity, while it induced a strong increase of Th2 associated cytokines (IL-13/IL-5) in the colon.	rmil-33	18-25	interleukin 13	Mus musculus	240-245
34089243-7	2021	The administration of vitamin E attenuated AHR, airway inflammation, and the level of IL-13 and ROS and enhanced the Nrf2 level in the older mice compared to the younger mice.	Vitamin E	22-31	interleukin 13	Mus musculus	86-91
34294130-11	2021	ECP, IL-4, IL-5 and IL-13 were decreased after the AR mice CD8+ Tregs administration in mucosal cultures.	tregs	64-69	interleukin 13	Mus musculus	20-25
34188444-10	2021	Curcumol relieved collagen deposition in airway tissues, inflammation cell recruitment in BALF, and reduced the up-regulation of serum ovalbumin-IgE, IL-4, IL-5, and IL-13 and BALF VEGFA in chronic asthmatic mice.	curcumol	0-8	interleukin 13	Mus musculus	166-171
35123286-7	2022	Using a murine asthma model, our results demonstrated that oral administration of 50 mg/kg of acteoside decreased levels of Th2-type cytokines, such as IL-4, IL-5, and IL-13, whereas the level of IL-10 and the frequency of CD4+Foxp3+ Tregs were augmented.	acteoside	94-103	interleukin 13	Mus musculus	168-173
34079051-10	2021	OEA increased the numbers of IL-5- or IL-13-producing ILC2s in a mouse model.	oleoylethanolamide	0-3	interleukin 13	Mus musculus	38-43
34134959-6	2021	TCDD treatment significantly decreased inflammatory cells and mucus production in the lungs of asthmatic mice, and BALFs from TCDD-treated mice with CRE challenge contained lowered levels of the proinflammatory factors including IL-4, IL-13 and IL-17A (P < 0.001) but increased anti-inflammatory factors including IL-10, IL-22 and TGF-beta1 (P < 0.001).	Polychlorinated Dibenzodioxins	126-130	interleukin 13	Mus musculus	235-240
35533451-10	2022	G-1 significantly decreased the Th2 population and levels of IL-4, IL-5, IL-13 and GATA-3; these effects were attenuated by BPA.	bisphenol A	124-127	interleukin 13	Mus musculus	73-78
35619631-10	2022	BDMC not only decreased the production of OVA-specific immunoglobulin (OVA-sIg)E, IgG1, histamine, mouse mast cell protease-1, diamine oxidase, cytokines (IL-4, IL-5 and IL-13) but increased cytokines interferon-gamma production.	bisdemethoxycurcumin	0-4	interleukin 13	Mus musculus	170-175
35634683-6	2022	Moreover, SHE significantly inhibited the proliferation of mast cells and decreased the expression of IL-13 on CD4+ cells prompted by elevated thymic stromal lymphopoietin (TSLP) expression in DNCB-induced AD in mice.	Dinitrochlorobenzene	193-197	interleukin 13	Mus musculus	102-107
35608904-0	2022	IL-13-programmed airway tuft cells produce PGE2, which promotes CFTR-dependent mucociliary function.	Dinoprostone	43-47	interleukin 13	Mus musculus	0-5
35608904-3	2022	Using bulk and single cell RNA sequencing of airway epithelium and mouse modeling, we find that IL-13 expands and programs airway tuft cells towards eicosanoid metabolism, and that tuft cell deficiency leads to a reduction in airway prostaglandin E2 (PGE2)concentration.	Eicosanoids	149-159	interleukin 13	Mus musculus	96-101
35608904-3	2022	Using bulk and single cell RNA sequencing of airway epithelium and mouse modeling, we find that IL-13 expands and programs airway tuft cells towards eicosanoid metabolism, and that tuft cell deficiency leads to a reduction in airway prostaglandin E2 (PGE2)concentration.	Dinoprostone	233-249	interleukin 13	Mus musculus	96-101
35608904-3	2022	Using bulk and single cell RNA sequencing of airway epithelium and mouse modeling, we find that IL-13 expands and programs airway tuft cells towards eicosanoid metabolism, and that tuft cell deficiency leads to a reduction in airway prostaglandin E2 (PGE2)concentration.	Dinoprostone	251-255	interleukin 13	Mus musculus	96-101
35348023-9	2022	In vitro azithromycin also inhibited ATP-induced secretion of Muc5ac and Muc5b in tracheal segments from IL-13-exposed mice.	Azithromycin	9-21	interleukin 13	Mus musculus	105-110
35348023-9	2022	In vitro azithromycin also inhibited ATP-induced secretion of Muc5ac and Muc5b in tracheal segments from IL-13-exposed mice.	Adenosine Triphosphate	37-40	interleukin 13	Mus musculus	105-110
35247664-3	2022	In addition, KU812 experimentation revealed lower levels of beta-hexosaminidase, histamine, tryptase, interleukin 4 (IL-4)/IL-13 in glycated protein-treated mice compared with native PV-treated ones.	ku812	13-18	interleukin 13	Mus musculus	123-128
35483233-0	2022	Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis.	liproxstatin-1	0-14	interleukin 13	Mus musculus	30-35
35450036-4	2022	This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells.	Simvastatin	91-102	interleukin 13	Mus musculus	119-124
35490266-8	2022	Treatment with azithromycin significantly decreased IL-13 level, mucus secretion, and gene expression of IL-33, Muc5ac, and Muc5b; compared to the non-treated asthma group.	Azithromycin	15-27	interleukin 13	Mus musculus	52-57
35227979-6	2022	Pharmacological examination with ovalbumin-induced mice demonstrated that XC267 significantly reduced the levels of IL-4, IL-13, and IgE after oral administration of 10 mg/kg.	xc267	74-79	interleukin 13	Mus musculus	122-127
35450036-4	2022	This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells.	Simvastatin	91-102	interleukin 13	Mus musculus	168-173
35450036-5	2022	To this end, IL-13 was conjugated to LCL-SIM which was obtained via the lipid film hydration method.	lcl-sim	37-44	interleukin 13	Mus musculus	13-18
35450036-12	2022	The in vitro data showed that IL-13-functionalized LCL were preferentially taken up by tumor-associated macrophages and indicated that sequential administration of IL-13-LCL-SIM and PEG-EV-DOX had the strongest antiproliferative effect on tumor cells co-cultured with tumor-associated macrophages (TAMs).	lcl-sim	170-177	interleukin 13	Mus musculus	30-35
35450036-12	2022	The in vitro data showed that IL-13-functionalized LCL were preferentially taken up by tumor-associated macrophages and indicated that sequential administration of IL-13-LCL-SIM and PEG-EV-DOX had the strongest antiproliferative effect on tumor cells co-cultured with tumor-associated macrophages (TAMs).	lcl-sim	170-177	interleukin 13	Mus musculus	164-169
35450036-12	2022	The in vitro data showed that IL-13-functionalized LCL were preferentially taken up by tumor-associated macrophages and indicated that sequential administration of IL-13-LCL-SIM and PEG-EV-DOX had the strongest antiproliferative effect on tumor cells co-cultured with tumor-associated macrophages (TAMs).	peg-ev-dox	182-192	interleukin 13	Mus musculus	30-35
35166628-8	2022	In addition, AT-II inhibited IL-4/IL-13-induced activation of the STAT6 signaling pathway that is vital in the M2-like polarization of macrophages.	atractylenolide II	13-18	interleukin 13	Mus musculus	34-39
35166628-7	2022	RESULTS: AT-II (2.5 and 5 microM) did not cause significant inhibition of A549 cell viability but markedly inhibited IL-4/IL-13-induced M2-like polarization, evidenced by the decreased expression of the M2 surface marker CD206, down-regulation of specific M2-marker genes (Arg-1, IL-10 and TGF-beta) as well as inhibition of M2 macrophages-mediated invasion and migration of A549 cells.	atractylenolide II	9-14	interleukin 13	Mus musculus	122-127
35359977-4	2022	We developed B-IL-4/13 iKO mice carrying a tamoxifen-inducible B cell-specific deletion of IL-4 and IL-13.	Tamoxifen	43-52	interleukin 13	Mus musculus	100-105
35094142-8	2022	Furthermore, BETi selectively induced greater apoptosis in M2-like macrophages (PMA and IL-4, IL-13-differentiated THP-1) (31.3%-36.1%) than in M1-like macrophages (PMA and LPS-differentiated THP-1) (12.4%-18.5%) (p < 0.01).	beti	13-17	interleukin 13	Mus musculus	94-99
35260535-6	2022	In vitro, TIM3+CD8+ T cells cultured with cisplatin, apoptotic cells, or phosphatidylserine liposomes produced IL-13, which induced IL-10 in macrophages.	Cisplatin	42-51	interleukin 13	Mus musculus	111-116
35260535-9	2022	Our data indicated that cell damage induced by cisplatin activated TIM3 on CD8+ T cells, leading to increased IL-13 production, which in turn induced macrophage IL-10 production and resolution of CIPN.	Cisplatin	47-56	interleukin 13	Mus musculus	110-115
35203267-6	2022	However, the co-stimulation with prostaglandin (PG) E2 resulted in a marked increase in the secretion of various cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-6, and IL-13, accompanied by an increase in their mRNA levels.	Prostaglandins	33-46	interleukin 13	Mus musculus	185-190
35014685-11	2022	IL-4, IL-5 and IL-13 levels in the bronchoalveolar lavage fluid were significantly lower following DEX treatment.	Dexmedetomidine	99-102	interleukin 13	Mus musculus	15-20
35007167-4	2022	BoxA treatment significantly ameliorated AR symptoms, decreased level of histamine, OVA-specific antibodies, suppressed the infiltration of immune cells in nasal tissues, inhibited the expression of IL-4, IL-6, IL-5, TNF-alpha, IL-13, IL-17, IL-2 while promoting the expression of IL-10, suppressed the expression of HMGB1, TLR2, and TLR4 in AR mice.	boxa	0-4	interleukin 13	Mus musculus	228-233
35203267-6	2022	However, the co-stimulation with prostaglandin (PG) E2 resulted in a marked increase in the secretion of various cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-6, and IL-13, accompanied by an increase in their mRNA levels.	Dinoprostone	48-54	interleukin 13	Mus musculus	185-190
35200662-4	2022	Moreover, DHB suppressed the secretion and/or the expression of the allergic cytokines, interleukin (IL)-4, IL-5, IL-6, IL-13, and tumor necrosis factor (TNF)-alpha, and the chemokine, thymus activation-regulated chemokine (TARC), by regulating the phosphorylation of IkappaBalpha and the translocation of cytoplasmic NF-kappaB into the nucleus.	protocatechualdehyde	10-13	interleukin 13	Mus musculus	120-125
35280398-9	2022	In animals treated with poly (I:C), the levels of serum IL-4, IL-13 and TSLP increased significantly, while the level of IFN-gamma did not change.	Poly I-C	24-34	interleukin 13	Mus musculus	62-67
35060690-7	2022	This IL13-dependent induction was not shown in liver slices of STAT6-deficient mice and when wild type slices were cotreated with TGFbeta receptor 1 kinase inhibitor galunisertib, STAT6 inhibitor AS1517499, or AP1 inhibitor T5224.	LY-2157299	166-178	interleukin 13	Mus musculus	5-9
35356877-4	2022	Results DEK protein was highly expressed in the lung tissues of OVA group mice and decreased in the DTA-64 group mice; DTA-64 reduced the infiltration of eosinophils and neutrophils around the airways, down-regulated serum OVA-specific IgE and IL-4, IL-5, IL-13 in BALF, and up-regulated IFN-gamma; DTA-64 also reduced the expressions of vimentin, alpha-SMA, Snail+Slug in the lung tissue, and up-regulated epithelial marker E-cadherin.	deoxythymidylyl-3'-5'-deoxyadenylate	119-122	interleukin 13	Mus musculus	256-261
35060690-7	2022	This IL13-dependent induction was not shown in liver slices of STAT6-deficient mice and when wild type slices were cotreated with TGFbeta receptor 1 kinase inhibitor galunisertib, STAT6 inhibitor AS1517499, or AP1 inhibitor T5224.	3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid	224-229	interleukin 13	Mus musculus	5-9
34022666-11	2021	Catalpol-treated mice had significantly lower levels of helper T cell type 2 (Th2) cytokines (IL-4, IL-5, and IL-13), PGD2, eotaxin-1, and C-X-C chemokine ligand-1 (CXCL1) in bronchoalveolar lavage fluid (BALF) than did the allergic group.	catalpol	0-8	interleukin 13	Mus musculus	110-115
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interleukin 13	Mus musculus	141-146
33512727-5	2021	Additionally, the current investigations also show that the TGF-beta mediated esophageal and lung fibrosis is also reduced in Aspergillus-challenged, CD2-IL-5 transgenic, and DOX-responsive IL-13 mice.	Doxorubicin	175-178	interleukin 13	Mus musculus	190-195
33512727-7	2021	Taken together, we provide in vivo and in vitro evidence that tacrolimus ameliorates eosinophil levels and associated pathogenesis in allergen-, IL-5- and IL-13-induced EoE, EG, and asthma pathogenesis.	Tacrolimus	62-72	interleukin 13	Mus musculus	155-160
34023442-14	2021	RESULTS: Que treatment decreased the clinical score and left ankle thickness of CIA mice, attenuated the synovial inflammation and hyperplasia and bone/cartilage destruction in ankle joints, and decreased the secretion of IL-6, TNF-alpha, IL-1beta, IL-8, IL-13, and IL-17.	Quercetin	9-12	interleukin 13	Mus musculus	255-260
34022666-7	2021	Administration of catalpol also suppressed production of prostaglandin D2 (PGD2), interleukin (IL)-6, and IL-13, while not affecting tumor necrosis factor (TNF)-alpha production.	catalpol	18-26	interleukin 13	Mus musculus	106-111
33601665-7	2021	Both PFOS and PFOA exacerbated lung tissue inflammation (greater number of eosinophils and mucus hyperproduction), upregulated Th2 cytokine production (IL-4 and IL-13), and promoted Th2 cells and STAT6 activation.	perfluorooctane sulfonic acid	5-9	interleukin 13	Mus musculus	161-166
33747193-8	2021	The results demonstrated that GA and dexamethasone treatment mitigated airway inflammation, inflammatory cell infiltration and airway remolding, with a concomitant decrease in the expression levels of IL-4, IL-5, IL-13 and IL-17, in mice with OVA-induced asthma.	Glycyrrhizic Acid	30-32	interleukin 13	Mus musculus	213-218
33747193-8	2021	The results demonstrated that GA and dexamethasone treatment mitigated airway inflammation, inflammatory cell infiltration and airway remolding, with a concomitant decrease in the expression levels of IL-4, IL-5, IL-13 and IL-17, in mice with OVA-induced asthma.	Dexamethasone	37-50	interleukin 13	Mus musculus	213-218
33640443-6	2021	Additionally, IL-13 and IL-17 in BALF were significantly increased in the PHMG-P exposure groups.	polyhexamethyleneguanidine	74-80	interleukin 13	Mus musculus	14-19
33875623-6	2021	Administration of 4-CMTB decreased the immune cell numbers in the bronchoalveolar lavage fluid and suppressed the expression of inflammatory Th2 cytokines (IL-4, IL-5, and IL-13) in the lung tissues.	4-CMTB	18-24	interleukin 13	Mus musculus	172-177
33601665-7	2021	Both PFOS and PFOA exacerbated lung tissue inflammation (greater number of eosinophils and mucus hyperproduction), upregulated Th2 cytokine production (IL-4 and IL-13), and promoted Th2 cells and STAT6 activation.	perfluorooctanoic acid	14-18	interleukin 13	Mus musculus	161-166
33873095-9	2021	The WT-OVA + CS group also showed higher Penh value, levels of IL-5 and IL-13 in BALF and lung tissue injury scores when compared with the WT-OVA group and WT-CS group.	Cesium	13-15	interleukin 13	Mus musculus	72-77
33873095-12	2021	Compared with the WT-OVA + CS group, mice in the TRPA1-/--OVA + CS showed a significant decrease in the number of inflammatory cells, levels of IL-4, IL-5 and IL-13 in BALF, Penh value and lung tissue injury score, and a downregulation of Claudin-2 expression while an upregulation of ZO-1 and Occludin expressions.	Cesium	64-66	interleukin 13	Mus musculus	159-164
33883974-6	2021	All three doses of BHMC (0.1-10 mg/kg) significantly reduced the number of eosinophils, lymphocytes, macrophages, and neutrophils, as well as the levels of Th2 cytokines (IL-4, IL-5 and IL-13) in bronchoalveolar lavage fluid (BALF) as compared to OVA-challenged mice.	bhmc	19-23	interleukin 13	Mus musculus	186-191
33712513-5	2021	Following mouse spinal cord demyelination, local LPS/IL4/IL13 deposition markedly increased lesional phagocytic macrophages/microglia, lactate and HBEGF, matrix remodeling, oligodendrogenesis and remyelination.	Lactic Acid	135-142	interleukin 13	Mus musculus	57-61
33725040-10	2021	Treatment with Zingerone also decreased the level of interleukin (IL)-4, IL-5, IL-13, and increased the level of interferon gamma (IFN-gamma) in the BALF and attenuated airway hyperresponsiveness (AHR).	zingerone	15-24	interleukin 13	Mus musculus	79-84
33828561-12	2021	In parallel, ADP reduced reactive oxygen species (ROS) formation and tumor necrosis factor-alpha (TNF-alpha) levels, while increased IL-13 levels in the skin.	Adenosine Diphosphate	13-16	interleukin 13	Mus musculus	133-138
33792078-7	2021	The concentrations of IL-4, IL-5 and IL-13, and the numbers of ILC2s in BALF were also reduced by tiotropium treatment.	Tiotropium Bromide	98-108	interleukin 13	Mus musculus	37-42
33859711-7	2021	GGDE reduced the levels of IgE, TNF-alpha, IL-13, eotaxin, and VEGF and mast cell/eosinophil infiltration and prevented the decreases in the levels of involucrin and loricrin in the skin.	ggde	0-4	interleukin 13	Mus musculus	43-48
33748288-7	2021	Mechanistically, NMU-23 administration induced the expansion of ILC2 and elevated eosinophil, IL-5, and IL-13 expression in the joint of arthritic mice.	nmu-23	17-23	interleukin 13	Mus musculus	104-109
31175714-5	2021	RESULTS: In obese mice, co-administration of magnesium and dexamethasone decreased IL-13 in bronchoalveolar lavage fluid and total and OVA-specific IgE in serum, and reduced alpha-smooth muscle actin-positive areas in the bronchi compared with mice treated with dexamethasone alone.	Magnesium	45-54	interleukin 13	Mus musculus	83-88
31175714-5	2021	RESULTS: In obese mice, co-administration of magnesium and dexamethasone decreased IL-13 in bronchoalveolar lavage fluid and total and OVA-specific IgE in serum, and reduced alpha-smooth muscle actin-positive areas in the bronchi compared with mice treated with dexamethasone alone.	Dexamethasone	59-72	interleukin 13	Mus musculus	83-88
33688686-6	2021	Following anti-IL-13 treatment in infected mice, in the lung, hyaluronan synthase 1 ( Has1 ) was the most downregulated gene and hyaluronan accumulation was decreased.	Hyaluronic Acid	62-72	interleukin 13	Mus musculus	15-20
33397719-4	2021	Specific cell clusters of basophils, type 2 innate lymphoid cells (ILC2), and CD8+ memory T cells were the predominant sources of interleukin (IL)-4 and IL-13 transcripts whose expressions were dexamethasone resistant.	Dexamethasone	194-207	interleukin 13	Mus musculus	153-158
33450585-8	2021	Gelatin methacrylate hydrogels containing interleukin-4 (IL4) and IL13-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles were designed to promote the M2 phenotype in a murine subcutaneous in vivo model.	Methacrylates	8-20	interleukin 13	Mus musculus	66-70
33450585-8	2021	Gelatin methacrylate hydrogels containing interleukin-4 (IL4) and IL13-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles were designed to promote the M2 phenotype in a murine subcutaneous in vivo model.	Polylactic Acid-Polyglycolic Acid Copolymer	78-107	interleukin 13	Mus musculus	66-70
33450585-10	2021	Biochemical analysis and second harmonic generation microscopy showed that the release of IL4+IL13 increased total sulfated glycosaminoglycan content and decreased fibril alignment, which is typically associated with less fibrotic tissue.	Glycosaminoglycans	124-141	interleukin 13	Mus musculus	94-98
33338503-7	2021	Furthermore, when chlorine was exposed chronically, increased the airway remodeling with collagen deposition and epithelial cells thickness, positive cells for IL-1beta, iNOS, IL-17 in the airways and in the alveolar walls and ROCK-2 in the alveolar walls, lung inflammation with increased levels of IL-5, IL-13, IL-1beta and TNF-alpha in the lung homogenate, and also, induced the acid mucus production by the nasal epithelium.	Chlorine	18-26	interleukin 13	Mus musculus	306-311
32535962-8	2021	Bosentan application also significantly reduced the gene expression of Il13, Il17, and Ifng in the treated lesions.	Bosentan	0-8	interleukin 13	Mus musculus	71-75
33407872-8	2021	In OVA animals, the administration of Nor-EVs or Hypo-EVs significantly ameliorated the BALF total cells, eosinophils, and pro-inflammatory mediators (IL-4 and IL-13) in asthmatic mice.	nor-evs	38-45	interleukin 13	Mus musculus	160-165
33407872-8	2021	In OVA animals, the administration of Nor-EVs or Hypo-EVs significantly ameliorated the BALF total cells, eosinophils, and pro-inflammatory mediators (IL-4 and IL-13) in asthmatic mice.	hypo-evs	49-57	interleukin 13	Mus musculus	160-165
32648964-10	2021	Tamoxifen decreased IL-5 and IL-13 production and BAL eosinophils.	Tamoxifen	0-9	interleukin 13	Mus musculus	29-34
32632049-10	2021	Carnosol treatment inhibited the increases of IL-4 and IL-13 cytokines expression in both BALF and the lungs.	carnosol	0-8	interleukin 13	Mus musculus	55-60
33113503-13	2021	Tilianin suppressed the expression of Th2-related cytokines, IL-13 and IL-33 in lung tissues.	tilianin	0-8	interleukin 13	Mus musculus	61-66
32846422-10	2021	Nasal administration of LPA significantly increased the number of total cells and IL-13 in BALF via regulating the production of IL-33 and CCL-2-derived infiltrating macrophages.	lysophosphatidic acid	24-27	interleukin 13	Mus musculus	82-87
33046682-9	2020	For instance, in IL-13 TG mice lung Mesorhyzobium significantly affected the alpha diversity of both lung and gut microbiomes.	mesorhyzobium	36-49	interleukin 13	Mus musculus	17-22
33374657-10	2020	Furthermore, PGT-treated mice showed a significant reduction in IL-13 and a mild reduction in IL-5 in lungs.	pgt	13-16	interleukin 13	Mus musculus	64-69
33342312-9	2022	Administration of NaHS considerably decreased the levels of BALF interleukin-13, plasma tumor necrosis factor-alpha (TNF-alpha), lung malondialdehyde (MDA) and lung phosphorylated nuclear factor-kappa B (p-NF-kappaB) expression and scores of peribronchial inflammatory cell infiltration, goblet cell hyperplasia and subepithelial fibrosis and increased the activity of lung superoxide dismutase (SOD).	sodium bisulfide	18-22	interleukin 13	Mus musculus	65-79
33170612-4	2020	Rapamycin was used to activate the process of autophagy, which was impaired in the moderate TBI model, and this treatment reversed the expression of pyroptosis associated proteins, interleukin-13 (IL-13) and the pJAK-1 pathway, which were upregulated significantly after TBI.	Sirolimus	0-9	interleukin 13	Mus musculus	181-195
33170612-4	2020	Rapamycin was used to activate the process of autophagy, which was impaired in the moderate TBI model, and this treatment reversed the expression of pyroptosis associated proteins, interleukin-13 (IL-13) and the pJAK-1 pathway, which were upregulated significantly after TBI.	Sirolimus	0-9	interleukin 13	Mus musculus	197-202
33188077-6	2020	In this study, we identified potential mouse Il13 enhancers using histone modification monomethylation at lysine residue 4 on histone 3 (H3K4me1) chromatin immunoprecipitation sequencing and acetylation at lysine residue 27 on histone 3 (H3K27ac) chromatin immunoprecipitation sequencing.	Lysine	106-112	interleukin 13	Mus musculus	45-49
33188077-6	2020	In this study, we identified potential mouse Il13 enhancers using histone modification monomethylation at lysine residue 4 on histone 3 (H3K4me1) chromatin immunoprecipitation sequencing and acetylation at lysine residue 27 on histone 3 (H3K27ac) chromatin immunoprecipitation sequencing.	Lysine	206-212	interleukin 13	Mus musculus	45-49
33316284-9	2021	MC-derived IL-13 inhibited the Th1 response in CHS to DNFB.	Dinitrofluorobenzene	54-58	interleukin 13	Mus musculus	11-16
32977946-4	2020	IL-33, but not IL-25 or TSLP, and type 2 cytokines such as IL-5 and IL-13 were critically involved in silica"s exacerbation of OVA-induced airway eosinophilia in mice.	Silicon Dioxide	102-108	interleukin 13	Mus musculus	68-73
32977946-7	2020	These observations suggest that IL-33 induced in epithelial cells by silica activates ILCs to produce IL-5 and/or IL-13, contributing to silica"s exacerbation of OVA-induced airway eosinophilia in mice.	Silicon Dioxide	69-75	interleukin 13	Mus musculus	114-119
32977946-7	2020	These observations suggest that IL-33 induced in epithelial cells by silica activates ILCs to produce IL-5 and/or IL-13, contributing to silica"s exacerbation of OVA-induced airway eosinophilia in mice.	Silicon Dioxide	137-143	interleukin 13	Mus musculus	114-119
32828819-11	2020	Administration of succinate to mice expanded tuft cells and reduced intestinal inflammation in TNFDeltaARE/+ mice and anti-CD3E-treated mice, increased GATA3+ cells and type 2 cytokines (IL22, IL25, IL13), and decreased RORGT+ cells and type 17 cytokines (IL23) in a tuft cell-dependent manner.	Succinic Acid	18-27	interleukin 13	Mus musculus	199-203
33285161-8	2021	Inhaled LTD4 blocked LTC4-mediated, potentiation of ovalbumin (OVA)-induced eosinophilic inflammation, recruitment of platelet-adherent eosinophils, and increases in IL-33, IL-4, IL-5, and IL-13 in the lung tissue.	Leukotriene D4	8-12	interleukin 13	Mus musculus	189-194
32571119-7	2020	Furthermore, miR-92a blocked interleukin (IL)-13-induced MUC5AC luciferase activity in 16HBE.	mir-92a	13-20	interleukin 13	Mus musculus	29-48
33039967-9	2020	Alpinetin also decreased the OVA-induced levels of IL-4, IL-5, IL-13 and IgE.	alpinetin	0-9	interleukin 13	Mus musculus	63-68
32571119-7	2020	Furthermore, miR-92a blocked interleukin (IL)-13-induced MUC5AC luciferase activity in 16HBE.	16hbe	87-92	interleukin 13	Mus musculus	29-48
32457418-6	2020	JTE-013 administration also significantly decreased the lymph nodes sizes, the levels of inflammatory cytokines (IL-4, IL-13, IL-17, and IFN-gamma) in the ears and lymph nodes, and the levels of chemokines CCL17 and CCL22 in ears.	JTE 013	0-7	interleukin 13	Mus musculus	119-124
31942829-5	2020	In all treatment groups, mice were administrated vitamins 30 min before each challenge (three times per week for 8 consecutive weeks).Results: In comparison with the asthma group, co-administration of ineffective doses of ascorbic acid and calcitriol led to the decreased levels of IL-13 (50.5 +- 1.85 vs. 42.13 +- 0.37 pg/mL, p = 0.02) and IgE (58.74 +- 0.43 vs. 45.78 +- 2.05 ng/mL, p = 0.003) as well as the reduction of goblet hyperplasia and subepithelial fibrosis (5 vs. 1 score, p = 0.001 and 5 vs. 2 score, p = 0.001, respectively).Discussion and conclusions: Combination of ascorbic acid with calcitriol in ineffective doses improves airway remodelling due to additive effects possibly through reduction of oxidative stress and inflammation.	Ascorbic Acid	222-235	interleukin 13	Mus musculus	282-287
31942829-5	2020	In all treatment groups, mice were administrated vitamins 30 min before each challenge (three times per week for 8 consecutive weeks).Results: In comparison with the asthma group, co-administration of ineffective doses of ascorbic acid and calcitriol led to the decreased levels of IL-13 (50.5 +- 1.85 vs. 42.13 +- 0.37 pg/mL, p = 0.02) and IgE (58.74 +- 0.43 vs. 45.78 +- 2.05 ng/mL, p = 0.003) as well as the reduction of goblet hyperplasia and subepithelial fibrosis (5 vs. 1 score, p = 0.001 and 5 vs. 2 score, p = 0.001, respectively).Discussion and conclusions: Combination of ascorbic acid with calcitriol in ineffective doses improves airway remodelling due to additive effects possibly through reduction of oxidative stress and inflammation.	Calcitriol	240-250	interleukin 13	Mus musculus	282-287
33244669-2	2021	Results showed that compared with the control group, no differential expression proteins (DEPs) were found in the 1 mmol/L fluoride group; however, eight DEPs were upregulated in the 2.5 mmol/L fluoride group, including macrophage inflammatory protein-3alpha (MIP-3alpha), interleukin-21 (IL-21), IL-13, IL-17F, IL-28A, transforming growth factor type beta 1 (TGF-beta1), IL-23, and IL-17A.	Fluorides	194-202	interleukin 13	Mus musculus	297-302
33244669-3	2021	In addition, five DEPs (MIP-3alpha, IL-13, IL-21, TGF-beta1, and IL-17F) were upregulated in the 2.5 mmol/L fluoride group compared with the 1 mmol/L fluoride group.	Fluorides	108-116	interleukin 13	Mus musculus	36-41
33182035-8	2020	In ovalbumin (OVA)-administered asthmatic mice, THCA exerted inhibitory activity on IL-5, IL-13, and MCP-1 in bronchoalveolar lavage fluid (BALF) and on OVA-specific immunoglobulin E (IgE) in serum.	thca	48-52	interleukin 13	Mus musculus	90-95
32487782-6	2020	DNCB-induced increase of lymph nodes sizes and elevated inflammatory cytokines (IL-4, IL-13, IL-17, and IFN-gamma) in lymph nodes were also significantly reduced by the JTE-013 treatment.	Dinitrochlorobenzene	0-4	interleukin 13	Mus musculus	86-91
32487782-6	2020	DNCB-induced increase of lymph nodes sizes and elevated inflammatory cytokines (IL-4, IL-13, IL-17, and IFN-gamma) in lymph nodes were also significantly reduced by the JTE-013 treatment.	JTE 013	169-176	interleukin 13	Mus musculus	86-91
32491281-10	2020	In the asthma model, ISO, in combination with DEX, showed an additive inhibitory effect on AHR, inflammation, and the number of activated MCs in the lungs and decreased the levels of interleukin (IL)-4, IL-5, IL-6, IL-13, tumor necrosis factor (TNF)-a, and C-C motif chemokine ligand (CCL)-2 in bronchoalveolar lavage fluid.	isoimperatorin	21-24	interleukin 13	Mus musculus	215-220
33182052-0	2020	4-Carvomenthenol ameliorates the murine combined allergic rhinitis and asthma syndrome by inhibiting IL-13 and mucus production via p38MAPK/NF-kappaB signaling pathway axis.	4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol	0-16	interleukin 13	Mus musculus	101-106
33182052-8	2020	We analyzed the allergic rhinitis signals as nasal frictions and sneezing and observed that carvo decreased these two signals as well as serum OVA-specific IgE titer, type 2 cytokine synthesis, mainly IL-13, with increasing of IL-10 production.	4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol	92-97	interleukin 13	Mus musculus	201-206
32491281-10	2020	In the asthma model, ISO, in combination with DEX, showed an additive inhibitory effect on AHR, inflammation, and the number of activated MCs in the lungs and decreased the levels of interleukin (IL)-4, IL-5, IL-6, IL-13, tumor necrosis factor (TNF)-a, and C-C motif chemokine ligand (CCL)-2 in bronchoalveolar lavage fluid.	Dexamethasone	46-49	interleukin 13	Mus musculus	215-220
33178840-7	2020	In the treatment of BPD with dexamethasone, the number of ILC2s and M2 macrophages and levels of IL-4 and IL-13 decreased with remission as compared to the control group.	Dexamethasone	29-42	interleukin 13	Mus musculus	106-111
32519269-6	2020	RA treatment greatly diminished the number of inflammatory cells; decreased IL-4, IL-5, and IL-13 production; increased IFN-gamma secretion; significantly downregulated ROS production; and markedly upregulated the activities of SOD, GPx, and CAT.	rosmarinic acid	0-2	interleukin 13	Mus musculus	92-97
32717226-10	2020	In OVA-sensitized animals, dehydrodieugenol reduced lung inflammatory cell numbers and the lung concentrations of IL-4, IL-13, IL-17, and IL-10.	dehydrodieugenol	27-43	interleukin 13	Mus musculus	120-125
32855679-10	2020	IL-37 administration also decreased the number of eosinophils in the nasal mucosa and the thickness of the nasal mucosa, as well as the serum and nasal lavage fluid levels of IgE, IgG1, IgG2a, IL-4, IL-13, IL-17a and CCL11, but the level of IFN-gamma decreased.	il-37	0-5	interleukin 13	Mus musculus	199-204
33165354-6	2020	In the present study, we showed that asatone could protect mice against OVA-induced asthma, as manifested by attenuating inflammation infiltration, mucus production, and airway hyperreactivity and suppressing the elevation of IL-4, IL-5, and IL-13 in broncho-alveolar lavage fluid.	ASATONE	37-44	interleukin 13	Mus musculus	242-247
32693359-6	2020	Real-time results demonstrated that pro/anti-inflammatory cytokine genes expression was reversed in IL-11, 13-hADSCs treatment group in comparison to the untreated EAE group.Expression of IL-11 as a neurotrophic cytokine and IL-13 as an anti-inflammatory cytokine by hADSCs could increase the immunomodulatory and neuroprotective effects of hADSCs and be a powerful candidate in stem cell therapy for future treatment of MS.	13-hadscs	107-116	interleukin 13	Mus musculus	225-230
32700747-13	2020	It was also observed that osthole significantly inhibited the release of Th2-type cytokines (IL-4, IL-5 and IL-13) and upregulated the IFN-gamma level in BALF.	osthol	26-33	interleukin 13	Mus musculus	108-113
32619677-7	2020	In BALB/c, PNU-282987 treatment reduced the number of eosinophils in the blood, BAL fluid, and around airways, and also decreased pulmonary levels of IL-4,IL-13,IL-17, and IgE in the serum of OVA-exposed mice.	PNU-282987	11-21	interleukin 13	Mus musculus	155-160
32915886-5	2020	The expressions of Th2 cytokines including IL-5 and IL-13 were decreased in neonatal mice from ROFA-exposed mothers fed B. breve M-16V.	rofa	95-99	interleukin 13	Mus musculus	52-57
32964057-10	2020	OVA and BPA coexposure significantly increased IL-4 and IL-13 protein levels compared to those after OVA exposure alone.	bisphenol A	8-11	interleukin 13	Mus musculus	56-61
33205009-5	2020	Oxazolone also induces Il4/Il13 expression in newly infiltrating basophils, and Il4ra and Ccl24, most prominently in APCs.	Oxazolone	0-9	interleukin 13	Mus musculus	27-31
32087283-6	2020	Moreover, DHT also regulated the mRNA levels of the anti-inflammatory cytokines IL-10 and IL-13 in the brain.	Dihydrotestosterone	10-13	interleukin 13	Mus musculus	90-95
32894174-9	2020	The attenuated phospho-p65 protein levels and the mRNA levels of pro-inflammatory cytokines (IL-6, IL-12 and TNF-alpha) were observed in the livers from fucoidan-treated S. japonicum-infected mice; however, the mRNA levels of anti-inflammatory cytokines (IL-4 and IL-13) were increased.	fucoidan	153-161	interleukin 13	Mus musculus	264-269
32894174-13	2020	Additionally, fucoidan promoted the mRNA levels of IL-4 and IL-13 in macrophages.	fucoidan	14-22	interleukin 13	Mus musculus	60-65
32276028-6	2020	rs145868092 is a leucine to phenylalanine substitution in IL13RA1 affecting a residue critical for IL-13 binding.	Leucine	17-24	interleukin 13	Mus musculus	99-104
32276028-6	2020	rs145868092 is a leucine to phenylalanine substitution in IL13RA1 affecting a residue critical for IL-13 binding.	Phenylalanine	28-41	interleukin 13	Mus musculus	99-104
33013383-6	2020	In OVA-induced asthmatic mice, FMT treatments significantly ameliorated lung function, alleviated lung inflammation including infiltration of inflammatory cells, the elevated levels of interleukin (IL)-4, IL-5, and IL-13, immunoglobulin (Ig) E, C-C motif chemokine ligand 5 (CCL5, also known as RANTES), CCL11 (also called Eotaxin-1), and IL-17A.	formononetin	31-34	interleukin 13	Mus musculus	215-220
32768968-7	2020	PA reduced the relative mRNA expression of PAR-2, TNF-alpha, IL-4 and IL-13 in the cells.	Protactinium	0-2	interleukin 13	Mus musculus	70-75
32768968-10	2020	PA dose-dependently reduced serum IgE and TNF-alpha concentrations and the mRNA expression of TNF-alpha, IL-4, and IL-13 in dorsal skin.	Protactinium	0-2	interleukin 13	Mus musculus	115-120
32279475-8	2020	Treatment with 4-CMTB reduced DNCB-induced increases in Th2 cytokine (IL-4 and IL-13) levels in the ears, but did not alter Th1 or Th17 cytokine (IFN-gamma and IL-17) levels.	4-CMTB	15-21	interleukin 13	Mus musculus	79-84
32625168-14	2020	Additionally, flunisolide effectively suppressed the responses of proliferation and MCP-1/CCL-2 production from IL-13 stimulated lung fibroblasts from silica- or saline-challenged mice.	flunisolide	14-25	interleukin 13	Mus musculus	112-117
32625168-14	2020	Additionally, flunisolide effectively suppressed the responses of proliferation and MCP-1/CCL-2 production from IL-13 stimulated lung fibroblasts from silica- or saline-challenged mice.	Silicon Dioxide	151-157	interleukin 13	Mus musculus	112-117
32617136-9	2020	The BALF from the mice treated with Bilsaan showed significantly lower levels of IL-4, IL-5, IL-13, and IgE.	bilsaan	36-43	interleukin 13	Mus musculus	93-98
32526223-7	2020	Moreover, Tregs effectively expanded the number of ILC2s and increased their production of IL-13 in vivo and in vitro.	tregs	10-15	interleukin 13	Mus musculus	91-96
32526223-10	2020	These results show that Tregs may play a partial protective role against atherosclerosis by expanding the number of ILC2s and consequently increasing IL-13 production.	tregs	24-29	interleukin 13	Mus musculus	150-155
32477356-5	2020	Interestingly, Il13 but not Il4 or Il5 gene expression in the lungs was dramatically decreased in HDME-exposed Cd2 -/- mice.	hdme	98-102	interleukin 13	Mus musculus	15-19
32477356-7	2020	Consistently, gene expression of microRNAs regulating mucin production, inflammation, airway smooth muscle cell proliferation and IL-13 transcripts were increased in the lungs of HDME-exposed Cd2 -/- mice.	hdme	179-183	interleukin 13	Mus musculus	130-135
32279475-8	2020	Treatment with 4-CMTB reduced DNCB-induced increases in Th2 cytokine (IL-4 and IL-13) levels in the ears, but did not alter Th1 or Th17 cytokine (IFN-gamma and IL-17) levels.	Dinitrochlorobenzene	30-34	interleukin 13	Mus musculus	79-84
32355002-2	2020	We found that the type 2 cytokine interleukin-13 (IL-13) is induced in exercising muscle, where it orchestrates metabolic reprogramming that preserves glycogen in favor of fatty acid oxidation and mitochondrial respiration.	Glycogen	151-159	interleukin 13	Mus musculus	34-48
32185800-3	2020	Rbs contributed to the decrease of inflammatory cytokines (TNF-alpha, IL-13, IL-6, IL-5, and IL-4) inside the BALF of mice with asthma.	rubusoside	0-3	interleukin 13	Mus musculus	70-75
32301489-12	2020	Moreover, NAD+ treatment up-regulated the expressions of IL-13 and down-regulated the expression of IFN-gamma and IL-17.	NAD	10-14	interleukin 13	Mus musculus	57-62
32355536-0	2020	Effects of tristetraprolin on doxorubicin (adriamycin)-induced experimental kidney injury through inhibiting IL-13/STAT6 signal pathway.	Doxorubicin	30-41	interleukin 13	Mus musculus	109-114
32355536-0	2020	Effects of tristetraprolin on doxorubicin (adriamycin)-induced experimental kidney injury through inhibiting IL-13/STAT6 signal pathway.	Doxorubicin	43-53	interleukin 13	Mus musculus	109-114
32355536-11	2020	DOX significantly reduced TTP expression, stimulated IL-13/STAT6 pathway and elevated the levels of several factors related to renal injury, including inflammatory response, oxidative stress and cell apoptosis, which were significantly restored by the treatment of overexpression TTP in vitro.	Doxorubicin	0-3	interleukin 13	Mus musculus	53-58
32014718-15	2020	Furthermore low-dose aspirin treatment showed the modest attenuation of the selected Th2 cytokines, IL-10 and IL-13 when compared to low-dose aspirin with metformin (P < 0.01).	Aspirin	21-28	interleukin 13	Mus musculus	110-115
32355002-2	2020	We found that the type 2 cytokine interleukin-13 (IL-13) is induced in exercising muscle, where it orchestrates metabolic reprogramming that preserves glycogen in favor of fatty acid oxidation and mitochondrial respiration.	Glycogen	151-159	interleukin 13	Mus musculus	50-55
32355002-2	2020	We found that the type 2 cytokine interleukin-13 (IL-13) is induced in exercising muscle, where it orchestrates metabolic reprogramming that preserves glycogen in favor of fatty acid oxidation and mitochondrial respiration.	Fatty Acids	172-182	interleukin 13	Mus musculus	34-48
32355002-2	2020	We found that the type 2 cytokine interleukin-13 (IL-13) is induced in exercising muscle, where it orchestrates metabolic reprogramming that preserves glycogen in favor of fatty acid oxidation and mitochondrial respiration.	Fatty Acids	172-182	interleukin 13	Mus musculus	50-55
32355002-4	2020	By contrast, enhanced muscle IL-13 signaling was sufficient to increase running distance, glucose tolerance, and mitochondrial activity similar to the effects of exercise training.	Glucose	90-97	interleukin 13	Mus musculus	29-34
32410852-3	2020	We have previously shown that the T helper- (Th-) type 2 cytokines, Interleukin- (IL-) 4 and IL-13, mediate CD4+ T cell- or B cell-driven inflammation in the oxazolone-induced mouse model of ulcerative colitis.	Oxazolone	158-167	interleukin 13	Mus musculus	93-98
31757675-4	2020	Arginine supplementation significantly increased (P &lt; 0.05) cytokines expression in mouse ileal associated with T cell-dependent and T cell-independent pathways of SIgA induction, including IL-5, IL-6, IL-13, transforming growth factor (TGF-)beta2, TGF-beta3, TGF-betaR2, a proliferation-inducing ligand (APRIL), B cell-activating factor (BAFF), vasoactive intestinal peptide (VIP) receptor, and retinal dehydrogenases.	Arginine Vasopressin	0-8	interleukin 13	Mus musculus	205-250
31909648-7	2020	In vivo study showed that CuInS2/ZnS QDs increased the levels of IL-4 on day 1 and enhanced the levels of IL-10 and IL-13 on day 28 in mice.	cupric sulfide	26-32	interleukin 13	Mus musculus	116-121
31909648-7	2020	In vivo study showed that CuInS2/ZnS QDs increased the levels of IL-4 on day 1 and enhanced the levels of IL-10 and IL-13 on day 28 in mice.	Zinc	33-36	interleukin 13	Mus musculus	116-121
31724257-4	2020	HA treatment also reduced the levels of interleukin (IL)-5 and IL-13 in BALF and of OVA-specific immunoglobulin E in the serum compared with asthmatic control.	p-coumaric acids	0-2	interleukin 13	Mus musculus	63-68
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	interleukin 13	Mus musculus	107-112
32281499-7	2020	While AgNP exposure increased TNF-alpha, CXCL1, TGF-beta, HO-1, and IL-4 expression within healthy mouse spleens, MetS-treated animals demonstrated decreased CXCL1, IL-4, and IL-13 expression.	agnp	6-10	interleukin 13	Mus musculus	175-180
32161331-6	2020	Moreover, serum IgE and Th2 cytokines including IL-4 and IL-13 were decreased by nintedanib treatment.	nintedanib	81-91	interleukin 13	Mus musculus	57-62
32009324-15	2020	Treatment with resveratrol, a candidate drug against osteitis, diminished the expression of IL-13 and RUNX2, and the number of osteoblasts in OVA/SEB-treated mice.	resveratrol	15-26	interleukin 13	Mus musculus	92-97
32078753-4	2020	The sensitizing capacity of EC was also reduced in the BALB/c mouse model, which showed the significantly decreased levels of specific IgE, IgG, IgG1 and IgG2a, mMCP-1 and histamine in the mouse sera, as well as cytokine secretions of IL-4, IL-5, and IL-13, compared with the raw egg (RE) group.	ec	28-30	interleukin 13	Mus musculus	251-256
32220191-11	2020	Compared to the asthma model group, treatment with hydrogen significantly decreased the levels of IL-4 and IL-13 and increased the level of IFN-gamma in BALF ( P<0.05).	Hydrogen	51-59	interleukin 13	Mus musculus	107-112
31630176-8	2020	Although several prostaglandin (PG) derivatives are known to be ligands for PPARgamma, treatment with a COX inhibitor, acetyl salicylic acid, upregulated the IgE-mediated increase of Il13, Tnf, and Ptgs2 mRNA levels in a synergistic manner with PPARgamma siRNA.	Prostaglandins	32-34	interleukin 13	Mus musculus	183-187
31630176-8	2020	Although several prostaglandin (PG) derivatives are known to be ligands for PPARgamma, treatment with a COX inhibitor, acetyl salicylic acid, upregulated the IgE-mediated increase of Il13, Tnf, and Ptgs2 mRNA levels in a synergistic manner with PPARgamma siRNA.	Salicylic Acid	119-140	interleukin 13	Mus musculus	183-187
32166661-6	2020	And EGCG exerted obvious anti-inflammatory effects, which was manifested by alleviating microglia activation, decreasing pro-inflammatory cytokine (IL-1beta) and increasing anti-inflammatory cytokines (IL-10, IL-13).	epigallocatechin gallate	4-8	interleukin 13	Mus musculus	209-214
32410852-9	2020	These results suggest that IL-4/IL-13 signalling through IL-4Ralpha on nonhematopoietic intestinal epithelial or smooth muscle cells and hematopoietic macrophage/neutrophils has a redundant role in driving acute oxazolone colitis.	Oxazolone	212-221	interleukin 13	Mus musculus	32-37
31825972-8	2019	Two murine DC-SIGN-like family members, SIGNR3 and SIGNR5, were upregulated by IL-4/IL-13 in murine macrophages, but only SIGNR3 enhanced virus infection in a mannan-inhibited manner, suggesting that murine SIGNR3 plays a similar role to human DC-SIGN.	Mannans	159-165	interleukin 13	Mus musculus	84-89
31579973-0	2020	LPS induces steroid-resistant exacerbations in a mouse model of allergic airway disease collectively through IL-13 and pulmonary macrophage activation.	Steroids	12-19	interleukin 13	Mus musculus	109-114
31579973-8	2020	Depletion of pulmonary macrophages by administration of 2-chloroadenosine into the lungs suppressed AHR and reduced IL-13, TNFalpha and IFNgamma expression.	2-Chloroadenosine	56-73	interleukin 13	Mus musculus	116-121
32865913-5	2020	The observed results revealed that the levels of inflammatory cells including neutrophils, eosinophils, lymphocytes, and macrophages were effectively decreased by betulin treatment; furthermore, the inflammatory markers IL-4, IL-5, IL-13, and TNF-alpha levels were notably suppressed by betulin administration in OVA-challenged asthmatic mice.	betulin	163-170	interleukin 13	Mus musculus	232-237
31572383-8	2019	Budesonide inhibited airway hyperreactivity, eosinophil counts in the lung and bronchoalveolar lavage (BAL) and CCL11, IL-13, and IL-23p19 release in the BAL of mice sensitized and challenged with Af (p < 0.05).	Budesonide	0-10	interleukin 13	Mus musculus	119-124
31448678-3	2019	We examined the effect of LH2171 on cytokine production by antigen-stimulated murine naive splenocytes in vitro and demonstrated that it inhibited IL-4 and IL-13 production while enhancing IFN-gamma and IL-10 production.	lh2171	26-32	interleukin 13	Mus musculus	156-161
31106564-11	2019	Finally, ST2 deficiency diminished the bleomycin-induced B7H3 and IL-13 upregulation, suggesting a role for type 2 innate lymphoid cells (ILC2).	Bleomycin	39-48	interleukin 13	Mus musculus	66-71
31614422-9	2019	Additionally, NT reduced levels of IL-13 and TNF-alpha in BALF and IL-17A, IL12p40, RANTES, mouse mast cell protease and malondialdehyde in lung homogenates.	Neurotensin	14-16	interleukin 13	Mus musculus	35-40
31636619-7	2019	TSA administration effectively reduced the inflammatory factor levels of iNOS, TNF-alpha, IL-5, IL-6, and IL-13 in infected mice.	trichostatin A	0-3	interleukin 13	Mus musculus	106-111
33911646-11	2019	Concentrations of tissue IL-13 and IL-17 decreased after GlcN administration (each group: p=0.002 and p<0.001, respectively), but the concentrations of tissue IL-4 did not show differences across groups.	Glucosamine	57-61	interleukin 13	Mus musculus	25-30
33911646-14	2019	Conclusion: GlcN improved AD symptoms and decreased tissue IL-13, IL-17, and serum total IgE levels in an animal model.	Glucosamine	12-16	interleukin 13	Mus musculus	59-64
31240852-7	2019	Exposure to m-xylene increased the total number of inflammatory cells and the production of interleukin (IL)-4, IL-5, IL-13, and immunoglobulin E related to the Th2 immune response.	3-xylene	12-20	interleukin 13	Mus musculus	118-123
31526941-7	2019	In addition, cytokine expression analysis indicated significant (p > 0.05) elevation in levels of IFN-gamma, IL-2, IL-12, IL-13 and IL-17 in NATG pre-treated irradiated mice in comparison to radiation alone group.	N-acetyl tryptophan-glucopyranoside	141-145	interleukin 13	Mus musculus	122-127
31611798-6	2019	t-TUCB significantly inhibited allergen-induced IL-4 and IL-13, while a less pronounced reduction was noted with PTUPB and celecoxib.	4-(4-(3-(4-trifluoromethoxy-phenyl)ureido)cyclohexyloxy)benzoic acid	0-6	interleukin 13	Mus musculus	57-62
31804564-4	2019	Resveratrol suppressed IL-33-induced IL-6, IL-13, and TNF-alpha production in mouse bone marrow-derived mast cells (BMMCs), mouse fetal skin-derived mast cells, and human basophils.	resveratrol	0-11	interleukin 13	Mus musculus	43-48
31545206-5	2019	TBBPA upregulated the expression of pro-inflammatory cytokines, including IL-1beta, IL-6, and TNF-alpha, whereas it attenuated the LPS-stimulated expression of these pro-inflammatory cytokines, and the expression of anti-inflammatory cytokines, including IL-4, IL-10, and IL-13.	tetrabromobisphenol A	0-5	interleukin 13	Mus musculus	272-277
31970023-11	2019	Results: Among various fractions of AT, the ethyl acetate fraction of AT (EAT) showed the most significant suppressive effect on the mRNA expression of M2 macrophage markers, including arginase-1, interleukin (IL)-10 and mannose receptor C type 1 (MRC-1), up-regulated by treatment of IL-4 and IL-13.	ethyl acetate	44-57	interleukin 13	Mus musculus	294-299
31710085-4	2019	The increased number of inflammatory cells infiltrating the lung tissue, and the elevated levels of tumor necrosis factor-alpha and interleukin-13 were all decreased after sevoflurane treatment (all P &amp;lt; 0.05).	sevoflurane	172-183	interleukin 13	Mus musculus	132-146
30102994-14	2019	RESULTS: The treatment with E. mulungu extract significantly reduced bronchial hyperresponsiveness, significantly reduced the number of leukocytes, eosinophils, and lymphocytes in BAL, and significantly decreased the levels of IL-4 and IL-5, while increased levels of IL-13 and INF-gamma.	mulungu extract	31-46	interleukin 13	Mus musculus	268-273
31344274-8	2019	Acetylshikonin attenuated manifestation of nasal symptoms in sensitized mice and inhibited production of Th2-related OVA-specific IgE, IgG1, and Th2 cell-produced IL-4, IL-5, IL-13, and mast cell produced histamine; however, it had no effect on Th1 cell-produced cytokines, like INF-gamma.	acetylshikonin	0-14	interleukin 13	Mus musculus	175-180
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	U 0126	128-133	interleukin 13	Mus musculus	66-71
31555361-7	2019	Compared with the SCF single stimulation group, the production of IL-13 was significantly reduced in P815 cells stimulated with U0126 (ERK-MEK/pathway inhibitor) or H-89 (CREB inhibitor) combined with SCF stimulation group (P&lt;0.01).	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	165-169	interleukin 13	Mus musculus	66-71
31695569-15	2019	Conclusion: fRG and ginsenoside Rd may alleviate AR by suppressing IgE, IL-4, IL-5, and IL-13 expression and restoring the composition of gut microbiota.	ginsenoside Rd	20-34	interleukin 13	Mus musculus	88-93
31372938-5	2019	Systemic administration of IL-13 immediately after the ischemic insult significantly reduced the lesion volume, alleviated the infiltration of CD45+ leukocytes, and promoted the microglia/macrophage alternative activation within the ischemic region, as determined by arginase 1 (Arg1) immunoreactivity at 3 days post-ischemia (dpi).	3-aminodiphenyleneiodium	327-330	interleukin 13	Mus musculus	27-32
31572383-10	2019	O3 stimulated release of pro-neutrophilic mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of budesonide on CCL11, IL-13 and IL-23.	Ozone	0-2	interleukin 13	Mus musculus	154-159
31572383-10	2019	O3 stimulated release of pro-neutrophilic mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of budesonide on CCL11, IL-13 and IL-23.	Budesonide	133-143	interleukin 13	Mus musculus	154-159
31121415-10	2019	Furthermore, treatment of TAK-242 ameliorated lower airway symptoms including decreasing the frequency of CD45+SiglecF+CD11b+CD11c- eosinophils in BALF and IL13+ Th2 cells in the lungs.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	26-33	interleukin 13	Mus musculus	156-160
30741559-8	2019	Analyses of BAL fluid proteins indicated increased levels of transforming growth factor (TGF)-beta and the TGF-beta pathway mediator IL-13 in PPARgamma-KO mice that received MWCNT + ESAT-6 compared with wild-type or PPARgamma-KO mice that received MWCNT.	mwcnt	174-179	interleukin 13	Mus musculus	133-138
31043056-9	2019	These cells were induced to produce more IL-5 and IL-13 by rmIL-33.	rmil	59-63	interleukin 13	Mus musculus	50-55
31813873-8	2019	The treatment of spicatoside A in asthmatic mice significantly decreased the production of allergic mediator, OVA-specific IgE and Th2 cytokines, IL-4, IL-5 and IL-13 in sera and BALF.	5-(1-(glucopyranosyloxymethyl)ethenyl)-2-methyl-2-cyclohexen-1-one	17-30	interleukin 13	Mus musculus	161-166
31059793-7	2019	Cell numbers, IL-4, IL-5, and IL-13 levels in broncho-alveolar lavage fluid and serum IgE content were reduced significantly after administration of AGNP compared to free-AG treatment.	agnp	149-153	interleukin 13	Mus musculus	30-35
30702923-6	2019	Aspergillus antigen-challenged, doxycycline (DOX)-treated CC10-IL-15 transgenic mice exhibited decreased collagen accumulation, profibrotic cytokine (IL-13 and TGF-beta1) expression, and alpha-SMA+ and FSP1+ cells compared with IL-15-overexpressing mice not treated with DOX.	Doxycycline	45-48	interleukin 13	Mus musculus	150-155
31296924-5	2019	Numbers of Tregs and IFN-gamma+, IL-13+ and IL-17A+ CD4+ T helper (Th) cells in mesenteric lymph nodes increased during chronic DSS administration and mRNA for IFN-gamma and IL-17 in the inflamed colon tissue was upregulated.	dss	128-131	interleukin 13	Mus musculus	33-38
31373871-6	2019	Conditioned media from irradiated or 12S-HETE-treated primary pneumocytes contained elevated levels of IL-4 and IL-13 compared to untreated pneumocytes.	12(S)-HETE	37-45	interleukin 13	Mus musculus	112-117
31370242-6	2019	BCP significantly hampered the severity of the disease, reduced relevant pro-inflammatory cytokines, and increased the anti-inflammatory cytokine IL-13.	caryophyllene	0-3	interleukin 13	Mus musculus	146-151
31328158-4	2019	Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS).	Oxazolone	167-176	interleukin 13	Mus musculus	65-70
31328158-4	2019	Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS).	Oxazolone	167-176	interleukin 13	Mus musculus	111-116
30986521-3	2019	AIM OF THE STUDY: Our previous work showed that DZP suppresses CCl-4 induced hepatic fibrosis by downregulating the expression of interleukin-13.	Cefaclor	63-66	interleukin 13	Mus musculus	130-144
29600329-8	2019	The increased AHR was paralleled by increased BAL eosinophils, IL-5 and IL-13 production, and an enhanced ex vivo splenocyte activation in the ATI-fed groups.	4-Amino-2,2,5,5-tetramethyl-3-imidazoli-ne-1-yloxyl free radical	143-146	interleukin 13	Mus musculus	72-77
30797786-5	2019	Administration of candesartan and irbesartan decreased the number of immune cells in the bronchoalveolar lavage fluid and reduced the expression of Th2 (IL-4, IL-5, and IL-13) and Th1 cytokines (IL-2 and IFN-gamma) in the lung tissues of mice with ovalbumin-induced allergic asthma.	candesartan	18-29	interleukin 13	Mus musculus	169-174
30797786-5	2019	Administration of candesartan and irbesartan decreased the number of immune cells in the bronchoalveolar lavage fluid and reduced the expression of Th2 (IL-4, IL-5, and IL-13) and Th1 cytokines (IL-2 and IFN-gamma) in the lung tissues of mice with ovalbumin-induced allergic asthma.	Irbesartan	34-44	interleukin 13	Mus musculus	169-174
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	dehydroxymethylepoxyquinomicin	5-10	interleukin 13	Mus musculus	137-142
30702923-6	2019	Aspergillus antigen-challenged, doxycycline (DOX)-treated CC10-IL-15 transgenic mice exhibited decreased collagen accumulation, profibrotic cytokine (IL-13 and TGF-beta1) expression, and alpha-SMA+ and FSP1+ cells compared with IL-15-overexpressing mice not treated with DOX.	Doxycycline	32-43	interleukin 13	Mus musculus	150-155
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	Tacrolimus	15-25	interleukin 13	Mus musculus	137-142
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	Dinitrochlorobenzene	35-39	interleukin 13	Mus musculus	137-142
30537633-9	2019	Administration of salvianolic acid A and tanshinone IIA reduced the expression and secretion of Th2 cytokines (IL-4 and IL-13) in the bronchoalveolar lavage fluid and lung tissues of mice with ovalbumin-induced allergic asthma.	salvianolic acid A	18-36	interleukin 13	Mus musculus	120-125
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	interleukin 13	Mus musculus	255-260
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	lys-asa	67-74	interleukin 13	Mus musculus	255-260
31019244-5	2019	The inhibitory action of glucagon occurred in parallel with reduction of OVA-induced generation of IL-4, IL-5, IL-13, TNF-alpha, eotaxin-1/CCL11, and eotaxin-2/CCL24 but not MDC/CCL22 and TARC/CCL17.	Glucagon	25-33	interleukin 13	Mus musculus	111-116
30660871-6	2019	We found that Cy-3-g significantly inhibited OVA-induced inflammatory cell infiltration and mucus hyper-production in lung tissues, reduced the production of interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) in BALF.	cyanidin-3-o-glucoside	14-20	interleukin 13	Mus musculus	205-219
30660871-6	2019	We found that Cy-3-g significantly inhibited OVA-induced inflammatory cell infiltration and mucus hyper-production in lung tissues, reduced the production of interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) in BALF.	cyanidin-3-o-glucoside	14-20	interleukin 13	Mus musculus	221-226
31011288-9	2019	IL-13 and MIP-1beta showed higher levels in the MI/R serum at day 14 than at day 7. mRNA levels of IL-4, IL-6, IL-13, and IL-27 were increased in the day 7 group compared to the sham, while MIP-1beta, MCP-3, and GRO-alpha mRNA levels showed no significant difference between the MI/R and sham groups in blood mononuclear cells.	r	51-52	interleukin 13	Mus musculus	0-5
30326727-1	2019	Chemoattractant receptor homologous with T-helper cell type 2 cells (CRTH2), a receptor for prostaglandin D2, is preferentially expressed on T-helper cell type 2 lymphocytes, group 2 innate lymphoid cells, eosinophils, and basophils, and elicits the production of type 2 cytokines, including profibrotic IL-13.	Prostaglandin D2	92-108	interleukin 13	Mus musculus	304-309
30474283-4	2019	As a result, the Syringic acid treatment was found to suppress the inflammatory cells; eosinophil, neutrophil, macrophage, lymphocyte, and other inflammatory markers including IL-4, IL-5, IL-13, and TNF-alpha in the BALF of OVA-induced asthmatic mice.	syringic	17-25	interleukin 13	Mus musculus	188-193
30736391-5	2019	BV2 murine microglia cells treated with both Abeta25-35 peptide and extract showed a lower pro-inflammatory (IL-6, IL-1beta, TNF-alpha) and a higher anti-inflammatory (IL-4, IL-10, IL-13) cytokine production compared to cells treated with Abeta only.	abeta25-35 peptide	45-63	interleukin 13	Mus musculus	181-186
30874868-5	2019	RESULTS: In mice with AR, AST2017-01 and chrysophanol markedly decreased number of rubs, IgE, histamine, thymic stromal lymphopoietin, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-4, IL-5, and IL-13 in serum or nasal mucosa tissues.	chrysophanic acid	41-53	interleukin 13	Mus musculus	204-209
30991656-7	2019	DA treatment effectively inhibited methacholine responsiveness, inflammatory cell infiltration, proinflammatory cytokines such as interleukin (IL)-5 and IL-13, and immunoglobulin (Ig) E in OVA-induced asthma model.	amsonic acid	0-2	interleukin 13	Mus musculus	153-158
29914792-9	2019	The effect of simvastatin and BMSCs combination therapy on serum specific IgE levels as well as lung IL-13 and TGF-beta levels were significantly higher than the effect of BMSCs and simvastatin alone (P &lt; 0.001 for IL-13 and P &lt; 0.01 for other cases).	Simvastatin	14-25	interleukin 13	Mus musculus	218-223
30661601-9	2019	Montelukast predominantly diminished the cell count, while clopidogrel potently inhibited the release of interleukin (IL)-4, IL-5, and IL-13.	Clopidogrel	59-70	interleukin 13	Mus musculus	135-140
30761137-8	2019	In addition, propionate was found to negatively impact in vitro differentiation of IL-13-expressing T cells.	Propionates	13-23	interleukin 13	Mus musculus	83-88
30339498-12	2019	NEW &amp; NOTEWORTHY Here, we demonstrate, for the first time, that IL-13 is involved in neonatal cardiomyocyte cell cycle activity and heart regeneration in vivo.	Adenosine Monophosphate	5-8	interleukin 13	Mus musculus	68-73
29914792-8	2019	However, IL-13 and TGF-beta levels were significantly decreased by BMSCs and BMSC + simvastatin combination therapy (P &lt; 0.05 for all cases).	Simvastatin	84-95	interleukin 13	Mus musculus	9-14
29914792-10	2019	CONCLUSIONS: Simvastatin and BMSCs combination therapy affects serum IgE as well as lung IL-13 and TGFbeta levels more than BMSC therapy and simvastatin therapy alone which may be due to increased BMSCs migration into the lung tissue.	Simvastatin	13-24	interleukin 13	Mus musculus	89-94
30260499-7	2019	CS-exposed Rorafl/fl Il7rCre mice were protected from emphysema, but had increased IL-33/IL-13 expression and collagen deposition compared to WT CS-exposed mice.	Cesium	0-2	interleukin 13	Mus musculus	89-94
30713573-7	2019	Further studies indicated that SHL suppressed SP-elevated mouse mast cell protease-1 and IgE levels, prevented Th2 differentiation in mediastinal lymph nodes, and lowered Th2 cytokine (e.g., IL-4, IL-5, and IL-13) production in BALF.	sp	46-48	interleukin 13	Mus musculus	207-212
31234191-13	2019	COS treatment reduced Th2 cytokine (IL-4, IL-5, and IL-13) levels and increased the Th1 cytokine (IFN-gamma) level (p &lt; 0.05).	carbonyl sulfide	0-3	interleukin 13	Mus musculus	52-57
30599892-7	2019	Although curcumin treatment markedly reduced the interleukin (IL)-4 and IL-13 in serum and spleen, the elevated IL-17A did not decrease.	Curcumin	9-17	interleukin 13	Mus musculus	72-77
30417508-9	2019	Cercarial exposure, compared to no exposure, resulted in increased serum, IL-1alpha, IL-13 and TGF-beta in bladder egg-injected mice.	cercarial	0-9	interleukin 13	Mus musculus	85-90
30574690-9	2019	AHR and levels of interleukin (IL)-4, IL-5, and IL-13 were decreased, after tiotropium administration.	Tiotropium Bromide	76-86	interleukin 13	Mus musculus	48-53
30458613-0	2018	Attenuating Effects of Nortrachelogenin on IL-4 and IL-13 Induced Alternative Macrophage Activation and on Bleomycin-Induced Dermal Fibrosis.	nortrachelogenin	23-39	interleukin 13	Mus musculus	52-57
30619345-7	2018	The data showed that resveratrol significantly reduced IL-5, IL-13, and TGF-beta in the serum and BALF in mice with OVA-induced asthma.	Resveratrol	21-32	interleukin 13	Mus musculus	61-66
30462474-7	2018	Resveratrol delivery from the scaffold augments this anti-inflammatory environment by decreasing monocyte and lymphocyte numbers at the implant site and increasing expression of IL-10 and IL-13, cytokines that promote healthy adipose tissue.	Resveratrol	0-11	interleukin 13	Mus musculus	188-193
30286334-11	2018	In conclusion; Gabapentin"s modulatory effect on IL-4, IL-13 and TNFalpha activities accounts for the observed anti-inflammatory and anti-allergic properties.	Gabapentin	15-25	interleukin 13	Mus musculus	55-60
30415164-9	2018	ALO-treated asthmatic mice also decreased the protein levels of interleukin (IL)-4, IL-5, IL-13, IFN-gamma, and IgE in BALF and attenuated AHR.	aloperine	0-3	interleukin 13	Mus musculus	90-95
30242842-3	2018	Metformin at relatively low doses was shown to suppress FcepsilonR1-mediated degranulation, IL-13, TNF-alpha and sphingosine-1-phosphate (S1P) secretion in murine bone marrow-derived mast cells (BMMCs).	Metformin	0-9	interleukin 13	Mus musculus	92-97
29522844-9	2018	RESULTS: We show that butyrate, but not acetate or propionate, inhibited IL-13 and IL-5 production by murine ILC2s.	Butyrates	22-30	interleukin 13	Mus musculus	73-78
30187827-10	2018	Following stimulation with DWF, significant differences (P &lt; 0.05) were detected in the secretion of two chemokines [granulocyte macrophage colony-stimulating factor (GMCSF) and Eotaxin], three proinflammatory cytokines (TNFalpha, IFNgamma, and IL9), and four anti-inflammatory cytokines (IL10, IL4, IL13, and IL3).	CHEMBL3287310	27-30	interleukin 13	Mus musculus	303-307
30405619-9	2018	Moreover, IL-13 concentrations were only significantly suppressed in mice treated with budesonide while fed GOS.	Budesonide	87-97	interleukin 13	Mus musculus	10-15
30291166-2	2018	In this study, we asked whether IL-4 and IL-13 signaling through the HR mobilizes other STAT molecules to shape ETP fate decision.	etp	112-115	interleukin 13	Mus musculus	41-46
30191679-11	2018	Meanwhile, gallic acid reduced IL-5 and IL-13 levels in BALF and decreased expression of IL-33 in the lungs.	Gallic Acid	11-22	interleukin 13	Mus musculus	40-45
30127087-5	2018	Using wild-type and PGI2 receptor (IP) knockout mice, we found that the PGI2 analog cicaprost dose-dependently inhibited IL-33-driven IL-4, IL-5, and IL-13 production by CD4+ T cells in an IP-specific manner.	cicaprost	84-93	interleukin 13	Mus musculus	150-155
29752146-6	2018	In addition, the PAC-14028 cream significantly inhibited cutaneous inflammation by decreasing the expression of serum IgE, and the epidermal expression of IL-4, and IL-13 in Ox-AD mice.	N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide	17-26	interleukin 13	Mus musculus	165-170
29856968-6	2018	In an AR animal model, ABT-737 significantly diminished clinical symptoms of AR and the levels of AR biomarkers, specifically IgE, histamine, hypoxia-inducible factor-1alpha, VEGF, TSLP, IL-1beta, IL-4, IL-5, IL-6, IL-13, TNF-alpha, intercellular adhesion molecule-1, and macrophage inflammatory protein-2.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	23-26	interleukin 13	Mus musculus	215-220
29894863-12	2018	Catechin could reduce the levels of interleukin-5, interleukin-13, and ovalbumin-specific immunoglobulin-E in the serum and restored the T helper type 2/T helper type 1 cell balance and also had anti-thymic stromal lymphopoietin effects.	Catechin	0-8	interleukin 13	Mus musculus	51-65
29882826-10	2018	Tiotropium bromide improved bronchoconstriction, and reduced neutrophil numbers, decreased the concentrations of IL-5, IL-6, IL-13, and KC/CXCL1 in BALF.	Tiotropium Bromide	0-18	interleukin 13	Mus musculus	125-130
29532264-7	2018	The results showed that propofol significantly decreased the number of eosinophils and the levels of IL-4, IL-5, IL-6, IL-13, and TNF-alpha in BALF.	Propofol	24-32	interleukin 13	Mus musculus	119-124
29910099-7	2018	RESULTS: Dex significantly suppressed antigen-induced NHR, inflammatory cell infiltration, and IL-4, IL-5, IL-6, and IL-13 expression in immunized mice.	Dexamethasone	9-12	interleukin 13	Mus musculus	117-122
29986831-11	2018	Collectively, these results demonstrate that flavocoxid mitigates the allergic airway inflammation induced by ovalbumin through attenuation of IL-13, NO expressions and oxidative stress.	flavocoxid	45-55	interleukin 13	Mus musculus	143-148
30025085-12	2018	Topical application of latanoprost increased CD4+ T cells infiltration, with increased production of IFN-gamma and IL-17A and decreased production of IL-13 in conjunctiva.	Latanoprost	23-34	interleukin 13	Mus musculus	150-155
29962852-11	2018	In BMMCs, adenine inhibited the LPS-induced production of TNF-alpha, IL-6 and IL-13 and also hindered phosphorylation of NF-kappaB and Akt.	Adenine	10-17	interleukin 13	Mus musculus	78-83
29890625-5	2018	We investigated: 1. the occurrence of effective sensitization to PNT by analysing acute allergic skin response, anaphylactic symptoms score, body temperature, serum mucosal mast cell protease-1 (mMCP-1) and anti-PNT immunoglobulin E (IgE) levels; 2. hepatic involvement by analysing interleukin (IL)-4, IL-5, IL-13, IL-10 and IFN-&amp;gamma; mRNA expression; 3. hepatic mitochondrial oxidation rates and efficiency by polarography, and hydrogen peroxide (H2O2) yield, aconitase and superoxide dysmutase activities by spectrophotometry.	Pentamidine	65-68	interleukin 13	Mus musculus	309-314
29910732-8	2018	Administration of BLM and DNCB increased the levels of IL-4 and IL-13 production in spleen cells and eotaxin-2 mRNA expression in dorsal skin, compared to NC/Nga mice treated with DNCB alone.	Dinitrochlorobenzene	26-30	interleukin 13	Mus musculus	64-69
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	interleukin 13	Mus musculus	85-90
29782549-8	2018	BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice.	Bleomycin	16-25	interleukin 13	Mus musculus	164-169
29494957-10	2018	PAG also reduced serum concentrations of type 2 helper T cell (Th2) cytokines (Interleukin-(IL)-4, IL-5, and IL-13) as well as histamine, mast cell protease-1 (MCP-1), and immunoglobulin (Ig)E. PAG blocked the degranulation of mast cells and infiltration of eosinophils in intestine.	pag	0-3	interleukin 13	Mus musculus	109-114
29408536-8	2018	The in vitro effect of VIP on interleukin-13-induced proliferation of ASMCs was studied by examining the effects of VIP on expression of ERK1/2, phospho-ERK1/2 and Cav-1 in ASMCs, as well as changes in cell cycle distribution.	asmcs	70-75	interleukin 13	Mus musculus	30-44
29288825-16	2018	CIC-exposed mice had significantly increased levels of both IL-9 and IL-13.	cic	0-3	interleukin 13	Mus musculus	69-74
29242277-7	2018	Lastly, recombinant IL-13 acutely increased glucose metabolism in Lyz- GRP78-/- mice.	Glucose	44-51	interleukin 13	Mus musculus	20-25
29288730-4	2018	The expression of MUC5AC, TNF-alpha, Th2 cytokines (IL-4, IL-5, and IL-13) and STAT6 was further up-regulated in OVA plus SO2 treated mice compared with OVA alone treated mice.	Sulfur Dioxide	122-125	interleukin 13	Mus musculus	68-73
29455734-6	2018	In the serum of DNFB-induced AD mice, the levels of IgE, histamine, thymic stromal lymphopoietin (TSLP), interleukin (IL)-5, and IL-13 were significantly reduced by BS treatment.	Dinitrofluorobenzene	16-20	interleukin 13	Mus musculus	129-134
29593738-3	2018	Here, we demonstrated that prostaglandin E2 (PGE2) had a profound inhibitory effect on IL-33-induced ILC2 expansion and IL-5 and IL-13 production in vitro.	Dinoprostone	27-43	interleukin 13	Mus musculus	129-134
29593738-3	2018	Here, we demonstrated that prostaglandin E2 (PGE2) had a profound inhibitory effect on IL-33-induced ILC2 expansion and IL-5 and IL-13 production in vitro.	Dinoprostone	45-49	interleukin 13	Mus musculus	129-134
29593738-5	2018	In the IL-33-induced asthma model, coadministration of PGE2 or PGE1-alcohol resulted in diminished IL-5 and IL-13 production, reduced eosinophilia and alleviated lung pathology.	Dinoprostone	55-59	interleukin 13	Mus musculus	108-113
29593738-5	2018	In the IL-33-induced asthma model, coadministration of PGE2 or PGE1-alcohol resulted in diminished IL-5 and IL-13 production, reduced eosinophilia and alleviated lung pathology.	PGE1 alcohol	63-75	interleukin 13	Mus musculus	108-113
28606589-8	2018	Doxycycline-exposed, Aspergillus species extract-challenged CC10-IL-15 bitransgenic mice exhibited significantly reduced levels of proinflammatory cytokines (IL-4, IL-5, and IL-13) and decreased goblet cell hyperplasia.	Doxycycline	0-11	interleukin 13	Mus musculus	174-179
29158156-11	2018	Administration of sesquiterpene lactones decreased the number of immune cells, particularly eosinophils, and reduced the expression and secretion of Th2 cytokines (IL-4 and IL-13) in the bronchoalveolar lavage fluid and lung tissues of mice with ovalbumin-induced allergic asthma.	sesquiterpene lactones	18-40	interleukin 13	Mus musculus	173-178
29505573-14	2018	Blockade of MR almost completely reversed the capacity of CsTPs to suppress LPS-induced BMDCs surface markers CD80, CD86 and MHC-II expression, and further made these BMDCs fail to induce a Th2-skewed response as well as Th2 cell-associated cytokines IL-13 and IL-4 release in vitro.	cstps	58-63	interleukin 13	Mus musculus	251-256
29414651-2	2018	It can be activated by inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-13, inducing calcium responses to agonist in airway smooth muscle cells (ASMC).	Calcium	119-126	interleukin 13	Mus musculus	89-108
29276972-9	2018	Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-alpha, INF-gamma, IL-6) and pro-fibrotic (IL-13 and TGF-beta) interleukins and increased the plasma levels of IL-10.	deflazacort	0-11	interleukin 13	Mus musculus	121-126
29865080-7	2018	Meanwhile, ginsenoside Rf could alleviate the Abeta-induced inflammation reaction, such as the decrease of interferon-gamma (IFN-gamma) and active caspase-1 expression and the increase of interleukin-13.	ginsenoside Rf	11-25	interleukin 13	Mus musculus	188-202
29276972-9	2018	Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-alpha, INF-gamma, IL-6) and pro-fibrotic (IL-13 and TGF-beta) interleukins and increased the plasma levels of IL-10.	omega-3	16-23	interleukin 13	Mus musculus	121-126
29066614-3	2018	In this study, we hypothesized that the inhibition of the signal transducer and activator of transcription 6 (Stat6) pathway, a common downstream signaling pathway of IL-4 and IL-13, may be an interesting strategy by which to inhibit TAM differentiation and, thus, their protumorigenic activities.	tam	234-237	interleukin 13	Mus musculus	176-181
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	interleukin 13	Mus musculus	109-114
29304038-7	2018	IL13 conjugated liposomal doxorubicin was formulated and shown to bind and internalized in the MPNST cell culture model demonstrating cytotoxic effect.	Doxorubicin	26-37	interleukin 13	Mus musculus	0-4
29304038-8	2018	Our subsequent in vivo investigation in the STS26T MPNST sciatic nerve tumor model indicated that IL13 conjugated liposomal doxorubicin (IL13LIPDXR) was more effective in inhibiting tumor progression compared to unconjugated liposomal doxorubicin (LIPDXR).	Doxorubicin	124-135	interleukin 13	Mus musculus	98-102
29304038-8	2018	Our subsequent in vivo investigation in the STS26T MPNST sciatic nerve tumor model indicated that IL13 conjugated liposomal doxorubicin (IL13LIPDXR) was more effective in inhibiting tumor progression compared to unconjugated liposomal doxorubicin (LIPDXR).	Doxorubicin	235-246	interleukin 13	Mus musculus	98-102
28904023-3	2018	BMDCs were stimulated with ALA, 13-OH, or 13-oxo in the presence of IL-4 or IL-13 for 24 h, and significant increases in M2 macrophage markers CD206 and Arginase-1 (Arg1) were observed.	alpha-Linolenic Acid	27-30	interleukin 13	Mus musculus	76-81
28904023-3	2018	BMDCs were stimulated with ALA, 13-OH, or 13-oxo in the presence of IL-4 or IL-13 for 24 h, and significant increases in M2 macrophage markers CD206 and Arginase-1 (Arg1) were observed.	13-oh	32-37	interleukin 13	Mus musculus	76-81
28904023-3	2018	BMDCs were stimulated with ALA, 13-OH, or 13-oxo in the presence of IL-4 or IL-13 for 24 h, and significant increases in M2 macrophage markers CD206 and Arginase-1 (Arg1) were observed.	13-oxo	42-48	interleukin 13	Mus musculus	76-81
28874358-3	2017	Recent studies have identified a role for IL-13 in glucose metabolism, suggesting that a decoy receptor for IL-13 might increase circulating glucose levels.	Glucose	51-58	interleukin 13	Mus musculus	42-47
30352432-11	2018	The addition of IL-13 to neuronal cultures normalized the palmitate-mediated increase in IL-6 and AgRP expression, suggesting that microglia may protect surrounding neurons, at least in part, through the release of IL-13.	Palmitates	58-67	interleukin 13	Mus musculus	16-21
30352432-11	2018	The addition of IL-13 to neuronal cultures normalized the palmitate-mediated increase in IL-6 and AgRP expression, suggesting that microglia may protect surrounding neurons, at least in part, through the release of IL-13.	Palmitates	58-67	interleukin 13	Mus musculus	215-220
28798252-9	2017	The exogenous administration of the downregulated let-7b-p3 mimetic or inhibitors of upregulated miR-23a or miR-27a decreased eosinophil recruitment and mucus and collagen production via controlling the expression of IL-4, IL-5, and IL-13.	let-7b-p3	50-59	interleukin 13	Mus musculus	233-238
28874358-3	2017	Recent studies have identified a role for IL-13 in glucose metabolism, suggesting that a decoy receptor for IL-13 might increase circulating glucose levels.	Glucose	51-58	interleukin 13	Mus musculus	108-113
28802865-0	2017	Interleukin-13/interleukin-4 receptor pathway is crucial for production of Sda-sialomucin in mouse small intestinal mucosa by Nippostrongylus brasiliensis infection.	sda	75-78	interleukin 13	Mus musculus	0-14
29742501-4	2018	Furthermore, we also examined the effect of histamine on the secretion of MCP-1 and IL-13 from mast cells by ELISA.	Histamine	44-53	interleukin 13	Mus musculus	84-89
29742501-5	2018	RESULTS: The amplification of TLR3 mRNA and protein expression in mast cells was observed after incubation with histamine, which was accompanied by increasing secretion of IL-13 and MCP-1 via H1 receptor.	Histamine	112-121	interleukin 13	Mus musculus	172-177
29742501-7	2018	CONCLUSION: These results demonstrate that histamine up-regulates the expression of TLR3 and secretion of IL-13 and MCP-1 in mast cells, thus identifying a new mechanism for the histamine inducing allergic response.	Histamine	43-52	interleukin 13	Mus musculus	106-111
29742501-7	2018	CONCLUSION: These results demonstrate that histamine up-regulates the expression of TLR3 and secretion of IL-13 and MCP-1 in mast cells, thus identifying a new mechanism for the histamine inducing allergic response.	Histamine	178-187	interleukin 13	Mus musculus	106-111
29055190-8	2017	Treatment with pinocembrin significantly reduced Th2 cytokines interleukin (IL)-4, IL-5 and IL-13 in BALF, and OVA-specific IgE in serum.	pinocembrin	15-26	interleukin 13	Mus musculus	92-97
28802865-7	2017	Inoculation of recombinant IL-13 into the infected SCID mice restored expression of Sda-glycan.	sda-glycan	84-94	interleukin 13	Mus musculus	27-32
28802865-8	2017	Our results suggest that the IL-13/IL-4R axis is important for the production of Sda-sialomucins in the host intestinal mucosa with parasitic nematode infection.	sda	81-84	interleukin 13	Mus musculus	29-34
29029618-12	2017	In line, the level of inflammatory cytokines in serum such as interleukin (IL)-1beta, IL-13 and tumor necrosis factor-alpha were significantly inhibited in PHMW and DHMW groups compared to NeC group.	dhmw	165-169	interleukin 13	Mus musculus	86-123
29166590-4	2017	IL-33 promoted beta cell function through islet-resident group 2 innate lymphoid cells (ILC2s) that elicited retinoic acid (RA)-producing capacities in macrophages and dendritic cells via the secretion of IL-13 and colony-stimulating factor 2.	Tretinoin	124-126	interleukin 13	Mus musculus	205-242
28867182-9	2017	We found that upon OVA treatment the wild type mice had increased MDSC infiltration into the lung, up-regulation of KLF4 and TSLP gene expression, and higher levels of Th2 cytokines including IL4 and IL13.	ova	19-22	interleukin 13	Mus musculus	200-204
29022575-5	2017	However, a small concentration of gefitinib (0.62 mumol/L) significantly inhibited IL-13-induced M2-like polarization of macrophages, evidenced by the decreased expression of the M2 surface markers CD206 and CD163, down-regulation of specific M2-marker genes (Mrc1, Ym1, Fizz1, Arg1, IL-10 and CCL2) as well as inhibition of M2-like macrophage-mediated invasion and migration of LLC cells.	Gefitinib	34-43	interleukin 13	Mus musculus	83-88
29022575-6	2017	In RAW 264.7 cells, gefitinib inhibits IL-13-induced phosphorylation of STAT6, which was a crucial signaling pathway in macrophage M2-like polarization.	Gefitinib	20-29	interleukin 13	Mus musculus	39-44
28775096-7	2017	Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis.	Bleomycin	213-222	interleukin 13	Mus musculus	48-53
28874416-6	2017	In vivo administration of alpha-galactosylceramide or IL-33 increased IL-4 and IL-13 production, thereby increasing GDF15 levels in adipose tissue and in plasma of mice; however, these responses were abrogated in STAT6 knockout mice.	alpha-galactosylceramide	26-50	interleukin 13	Mus musculus	79-84
28782757-3	2017	Herein, we show that oral administration of osthole to BALB/c mice after ovalbumin (OVA) sensitization ameliorated all of the cardinal features of T helper 2 (Th2)-mediated allergic asthma; namely, the production of OVA-specific immunoglobulin E, airway hyperresponsiveness, airway inflammation and the production of Th2-type cytokines including interleukin (IL)-4, IL-5 and IL-13.	osthol	44-51	interleukin 13	Mus musculus	375-380
29094025-3	2017	The mRNA and protein expression of IL-13Ralpha1, PPARgamma, KLF4, SOCS1, STAT6, p-STAT6, and TGF-beta was measured in vitro with corilagin treatment after IL-13 stimulation and in vivo corilagin treatment after effectively killing the adult schistosomes in schistosome-infected mice.	corilagin	129-138	interleukin 13	Mus musculus	35-40
29087480-8	2017	Lack of CaMKII signaling attenuated catecholamine production mediated by cytokines IL-4 and IL-13, key inducers of type 2 immune response in primary macrophages.	Catecholamines	36-49	interleukin 13	Mus musculus	92-97
28422515-10	2017	Dexamethasone significantly attenuated IL-2- and IL-33-stimulated IL-5 and IL-13 production by both cell types.	Dexamethasone	0-13	interleukin 13	Mus musculus	75-80
28647381-7	2017	RESULTS: Administration of poly I:C to OVA-sensitized and -challenged mice increased the number of eosinophils and levels of IL-13, IL-9, CCL3, and CXCL1 in BAL fluid (BALF) and tended to increase airway responsiveness.	Poly I	27-33	interleukin 13	Mus musculus	125-130
28647381-8	2017	Montelukast significantly attenuated the poly I:C-induced increase in the number of eosinophils and levels of IL-13, IL-9, and CCL3 in BALF and airway hyperresponsiveness in both the reliever and controller models.	montelukast	0-11	interleukin 13	Mus musculus	110-115
28647381-8	2017	Montelukast significantly attenuated the poly I:C-induced increase in the number of eosinophils and levels of IL-13, IL-9, and CCL3 in BALF and airway hyperresponsiveness in both the reliever and controller models.	Poly I	41-47	interleukin 13	Mus musculus	110-115
28647381-8	2017	Montelukast significantly attenuated the poly I:C-induced increase in the number of eosinophils and levels of IL-13, IL-9, and CCL3 in BALF and airway hyperresponsiveness in both the reliever and controller models.	Carbon	48-49	interleukin 13	Mus musculus	110-115
28666799-5	2017	The results showed that ovatodiolide suppressed TH2 activation, including cell proliferation and production of the TH2 related cytokines, interleukin (IL)-4, IL-5, IL-13, IL-33, eosinophil chemotactic protein (eotaxin), and also reduced airway hyperresponsiveness.	ovatodiolide	24-36	interleukin 13	Mus musculus	164-169
28946610-8	2017	Moreover, CR significantly decreased proinflammatory mediators such as IL-9 and IL-13 in the heat-stressed hypothalamus.	Chromium	10-12	interleukin 13	Mus musculus	80-85
28515123-4	2017	ATRA suppressed IL13- or IL4-induced M2-type macrophages, and then inhibited migration of osteosarcoma cells as promoted by M2-type macrophages in vitro ATRA reduced the number of pulmonary metastatic nodes of osteosarcoma and decreased expression of M2-type macrophages in metastatic nodes both in intravenous injection and orthotopic transplantation models.	Tretinoin	0-4	interleukin 13	Mus musculus	16-20
28669409-7	2017	In addition, GSI also significantly down-regulated mRNA levels of cytokines IL-4, IL-6 and IL-13 induced by A23187, and this effect was dependent on MAPK pathway.	Calcimycin	108-114	interleukin 13	Mus musculus	91-96
28704401-9	2017	TDI-treated WT mice, receiving anti-IL-13, showed no AHR, in contrast to those receiving control antibody, despite increased levels of IgE.	Toluene 2,4-Diisocyanate	0-3	interleukin 13	Mus musculus	36-41
28704401-10	2017	Anti-IL-13 treatment in TDI-treated WT mice resulted in lower levels of serum IL-13, but did not induce changes in T- and B-cell numbers, and in the cytokine production profile.	Toluene 2,4-Diisocyanate	24-27	interleukin 13	Mus musculus	5-10
28704401-10	2017	Anti-IL-13 treatment in TDI-treated WT mice resulted in lower levels of serum IL-13, but did not induce changes in T- and B-cell numbers, and in the cytokine production profile.	Toluene 2,4-Diisocyanate	24-27	interleukin 13	Mus musculus	78-83
28717211-2	2017	When Raptor, a critical scaffold protein for mammalian target of rapamycin complex 1 (mTORC1), was acutely deleted in intestinal epithelium via Tamoxifen injection in Tritrichomonas muris (Tm) infected mice, tuft cells, IL-25 in epithelium and IL-13 in the mesenchyme were significantly reduced, but Tm burden was not affected.	Tamoxifen	144-153	interleukin 13	Mus musculus	244-249
28515123-6	2017	Quantitative genomic and functional analyses revealed that MMP12, a macrophage-secreted elastase, was elevated in IL13-skewed TAM polarization, whereas ATRA treatment downregulated IL13-induced secretion of MMP12.	Tretinoin	152-156	interleukin 13	Mus musculus	181-185
28360114-10	2017	SR3335 also attenuated lung mRNA expression of IL-13, Muc5ac, and Gob5 as well as mucous metaplasia.	SR 3335	0-6	interleukin 13	Mus musculus	47-52
28776450-6	2017	Our data showed that apocynin and allopurinol ameliorated AHR and reduced eosinophil peroxidase, as well as IL-4 and IL-13 levels.	acetovanillone	21-29	interleukin 13	Mus musculus	117-122
28776450-6	2017	Our data showed that apocynin and allopurinol ameliorated AHR and reduced eosinophil peroxidase, as well as IL-4 and IL-13 levels.	Allopurinol	34-45	interleukin 13	Mus musculus	117-122
28776450-8	2017	Aminoguanidine preserved lung function and shifted the Th2 to the Th1 response with a reduction of IL-4 and IL-13 and increase in IL-1beta production.	pimagedine	0-14	interleukin 13	Mus musculus	108-113
28360114-12	2017	SR3335 also blocked IL-25 and IL-33-induced ILC2 proliferation and IL-13 production ex vivo.	SR 3335	0-6	interleukin 13	Mus musculus	67-72
28418286-8	2017	The elevated level of immunoglobulin E (IgE) in serum and the mRNA levels of interferon gamma (IFN-gamma), interleukin 4 (IL-4) and IL-13 in the ear tissues, were also suppressed by DHMEQ.	dehydroxymethylepoxyquinomicin	182-187	interleukin 13	Mus musculus	132-137
28412624-7	2017	Thus, 1,25-(OH)2D3 may exert anti-allergic effects by suppressing Th17 responses and local production of IL-5 and IL-13 cytokines.	Calcitriol	6-18	interleukin 13	Mus musculus	114-119
28393183-10	2017	DHM also reduced the levels of IL-4, IL-5 and IL-13 in the BAL fluid, and reduced the secretion of OVA-specific IgE and IgG1 in the serum.	dihydromyricetin	0-3	interleukin 13	Mus musculus	46-51
28282577-5	2017	We found that the co-blockade of IL-13 and IL-25 with sIL-13R and sIL-25R was more effective than either agent alone at decreasing inflammatory cell infiltration, airway hyperresponsiveness (AhR) and airway remodeling including mucus production, extracellular collagen deposition, smooth muscle cell hyperplasia and angiogenesis in mice exposed to OVA.	sil-13r	54-61	interleukin 13	Mus musculus	33-38
28373582-4	2017	Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-beta1).	Poly I-C	12-43	interleukin 13	Mus musculus	189-194
28282577-5	2017	We found that the co-blockade of IL-13 and IL-25 with sIL-13R and sIL-25R was more effective than either agent alone at decreasing inflammatory cell infiltration, airway hyperresponsiveness (AhR) and airway remodeling including mucus production, extracellular collagen deposition, smooth muscle cell hyperplasia and angiogenesis in mice exposed to OVA.	sil-25r	66-73	interleukin 13	Mus musculus	33-38
28143779-3	2017	Our results show that osthole treatment significantly reduced the OVA-induced increase in serum IgE and inflammatory cytokines (IL-4, IL-5, IL-13) in bronchoalveolar lavage fluid (BALF), and decreased the recruitment of inflammatory cells in BALF and the lung.	osthol	22-29	interleukin 13	Mus musculus	140-145
28247333-7	2017	Notably, the inhibitory effects of 6-OHDA on IL-4-mediated induction of the anti-inflammatory marker genes IL-10, IL-13, and transforming growth factor-beta2 could be significantly alleviated by pretreatment with DEX in a dose-dependent manner (P &lt; 0.01).	Oxidopamine	35-41	interleukin 13	Mus musculus	114-157
28247333-7	2017	Notably, the inhibitory effects of 6-OHDA on IL-4-mediated induction of the anti-inflammatory marker genes IL-10, IL-13, and transforming growth factor-beta2 could be significantly alleviated by pretreatment with DEX in a dose-dependent manner (P &lt; 0.01).	Dexmedetomidine	213-216	interleukin 13	Mus musculus	114-157
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Tamoxifen	255-264	interleukin 13	Mus musculus	63-68
27782356-10	2017	Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition.	Simvastatin	0-11	interleukin 13	Mus musculus	117-122
28359154-6	2017	In addition, the production of interleukin (IL)-4 and IL-13 was diminished in the ESO groups compared to the non-ESO-treated group.	Epoxidized soya bean oil	82-85	interleukin 13	Mus musculus	54-59
28275135-4	2017	In addition, in a murine model of ILC2 expansion in the liver, polyinosinic-polycytidylic acid, an NK cell-activating agent, inhibited ILC2 proliferation, IL-5 and IL-13 production, and eosinophil recruitment.	Poly I-C	63-94	interleukin 13	Mus musculus	164-169
28428709-9	2017	5-FU-induced expression of IL-13, IL-17A, TNF-alpha, and IFN-gamma in the ileum was Fn14 dependent.	Fluorouracil	0-4	interleukin 13	Mus musculus	27-32
28428709-10	2017	The severity of 5-FU-induced diarrhea was lower in IL-13Ralpha1 KO mice, indicating major role for IL-13 signaling via IL-13Ralpha1 in pathogenesis.	Fluorouracil	16-20	interleukin 13	Mus musculus	51-56
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Estradiol	112-121	interleukin 13	Mus musculus	63-68
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Estradiol	143-152	interleukin 13	Mus musculus	63-68
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Estradiol	143-152	interleukin 13	Mus musculus	63-68
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Estradiol	143-152	interleukin 13	Mus musculus	63-68
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Estradiol	143-152	interleukin 13	Mus musculus	63-68
28395712-10	2017	Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group.	Tamoxifen	255-264	interleukin 13	Mus musculus	63-68
28159725-12	2017	SC+TOL also decreased serum IgE and IgG1 levels and the expression of IFN-gamma, IL-4, and IL-13 mRNA in dorsal skin in DNCB-treated Nc/Nga mice.	Dinitrochlorobenzene	120-124	interleukin 13	Mus musculus	91-96
28061526-2	2017	Here we utilized a novel targeted metallofullerene nanoparticle based magnetic resonance imaging (MRI) probe IL-13-TAMRA-Gd3N@C80(OH)30(CH2CH2COOH)20 to detect CPO in mouse tibia via overexpressed IL-13Ralpha2 receptors.	cpo	160-163	interleukin 13	Mus musculus	109-114
28107754-8	2017	The results showed that hyperoside significantly reduced the inflammatory cells infiltration and the levels of IL-4, IL-5, IL-13, and IgE.	hyperoside	24-34	interleukin 13	Mus musculus	123-128
28061526-2	2017	Here we utilized a novel targeted metallofullerene nanoparticle based magnetic resonance imaging (MRI) probe IL-13-TAMRA-Gd3N@C80(OH)30(CH2CH2COOH)20 to detect CPO in mouse tibia via overexpressed IL-13Ralpha2 receptors.	metallofullerene	34-50	interleukin 13	Mus musculus	109-114
27345402-5	2017	DOX-MDSC promote breast tumor lung metastasis through MDSC miR-126a+ exosomal-mediated induction of IL-13+ Th2 cells and tumor angiogenesis.	Doxorubicin	0-3	interleukin 13	Mus musculus	100-105
28061526-2	2017	Here we utilized a novel targeted metallofullerene nanoparticle based magnetic resonance imaging (MRI) probe IL-13-TAMRA-Gd3N@C80(OH)30(CH2CH2COOH)20 to detect CPO in mouse tibia via overexpressed IL-13Ralpha2 receptors.	tamra-gd3n	115-125	interleukin 13	Mus musculus	109-114
28061526-2	2017	Here we utilized a novel targeted metallofullerene nanoparticle based magnetic resonance imaging (MRI) probe IL-13-TAMRA-Gd3N@C80(OH)30(CH2CH2COOH)20 to detect CPO in mouse tibia via overexpressed IL-13Ralpha2 receptors.	ch2ch2cooh	136-146	interleukin 13	Mus musculus	109-114
27345402-7	2017	DOX treatment not only increases interleukin (IL)-33 released from breast tumor cells, which is crucial for the induction of IL-13+ Th2 cells, but it also participates in the induction of IL-13 receptors and miR-126a expressed on/in the MDSCs.	Doxorubicin	0-3	interleukin 13	Mus musculus	125-130
27345402-7	2017	DOX treatment not only increases interleukin (IL)-33 released from breast tumor cells, which is crucial for the induction of IL-13+ Th2 cells, but it also participates in the induction of IL-13 receptors and miR-126a expressed on/in the MDSCs.	Doxorubicin	0-3	interleukin 13	Mus musculus	188-193
27345402-8	2017	IL-13 released from IL-13+Th2 cells then promotes the production of DOX-MDSC and MDSC miR-126a+ exosomes via MDSC IL-13R.	Doxorubicin	68-71	interleukin 13	Mus musculus	0-5
27345402-8	2017	IL-13 released from IL-13+Th2 cells then promotes the production of DOX-MDSC and MDSC miR-126a+ exosomes via MDSC IL-13R.	Doxorubicin	68-71	interleukin 13	Mus musculus	20-25
27862161-8	2017	beta-eudesmol suppresses the serum levels of histamine, IgE, interleukin (IL)-1beta, IL-4, IL-5, IL-6, IL-13, and vascular endothelial growth factor (VEGF) under PCA mice as well as PCA reactions.	beta-eudesmol	0-13	interleukin 13	Mus musculus	103-108
27845069-0	2016	Mechanism of Corilagin interference with IL-13/STAT6 signaling pathways in hepatic alternative activation macrophages in schistosomiasis-induced liver fibrosis in mouse model.	corilagin	13-22	interleukin 13	Mus musculus	41-46
27745702-4	2017	Similarly, there was delayed recovery and increased tubulointerstitial fibrosis in these diphtheria toxin-treated mice following tamoxifen-induced deletion of both IL-4 and IL-13, with increased levels of M1 and decreased levels of M2 markers in the macrophages/dendritic cells.	Tamoxifen	129-138	interleukin 13	Mus musculus	173-178
28134765-5	2017	Treatment with dTBP2 also decreased the serum levels of IgE and reduced IL-17A content in skin lesions and inhibited the expression of mRNAs of interleukin IL-4, IL-5, IL-6, IL-13, macrophage-derived chemokine (MDC), thymus and activation-regulated chemokine (TARC) and thymic stromal lymphopoietin (TSLP).	dtbp2	15-20	interleukin 13	Mus musculus	174-179
27908701-6	2017	l-theanine administration also significantly decreased the production of IgE, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-4, IL-5, IL-13, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma in BALF.	theanine	0-10	interleukin 13	Mus musculus	148-153
29038619-6	2017	Among various cytokines, levels of IL-1alpha, IL-1beta, IL-4, IL-6, and IL-13 were significantly elevated in nose or lung tissue from the CIH group.	cih	138-141	interleukin 13	Mus musculus	72-77
29062168-6	2017	IVE and AET ameliorated OVA-driven airway hyperresponsiveness (p &lt; 0.01), pulmonary eosinophilic infiltration (p &lt; 0.05), mucus hypersecretion (p &lt; 0.01), and IL-4, IL-5, IL-13, and CCR3 production (p &lt; 0.05), as well as IgE levels (p &lt; 0.01).	anethole	8-11	interleukin 13	Mus musculus	180-185
29199257-0	2017	[Retinoic Acid Prevents Dendritic Cells from Inducing Novel Inflammatory T Cells That Produce Abundant Interleukin-13].	Tretinoin	1-14	interleukin 13	Mus musculus	103-117
29199257-9	2017	These results suggest that MLN-DCs possess the latent ability to induce IL-13-producing inflammatory Th2 cells and that RA prevents them from inducing IL-13-dependent allergic or inflammatory responses to orally administered antigens.	Tretinoin	120-122	interleukin 13	Mus musculus	151-156
27776738-4	2017	Because Th2 cytokines, such as interleukin IL-4 and IL-13, can induce macrophage polarization into M2 macrophages, we treated the BMIMs with IL-4 and IL-13 in vitro.	bmims	130-135	interleukin 13	Mus musculus	52-57
27776738-4	2017	Because Th2 cytokines, such as interleukin IL-4 and IL-13, can induce macrophage polarization into M2 macrophages, we treated the BMIMs with IL-4 and IL-13 in vitro.	bmims	130-135	interleukin 13	Mus musculus	150-155
27845069-1	2016	This study tried to find the mechanism of Corilagin interference with interleukin (IL)-13/signal transducer and activator of transcription (STAT) 6 signaling pathways in IL-13-activated liver alternative activation macrophages in schistosomiasis-induced liver fibrosis in Balb/c mice.	corilagin	42-51	interleukin 13	Mus musculus	170-175
27845069-2	2016	As a result, IL-13 in serum and the mRNA expression of IL-13 Receptor alpha1, IL-4 Receptor alpha and downstream mediators supressor of cytokine signaling (SOCS) 1, Kruppel-like factor (KLF) 4, peroxisome proliferator-activated receptor (PPAR) delta in the liver tissue were significantly inhibited by Corilagin (P&lt;0.05 or 0.01).	corilagin	302-311	interleukin 13	Mus musculus	13-18
27845069-2	2016	As a result, IL-13 in serum and the mRNA expression of IL-13 Receptor alpha1, IL-4 Receptor alpha and downstream mediators supressor of cytokine signaling (SOCS) 1, Kruppel-like factor (KLF) 4, peroxisome proliferator-activated receptor (PPAR) delta in the liver tissue were significantly inhibited by Corilagin (P&lt;0.05 or 0.01).	corilagin	302-311	interleukin 13	Mus musculus	55-60
27845069-7	2016	In conclusion, Corilagin had potential to relieve hepatic fibrosis caused by egg granuloma in Schistosoma japonicum infection by decreasing the expression of molecules associated with IL-13/STAT6 signaling pathway in liver alternative activation macrophages.	corilagin	15-24	interleukin 13	Mus musculus	184-189
27581277-9	2016	Meanwhile, treatment of angelicin dose-dependently inhibited OVA-induced the production of IL-4, IL-5, and IL-13 in BALF and IgE in the serum.	angelicin	24-33	interleukin 13	Mus musculus	107-112
27685637-2	2016	With this study we provide evidence that lentiviral vector-mediated expression of the immune-modulating cytokine interleukin 13 (IL-13) induces an alternative activation program in both microglia and macrophages conferring protection against severe oligodendrocyte loss and demyelination in the cuprizone mouse model for multiple sclerosis (MS).	Cuprizone	295-304	interleukin 13	Mus musculus	113-127
27685637-2	2016	With this study we provide evidence that lentiviral vector-mediated expression of the immune-modulating cytokine interleukin 13 (IL-13) induces an alternative activation program in both microglia and macrophages conferring protection against severe oligodendrocyte loss and demyelination in the cuprizone mouse model for multiple sclerosis (MS).	Cuprizone	295-304	interleukin 13	Mus musculus	129-134
27685637-3	2016	First, IL-13 mediated modulation of cuprizone induced lesions was monitored using T2 -weighted magnetic resonance imaging and magnetization transfer imaging, and further correlated with quantitative histological analyses for inflammatory cell influx, oligodendrocyte death, and demyelination.	Cuprizone	36-45	interleukin 13	Mus musculus	7-12
27685637-4	2016	Second, following IL-13 immune gene therapy in cuprizone-treated eGFP+ bone marrow chimeric mice, we provide evidence that IL-13 directs the polarization of both brain-resident microglia and infiltrating macrophages towards an alternatively activated phenotype, thereby promoting the conversion of a pro-inflammatory environment toward an anti-inflammatory environment, as further evidenced by gene expression analyses.	Cuprizone	47-56	interleukin 13	Mus musculus	18-23
27685637-4	2016	Second, following IL-13 immune gene therapy in cuprizone-treated eGFP+ bone marrow chimeric mice, we provide evidence that IL-13 directs the polarization of both brain-resident microglia and infiltrating macrophages towards an alternatively activated phenotype, thereby promoting the conversion of a pro-inflammatory environment toward an anti-inflammatory environment, as further evidenced by gene expression analyses.	Cuprizone	47-56	interleukin 13	Mus musculus	123-128
29469388-13	2016	The content of IL-13 in the PBS group was (95.99 +- 31.14) pg/ml.	Lead	28-31	interleukin 13	Mus musculus	15-20
27424318-7	2016	Beneficial immunological effects were also observed: niclosamide decreased the production of effector memory CD4 and CD8 T cells, T-cell infiltration of the skin and visceral organs, and decreased productions of IL-4 and IL-13, and autoimmune B-cell activation.	Niclosamide	53-64	interleukin 13	Mus musculus	221-226
27568840-4	2016	Treatment of M1 macrophages with niacin (300muM) resulted in down-regulation of the p65 NF-kappaB phosphorylation, associated with a marked decrease in the levels of M1 markers, including CD86, IL-12, and IL-6, and a significant increase in the expressions of M2 markers, such as CD206, IL-10, and IL-13, suggesting that niacin causes a shift of M1 to M2.	Niacin	33-39	interleukin 13	Mus musculus	298-303
27309728-10	2016	The levels of TNF, IL-4, IL-5, and IL-13 were significantly decreased after treatment with cyclosporine.	Cyclosporine	91-103	interleukin 13	Mus musculus	35-40
27602597-12	2016	There were also TBT-induced increases in MIP-1beta, RANTES and IL-13.	tributyltin	16-19	interleukin 13	Mus musculus	63-68
27829467-0	2016	Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model.	Cuprizone	148-157	interleukin 13	Mus musculus	33-47
27829467-8	2016	In the second part of this study, we demonstrate that grafting of IL13-MSC, in addition to the recruitment of M2 polarised macrophages, limits cuprizone-induced microgliosis, oligodendrocyte death and demyelination.	Cuprizone	143-152	interleukin 13	Mus musculus	66-70
27829467-10	2016	CONCLUSIONS: Controlled and localised production of IL13 by means of intracerebral MSC grafting has the potential to modulate cell graft- and pathology-associated microglial/macrophage responses, and to interfere with oligodendrocyte death and demyelinating events in the cuprizone mouse model.	Cuprizone	272-281	interleukin 13	Mus musculus	52-56
27643741-8	2016	STAT6 silence suppressed IL-13-increased acetylcholine level.	Acetylcholine	41-54	interleukin 13	Mus musculus	25-30
27716424-9	2016	SE-A treatment significantly reduced the number of airway eosinophils, IL-4 and IL-13 levels, mucus production, and inflammatory infiltration, as compared with the corresponding levels in the untreated, OVA-induced mice, and had similar effects to dexamethasone.	se-a	0-4	interleukin 13	Mus musculus	80-85
27613696-9	2016	Beneficial immunological effects were also observed because niclosamide decreased the activation of CD4+ and CD8+ T cells, autoimmune B cell activation, as well as IL-4 and IL-13 production in the skin.	Niclosamide	60-71	interleukin 13	Mus musculus	173-178
27764539-10	2016	Fluticasone reduced pro-inflammatory cells, such as eosinophils, and several cytokines, such as interleukin 4 (IL-4), IL-5, and IL-13, induced by repeated OVA challenges.	Fluticasone	0-11	interleukin 13	Mus musculus	128-133
27713021-8	2016	IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG.	Cromolyn Sodium	112-116	interleukin 13	Mus musculus	57-62
27485290-8	2016	Asthmatic mice exhibited elevated levels of NOx, IL-13 and TGF-beta1 that were reduced by DEXA and tiron.	Dexamethasone	90-94	interleukin 13	Mus musculus	49-54
27485290-8	2016	Asthmatic mice exhibited elevated levels of NOx, IL-13 and TGF-beta1 that were reduced by DEXA and tiron.	1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt	99-104	interleukin 13	Mus musculus	49-54
27456482-7	2016	We also showed that the PGI2 analogue cicaprost inhibited CD4 T cell proliferation and IL-5 and IL-13 expression in vitro, and IP deficiency diminished the stimulatory effect of indomethacin on STAT6-independent IL-5 and IL-13 responses in vivo.	Indomethacin	178-190	interleukin 13	Mus musculus	221-226
27439782-0	2016	Corilagin ameliorates schistosomiasis hepatic fibrosis through regulating IL-13 associated signal pathway in vitro and in vivo.	corilagin	0-9	interleukin 13	Mus musculus	74-79
27439782-2	2016	In this study we tried to investigate the effects of corilagin to ameliorate schistosomiasis hepatic fibrosis through regulating IL-13-associated signal pathway in vitro and in vivo.	corilagin	53-62	interleukin 13	Mus musculus	129-134
27439782-12	2016	In conclusion, corilagin could ameliorate schistosomiasis hepatic fibrosis by down-regulating the expression of IL-13 and signal molecules in IL-13 pathway.	corilagin	15-24	interleukin 13	Mus musculus	112-117
27439782-12	2016	In conclusion, corilagin could ameliorate schistosomiasis hepatic fibrosis by down-regulating the expression of IL-13 and signal molecules in IL-13 pathway.	corilagin	15-24	interleukin 13	Mus musculus	142-147
28239073-9	2016	In contrast, mRNA level of a Th2 cytokine IL-13 was significantly decreased by IMQ treatment and further suppressed by betamethasone.	Betamethasone	119-132	interleukin 13	Mus musculus	42-47
26884456-8	2016	Interleukin (IL)-13 levels were higher in the supernatants from low dose NQs + OVA-exposed mononuclear cells.	NQS	73-76	interleukin 13	Mus musculus	0-19
27456482-7	2016	We also showed that the PGI2 analogue cicaprost inhibited CD4 T cell proliferation and IL-5 and IL-13 expression in vitro, and IP deficiency diminished the stimulatory effect of indomethacin on STAT6-independent IL-5 and IL-13 responses in vivo.	cicaprost	38-47	interleukin 13	Mus musculus	96-101
27655547-9	2016	Compared with the control group, the asthma and capsaicin groups showed increases in the content of IL-13 and IL-8 in BALF and the mRNA expression of TRPV1 in lung tissue (P&lt;0.05).	Capsaicin	48-57	interleukin 13	Mus musculus	100-105
27353073-8	2016	Topical compd3 penetrates the skin and suppresses phorbol myristate acetate-induced IL-13, IL-22, IL-17F, and IL-23 transcription and calcipotriol-induced thymic stromal lymphopoietin expression in mouse skin.	Tetradecanoylphorbol Acetate	50-75	interleukin 13	Mus musculus	84-89
27655547-10	2016	Compared with the asthma group, the capsazepine and dexamethasone groups showed reductions in the content of IL-13 and IL-8 in BALF and the mRNA expression of TRPV1 in lung tissue (P&lt;0.05).	capsazepine	36-47	interleukin 13	Mus musculus	109-114
27655547-11	2016	The capsaicin group showed increases in the content of IL-13 and IL-8 in BALF (P&lt;0.05).	Capsaicin	4-13	interleukin 13	Mus musculus	55-60
27655547-10	2016	Compared with the asthma group, the capsazepine and dexamethasone groups showed reductions in the content of IL-13 and IL-8 in BALF and the mRNA expression of TRPV1 in lung tissue (P&lt;0.05).	Dexamethasone	52-65	interleukin 13	Mus musculus	109-114
27483441-12	2016	Moreover, the capacity of lymph node cells to produce IL-5 and IL-13 after AAI was drastically diminished in HFD mice compared to ND mice.	aai	75-78	interleukin 13	Mus musculus	63-68
27401058-11	2016	URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13.	URMC-099	0-8	interleukin 13	Mus musculus	80-85
27450020-8	2016	CONCLUSIONS: Beclomethasone influence on airway remodeling was mediated mainly via suppression of eosinophilic recruitment into the airways and reduction of interleukin-13 cytokine levels.	Beclomethasone	13-27	interleukin 13	Mus musculus	157-171
27071418-6	2016	RESULTS: We found that TSA treatment significantly decreased the number of ILC2 expressing IL-5 and IL-13 in the lungs challenged with Alternaria extract or rmIL-33 compared with vehicle treatment (p&lt;0.05).	trichostatin A	23-26	interleukin 13	Mus musculus	100-105
27005687-0	2016	Glutamine promotes intestinal SIgA secretion through intestinal microbiota and IL-13.	Glutamine	0-9	interleukin 13	Mus musculus	79-84
27005687-4	2016	Glutamine supplementation increased mouse ileal expression of cytokines associated with T cell-dependent and T cell-independent pathways of SIgA induction, including IL-5, IL-6, IL-13, transforming growth factor (TGF-beta), a proliferation-inducing ligand (APRIL), B cell-activating factor (BAFF), vasoactive intestinal peptide (VIP) receptor, and retinal dehydrogenases.	Glutamine	0-9	interleukin 13	Mus musculus	178-183
27005687-5	2016	Injecting an IL-13 antibody during glutamine supplementation reduced J-chain expression in the mouse ileum.	Glutamine	35-44	interleukin 13	Mus musculus	13-18
27071418-7	2016	TSA treatment significantly decreased protein expression of IL-5, IL-13, CCL11 and CCL24 in the lung homogenates from Alternaria extract-challenged mice or rmIL-33-challenged mice compared with vehicle treatment (p&lt;0.05).	trichostatin A	0-3	interleukin 13	Mus musculus	66-71
27270547-11	2016	Furthermore, expressions of inflammatory cytokines IL-4, IL-13, and TNF-alpha in skin lesions were down-regulated in 2% TET group compared with AD group (P = 0.035, 0.008, and 0.044, respectively).	Tetracycline	120-123	interleukin 13	Mus musculus	57-62
27330190-1	2016	Insulin receptor substrate 2 (IRS2) is an adaptor protein that becomes tyrosine-phosphorylated in response to the cytokines interleukin-4 (IL-4) and IL-13, which results in activation of the phosphoinositide 3-kinase (PI3K)-Akt pathway.	Tyrosine	71-79	interleukin 13	Mus musculus	149-154
27206490-16	2016	Treatment of CAFs with 1nM Everolimus showed a significant reduction in the expression of IL 8, IL 13, MCP1, MIF and Serpin E1.	cafs	13-17	interleukin 13	Mus musculus	96-101
27621809-9	2016	Elevated Th2 T cell counts and Th2 cytokines/chemokines (IL5, IL13, CCL17) were observed in mice treated with combined HDM/myriocin compared to HDM alone.	thermozymocidin	123-131	interleukin 13	Mus musculus	62-66
27098091-5	2016	Treatment with pristimerin caused a marked reduction in the levels of OVA-specific IgE, immune cells, and IL-4, IL-5, IL-13 secretion.	pristimerin	15-26	interleukin 13	Mus musculus	118-123
27102767-4	2016	Conversely, B6.gld mice given ethanol exhibited increases in collagen deposition, hepatic collagen gene expression, and profibrogenic cytokines (eg, transforming growth factor-beta and IL-13) and alterations in matrix remodeling proteins (eg, matrix metalloproteinases and tissue inhibitor of metalloproteinases) compared with wild-type mice.	Ethanol	30-37	interleukin 13	Mus musculus	185-190
27102767-6	2016	Importantly, a shift toward the expression of M2/Th2 cytokines (eg, IL-4 and IL-13) after ethanol exposure was observed in B6.gld mice compared with classical M1 cytokine expression in wild-type mice under similar conditions.	Ethanol	90-97	interleukin 13	Mus musculus	77-82
27119568-8	2016	Both lactate isomers also enhanced IL4 and IL13 promoter-driven activity of reporter constructs in murine and human cells.	Lactic Acid	5-12	interleukin 13	Mus musculus	43-47
27206490-16	2016	Treatment of CAFs with 1nM Everolimus showed a significant reduction in the expression of IL 8, IL 13, MCP1, MIF and Serpin E1.	CHEMBL2426582	23-26	interleukin 13	Mus musculus	96-101
27206490-16	2016	Treatment of CAFs with 1nM Everolimus showed a significant reduction in the expression of IL 8, IL 13, MCP1, MIF and Serpin E1.	Everolimus	27-37	interleukin 13	Mus musculus	96-101
26970183-6	2016	Furthermore, treatment with O1-10 Fabs inhibited the increase in levels of IL-13 (P&lt;0.01) and IL-17A production (P&lt;0.05) in the lymph nodes of the sensitized mice.	o1-10 fabs	28-38	interleukin 13	Mus musculus	75-80
26519740-0	2016	MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.	Gadolinium DTPA	87-102	interleukin 13	Mus musculus	41-55
26519740-6	2016	MR image intensity was evaluated in the brain in normal mice post injection of Gd-DTPA and IL-13-liposome-Gd-DTPA one day apart.	Gadolinium DTPA	106-113	interleukin 13	Mus musculus	91-96
26519740-7	2016	The specificity for glioma detection by IL-13-liposome-Gd-DTPA was demonstrated in an intracranial glioma mouse model and validated histologically.	Gadolinium DTPA	55-62	interleukin 13	Mus musculus	40-45
26519740-8	2016	RESULTS: The average size of IL-13-liposome-Gd-DTPA was 137 +- 43 nm with relaxivity of 4.0 +- 0.4 L/mmole-s at 7 Tesla.	Gadolinium DTPA	44-51	interleukin 13	Mus musculus	29-34
26519740-8	2016	RESULTS: The average size of IL-13-liposome-Gd-DTPA was 137 +- 43 nm with relaxivity of 4.0 +- 0.4 L/mmole-s at 7 Tesla.	Sulfur	106-108	interleukin 13	Mus musculus	29-34
26519740-10	2016	The MRI signal intensity was enhanced up to 15% post injection of IL-13-liposome-Gd-DTPA in normal brain tissue following a similar time course as that for the pituitary gland outside of the BBB.	Gadolinium DTPA	81-88	interleukin 13	Mus musculus	66-71
26519740-11	2016	MRI enhanced by IL-13-liposome-Gd-DTPA detected small tumor masses in addition to those seen with Magnevist-enhanced MRI.	Gadolinium DTPA	31-38	interleukin 13	Mus musculus	16-21
26519740-11	2016	MRI enhanced by IL-13-liposome-Gd-DTPA detected small tumor masses in addition to those seen with Magnevist-enhanced MRI.	Gadolinium DTPA	98-107	interleukin 13	Mus musculus	16-21
26519740-12	2016	CONCLUSIONS: IL-13-liposome-Gd-DTPA is able to pass through the uncompromised BBB and detect an early stage glioma that cannot be seen with conventional contrast-enhanced MRI.	Gadolinium DTPA	28-35	interleukin 13	Mus musculus	13-18
26797918-5	2016	Our study demonstrated that ES inhibited, OVA-induced eosinophil count, interleukin-4 (IL-4), IL-5, IL-13, and IL-17A levels were recovered in bronchoalveolar lavage fluid.	esculetin	28-30	interleukin 13	Mus musculus	100-105
26840656-8	2016	Furthermore, SCR suppressed DFE/DNCB-induced expression of IL-4, IL-13, IL-17, IL-18, TSLP, and IFN-gamma genes in the ear tissue.	1,1-difluoroethane	28-31	interleukin 13	Mus musculus	65-70
26895180-6	2016	Oroxylin A also inhibited the levels of IL-4, IL-5, IL-13, and OVA-specific IgE in BALF.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 13	Mus musculus	52-57
26840656-8	2016	Furthermore, SCR suppressed DFE/DNCB-induced expression of IL-4, IL-13, IL-17, IL-18, TSLP, and IFN-gamma genes in the ear tissue.	Dinitrochlorobenzene	32-36	interleukin 13	Mus musculus	65-70
26203683-8	2016	C57BL/6 mice exposed to ozone for 1 day had acute neutrophilic rhinitis, with airway epithelial necrosis and overexpression of mucosal Ccl2 (MCP-1), Ccl11 (eotaxin), Cxcl1 (KC), Cxcl2 (MIP-2), Hmox1, Il1b, Il5, Il6, Il13, and Tnf mRNA.	Ozone	24-29	interleukin 13	Mus musculus	216-220
27455660-6	2016	TSLP increased the production and mRNA expression of interleukin-13 (a growth factor of mast cells), its increase was significantly decreased by ZnO-NP (10 mug/mL).	zno-np	145-151	interleukin 13	Mus musculus	53-67
26676587-9	2016	Reciprocally, conditioned medium from macrophages treated with IL-4 + IL-13 and myofibroblast conditioned medium components, but not macrophages given IL-4 + IL-13 only, reduced myofibroblast migration, the expression of COX-2, and the production of PGE2 and PGD2 .	Dinoprostone	250-254	interleukin 13	Mus musculus	70-75
26721350-11	2016	Additionally, treatment with enrofloxacin early in life prior to OVA immunization results in increased production of type-2 (IL-4, IL-10 and IL-13) cytokines.	Enrofloxacin	29-41	interleukin 13	Mus musculus	141-146
26861679-8	2016	Thus, Suhuang administration alleviates the pathological changes of chronic asthma likely through inhibition of IL-13 and TGF-beta1.	suhuang	6-13	interleukin 13	Mus musculus	112-117
26564814-6	2016	Activated BM-derived MCs expressing surface CD1d and loaded with alpha-galactosylceramide were found to induce iNKT-cell proliferation and the release of IFN-gamma, IL-13, and IL-4 in a CD1d-restricted manner.	alpha-galactosylceramide	65-89	interleukin 13	Mus musculus	165-170
26431781-0	2015	Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels.	puag-haad	0-14	interleukin 13	Mus musculus	91-96
27576536-5	2016	RESULTS: The results showed that SA dose-dependently reduced inflammatory cell counts, levels of cytokines IL-4, IL-5 and IL-13, and OVA-specific IgE in bronchoalveolar lavage fluid.	sappanone A	33-35	interleukin 13	Mus musculus	122-127
26658290-4	2015	We found that 15 min exposure to ethanol inhibited antigen-induced degranulation, calcium mobilization, expression of proinflammatory cytokine genes (tumor necrosis factor-alpha, interleukin-6, and interleukin-13), and formation of reactive oxygen species in a dose-dependent manner.	Ethanol	33-40	interleukin 13	Mus musculus	198-212
26394284-4	2015	Using Litomosides sigmodontis (a strong Th2 polarizing filarial infection) we observed a robust Th2 response in the pleural cavity, where adult worms reside, marked by increased levels of IL-5 and IL-13 in infected mice.	litomosides	6-17	interleukin 13	Mus musculus	197-202
26778828-9	2016	The concentrations of IL-5 and IL-13 in the OVA/LPS group decreased significantly after azithromycin administration.	Azithromycin	88-100	interleukin 13	Mus musculus	31-36
26728323-8	2016	RESULTS: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the TNBS-induced colitis through decreasing IFNgamma in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-beta in the colon tissues, with uptrending Tregs in the MLN and LPMC.	rsjcystatin	27-38	interleukin 13	Mus musculus	217-222
26784930-7	2016	Also, chronic gefitinib treatment markedly decreased the levels of muc5ac and IL-13 in BALF, whereas the level of IFN-x03B3; did not change obviously.	Gefitinib	14-23	interleukin 13	Mus musculus	78-83
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Docosahexaenoic Acids	61-64	interleukin 13	Mus musculus	13-18
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Eicosapentaenoic Acid	65-68	interleukin 13	Mus musculus	13-18
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	74-79	interleukin 13	Mus musculus	13-18
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	119-124	interleukin 13	Mus musculus	13-18
26153764-0	2016	A protective role for IL-13 receptor alpha 1 in bleomycin-induced pulmonary injury and repair.	Bleomycin	48-57	interleukin 13	Mus musculus	22-27
26153764-4	2016	We report dysregulated levels of IL-13 receptors in the lungs of bleomycin-treated mice and to some extent in idiopathic pulmonary fibrosis patients.	Bleomycin	65-74	interleukin 13	Mus musculus	33-38
26153764-7	2016	Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling.	Bleomycin	23-32	interleukin 13	Mus musculus	70-75
26365358-4	2015	We show that IL-13 impairs ENaC-dependent sodium transport by activating the JAK1/2-STAT6 signalling pathway.	Sodium	42-48	interleukin 13	Mus musculus	13-18
26365358-8	2015	In the present study, we investigated whether IL-13 also acts as a potent modulator of epithelial sodium transport via ENaC, and the signalling components involved.	Sodium	98-104	interleukin 13	Mus musculus	46-51
26365358-11	2015	We show that IL-13, in both the cell model and in native intestinal tissue, impaired epithelial sodium absorption via ENaC (JNa ) as a result of decreased transcription levels of beta- and gamma-ENaC subunits and SGK1, a post-translational regulator of ENaC activity, due to impaired promoter activity.	Sodium	96-102	interleukin 13	Mus musculus	13-18
26335962-9	2015	In the airway inflammation mouse model, Der f 2-induced IL-13 production significantly decreased with treatment of TAK-242, a novel TLR4 inhibitor.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	115-122	interleukin 13	Mus musculus	56-61
26245530-16	2015	Fasudil down-regulated the levels of IL-17, IL-4 and IL-13 in the lung tissue of OVA-challenged mice.	fasudil	0-7	interleukin 13	Mus musculus	53-58
26431781-12	2015	Data showed that oxyresveratrol significantly suppressed Th2 (T helper cells) type immune response which was obvious by the reduction in mRNA expression levels of IL-4, IL-5, and IL-13.	puag-haad	17-31	interleukin 13	Mus musculus	179-184
26010476-8	2015	However, the expression levels of the T helper 2 (Th2) cytokines IL-4, IL-5, and IL-13 increased significantly after 24h of exposure to only ZnO NPs and then decreased gradually.	Zinc Oxide	141-144	interleukin 13	Mus musculus	81-86
26519529-3	2015	These pulmonary CD8(+) T cells differentiate into IL-13-producing Tc2 cells and play a major role in a bleomycin-induced model of fibrosis.	Bleomycin	103-112	interleukin 13	Mus musculus	50-55
25899567-6	2015	Functionally, RA increased DC induction of CD4(+) T-cell IL-10, while reducing CD4(+) T-cell IL-4 and IL-13, revealing a previously unidentified role for RA in regulating the ability of alternatively activated DCs to influence Th2 polarization.	Tretinoin	14-16	interleukin 13	Mus musculus	102-107
25899567-6	2015	Functionally, RA increased DC induction of CD4(+) T-cell IL-10, while reducing CD4(+) T-cell IL-4 and IL-13, revealing a previously unidentified role for RA in regulating the ability of alternatively activated DCs to influence Th2 polarization.	Tretinoin	154-156	interleukin 13	Mus musculus	102-107
26553631-0	2015	Combined exposure to protons and (56)Fe leads to overexpression of Il13 and reactivation of repetitive elements in the mouse lung.	Iron	37-39	interleukin 13	Mus musculus	67-71
26481537-4	2015	METHODS: The mice were sensitized to ovalbumin followed by aerosol allergen challenges and determination of chelidonine"s effect on enhanced pause (Penh), pulmonary eosinophilic infiltration, eotaxin-2, interleukin-4 (IL-4), IL-13, OVA-specific IgE production, and several transcription factors.	chelidonine	108-119	interleukin 13	Mus musculus	225-230
26481537-5	2015	RESULT: Chelidonine strongly suppressed airway eosinophilia, expression of eotaxin-2, IL-4, and IL-13 cytokine production in bronchoalveolar lavage fluid (BALF).	chelidonine	8-19	interleukin 13	Mus musculus	96-101
26341180-7	2015	Levels of IL-4, IL-5, IL-13 and TNF-alpha were also elevated with TDI-induction.	Toluene 2,4-Diisocyanate	66-69	interleukin 13	Mus musculus	22-27
26485286-4	2015	In stark contrast to Th17 cells and M1 macrophages, high salt blunted the alternative activation of BM-derived mouse macrophages stimulated with IL-4 and IL-13, M(IL-4+IL-13) macrophages.	Salts	57-61	interleukin 13	Mus musculus	154-159
26485286-4	2015	In stark contrast to Th17 cells and M1 macrophages, high salt blunted the alternative activation of BM-derived mouse macrophages stimulated with IL-4 and IL-13, M(IL-4+IL-13) macrophages.	Salts	57-61	interleukin 13	Mus musculus	168-173
26485286-5	2015	Salt-induced reduction of M(IL-4+IL-13) activation was not associated with increased polarization toward a proinflammatory M1 phenotype.	Salts	0-4	interleukin 13	Mus musculus	33-38
26485286-6	2015	In vitro, high salt decreased the ability of M(IL-4+IL-13) macrophages to suppress effector T cell proliferation.	Salts	15-19	interleukin 13	Mus musculus	52-57
26692869-2	2015	Results of hematoxylin-eosin and immunohistochemical staining demonstrated that inflammation contributed to the formation of a hypertrophic scar and increased the nerve density in scar tissue.Western blot assay verified that interleukin-13 expression was increased in scar tissue.	Hematoxylin	11-22	interleukin 13	Mus musculus	225-239
26086746-9	2015	Moreover, DEX inhibited the production of interleukin (IL)-4, IL-5, and IL-13 in the nasal cavity lavage fluid in this group.	Dexamethasone	10-13	interleukin 13	Mus musculus	72-77
26114860-7	2015	In addition, IL-4-mediated induction of anti-inflammatory marker genes IL-10, IL-13, and transforming growth factor-beta2 (TGF-beta2) were significantly attenuated by MPP+ in BV2 cells, which was restored by pretreatment with donepezil in a concentration-dependent manner.	mangion-purified polysaccharide (Candida albicans)	167-171	interleukin 13	Mus musculus	78-83
26692869-2	2015	Results of hematoxylin-eosin and immunohistochemical staining demonstrated that inflammation contributed to the formation of a hypertrophic scar and increased the nerve density in scar tissue.Western blot assay verified that interleukin-13 expression was increased in scar tissue.	Eosine Yellowish-(YS)	23-28	interleukin 13	Mus musculus	225-239
26053964-7	2015	In addition, rapamycin reduced the production of IL-6 and IL-13 by eosinophils.	Sirolimus	13-22	interleukin 13	Mus musculus	58-63
26241177-5	2015	Concomitantly, hydrogen sulfide prevented mast cell activity as well as FGF-2 and IL-13 upregulation.	Hydrogen Sulfide	15-31	interleukin 13	Mus musculus	82-87
26133060-11	2015	Zn-PP clearly inhibited AHR, pulmonary eosinophilia and IL-5 and IL-13 expression in the lung tissue.	zinc protoporphyrin	0-5	interleukin 13	Mus musculus	65-70
26067554-6	2015	The CDCA treatment further blocked the secretion of TH2 cytokines (IL-4, IL-5 and IL-13) and proinflammatory cytokine TNF-alpha indicate that the FXR and its agonists may have potential for treating allergic asthma.	Chenodeoxycholic Acid	4-8	interleukin 13	Mus musculus	82-87
26196745-4	2015	Here, we found that extracellular acidification increased the dinitrophenyl-conjugated human serum albumin (DNP-HSA)-induced production of interleukin (IL)-6 and IL-13 in MC/9 cells or bone marrow-derived mouse mast cells sensitized with anti-DNP IgE.	dinitrophenyl	62-75	interleukin 13	Mus musculus	162-167
26196745-4	2015	Here, we found that extracellular acidification increased the dinitrophenyl-conjugated human serum albumin (DNP-HSA)-induced production of interleukin (IL)-6 and IL-13 in MC/9 cells or bone marrow-derived mouse mast cells sensitized with anti-DNP IgE.	dnp-hsa	108-115	interleukin 13	Mus musculus	162-167
26196745-4	2015	Here, we found that extracellular acidification increased the dinitrophenyl-conjugated human serum albumin (DNP-HSA)-induced production of interleukin (IL)-6 and IL-13 in MC/9 cells or bone marrow-derived mouse mast cells sensitized with anti-DNP IgE.	2,4-Dinitrophenol	108-111	interleukin 13	Mus musculus	162-167
26713522-7	2015	RESULTS: The combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%+-2.59%) vs (61.15%+-7.58%), P&lt;0.05].	Lapatinib	28-37	interleukin 13	Mus musculus	104-109
26713522-7	2015	RESULTS: The combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%+-2.59%) vs (61.15%+-7.58%), P&lt;0.05].	Chlorogenic Acid	42-58	interleukin 13	Mus musculus	104-109
26169874-10	2015	The protective effects of olaparib were linked to a suppression of Th2 cytokines eotaxin, IL-4, IL-5, IL-6, IL-13, and M-CSF, and ovalbumin-specific IgE with an increase in the Th1 cytokine IFN-gamma.	olaparib	26-34	interleukin 13	Mus musculus	108-113
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 13	Mus musculus	217-222
25869601-10	2015	Mice that underwent Il-13 gene transfer showed regular body weight and normal serum concentrations of glucose and insulin, and less lipid accumulation in the liver.	Glucose	102-109	interleukin 13	Mus musculus	20-25
25944087-5	2015	Leflunomide, a STAT6 inhibitor, and IL-4 and/or IL-13 neutralizing antibodies antagonized the induction of MMR, Arg-1 and PPAR-gamma by curcumin in Raw264.7 cells.	Curcumin	136-144	interleukin 13	Mus musculus	48-53
26309610-6	2015	The serum level of IL-13 and TNF-alpha were lower than that of model group and praziquantel treated group.	Praziquantel	79-91	interleukin 13	Mus musculus	19-24
25619395-8	2015	RESULTS: Rosiglitazone administration significantly attenuated airway inflammation and remodeling in mice with OVA-induced asthma, which were evidenced by decreased counts of total cells, eosinophils and neutrophils, and decreased levels of IL-5 and IL-13 in BALF, and by decreased airway smooth muscle layer thickness and reduced airway collagen deposition.	Rosiglitazone	9-22	interleukin 13	Mus musculus	250-255
25599677-8	2015	Furthermore, Gln suppressed various allergic asthma phenotypes, such as neutrophil and eosinophil recruitments into the airway, airway levels of T helper type 2 (Th2) cytokines [interleukin (IL)-4, IL-5 and IL-13], airway hyperresponsiveness, mucin production and metabolites (leukotriene B4 and platelet-activating factor) through inhibiting cPLA2 in a MKP-1-dependent manner.	Glutamine	13-16	interleukin 13	Mus musculus	207-212
25781071-5	2015	In addition, oral administration of curine significantly inhibited eosinophil recruitment and activation, as well as, OVA-induced airway hyper-responsiveness in a mouse model of asthma, through inhibition of the production of IL-13 and eotaxin, and of Ca2+ influx.	curine	36-42	interleukin 13	Mus musculus	226-231
25737197-6	2015	Oral administration of PGG strongly suppressed production of type 2 T helper (IL-4 and IL-13), type 1 T helper (IFN-gamma), and pro-inflammatory cytokines (TNF-alpha and IL-6), but not anti-inflammatory cytokine (IL-10) from splenocytes of OVA-sensitized mice against OVA re-stimulation.	pgg	23-26	interleukin 13	Mus musculus	87-92
25595781-9	2015	Using an in vitro coculture system, macrophages isolated from in vivo bleomycin-challenged WT, but not IRAK-M(-/-), mice promoted increased collagen and alpha-smooth muscle actin expression from lung fibroblasts in an IL-13-dependent fashion.	Bleomycin	70-79	interleukin 13	Mus musculus	218-223
25530546-6	2015	Our study demonstrated that, compared with model group, puerarin inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-gamma level in bronchoalveolar lavage fluid; histological studies demonstrated that puerarin substantially inhibited OVA-induced eosinophilia in lung tissue compared with model group.	puerarin	56-64	interleukin 13	Mus musculus	152-157
25594684-5	2015	Intranasal challenge of Cd38-deficient mice with TNF-alpha or IL-13, or the environmental fungus Alternaria alternata, causes significantly attenuated methacholine responsiveness compared with wild-type mice, with comparable airway inflammation.	Methacholine Chloride	151-163	interleukin 13	Mus musculus	62-67
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	D-Glucitol-1,6-bisphosphate	34-37	interleukin 13	Mus musculus	139-144
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	41-51	interleukin 13	Mus musculus	139-144
25573403-10	2015	Zerumbone treatment also reduced the production of eotaxin, keratinocyte-derived chemokine (KC), interleukin (IL)-4, IL-5, IL-10, and IL-13, and promoted Th1 cytokine interferon (IFN)-gamma production in asthmatic mice.	zerumbone	0-9	interleukin 13	Mus musculus	134-139
26621445-4	2015	Resveratrol dose-dependently diminished the secretion of interleukin (IL)-3, IL-4, IL-13 as well as tumor necrosis factor (TNF)-alpha by the antigen stimulation from sensitized cells.	Resveratrol	0-11	interleukin 13	Mus musculus	83-88
25331546-5	2015	RESULTS: IL-13-dependent eosinophilic and Th2 inflammation was enhanced in mice depleted of alveolar macrophages using clodronate liposomes.	Clodronic Acid	119-129	interleukin 13	Mus musculus	9-14
25574053-4	2015	RESULTS: Recombinant Gal-1 and Dex administration on days 14 through 16 was effective in reducing the clinical signs of allergic conjunctivitis (AC), plasma anti-OVA IgE levels, Th2 (IL-4 and IL-13), and eotaxin/RANTES levels in the lymph nodes.	Dexamethasone	31-34	interleukin 13	Mus musculus	192-197
24988374-5	2015	Here, we tested the hypothesis that reactive oxygen species (ROS) are a critical signaling intermediary between IL-13 or allergen stimulation and TGF-beta-dependent airway remodeling.	Reactive Oxygen Species	36-59	interleukin 13	Mus musculus	112-117
24988374-5	2015	Here, we tested the hypothesis that reactive oxygen species (ROS) are a critical signaling intermediary between IL-13 or allergen stimulation and TGF-beta-dependent airway remodeling.	Reactive Oxygen Species	61-64	interleukin 13	Mus musculus	112-117
26347589-7	2015	In addition, the treatment of EAT-bearing mice with indomethacin has stimulated the IL-13 production and has significantly inhibited IL-6 in the 13th day of tumor growth.	Indomethacin	52-64	interleukin 13	Mus musculus	84-89
25433342-11	2015	Our data showed that PF oral administration significantly reduced airway hyperresponsiveness to aerosolized methacholine and decreased IL-5, IL-13, IL-17 and eotaxin levels in the BALF, and decreased IgE level in the serum.	peoniflorin	21-23	interleukin 13	Mus musculus	141-146
26300589-6	2015	Treatment of ovalbumin-sensitized and ovalbumin-challenged BALB/c mice with DMPF-1 (0.2-100 mg/kg) demonstrated significant reduction in the secretion and gene expression of CC chemokines (RANTES, eotaxin-1, and MCP-1) and Th2 cytokines (IL-4, IL-5, and IL-13).	2,5-dimethyl-4-(1-pyrrolidinyl)-3(2h)-furanone	76-80	interleukin 13	Mus musculus	254-259
25551570-9	2014	Instillation of bleomycin but not Ad increased the expression of IL-1alpha, IL-13 and IL-16.	Bleomycin	16-25	interleukin 13	Mus musculus	76-81
24996263-10	2014	OC-20 blocked the HDM-induced IgE response, and T cells incubated with dendritic cells (DCs) from Postn(-/-) mice or treated with OC-20 showed deficient DNA synthesis and IL-13 responses compared with T cells incubated with wild-type DCs.	oc-20	130-135	interleukin 13	Mus musculus	171-176
25472740-9	2014	RESULTS: Dp-challenged SP-D-/- mice demonstrate increased sub-epithelial fibrosis, collagen production, eosinophil infiltration, TGF-beta1, and IL-13 production, when compared to Dp-challenged WT mice.	dp	9-11	interleukin 13	Mus musculus	144-149
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Mesalamine	21-42	interleukin 13	Mus musculus	154-159
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Mesalamine	44-49	interleukin 13	Mus musculus	154-159
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Salicylic Acid	28-42	interleukin 13	Mus musculus	154-159
25101553-6	2014	Oral administration of 65, 130 and 195 mg/kg 5-ASA significantly reduced the OVA induced total and differential leucocyte count, TNF-alpha, IL-6, IL-13, nitrite, nitrate, MDA, MPO and TPL levels in the lung lavage samples.	Mesalamine	45-50	interleukin 13	Mus musculus	146-151
25472740-11	2014	Purified eosinophils stimulated with Dp produced TGF-beta1 and IL-13, which was prevented by co-incubation with SP-D.	dp	37-39	interleukin 13	Mus musculus	63-68
25550915-12	2014	Baicalin and mesalazine treatment suppressed the expression of TNF-alpha, IL-6 and IL-13 mRNA (P &lt; 0.05), yet up-regulated the expression of IL-10 mRNA (P &lt; 0.05), compared to the DDS and control groups.	baicalin	0-8	interleukin 13	Mus musculus	83-88
25550915-12	2014	Baicalin and mesalazine treatment suppressed the expression of TNF-alpha, IL-6 and IL-13 mRNA (P &lt; 0.05), yet up-regulated the expression of IL-10 mRNA (P &lt; 0.05), compared to the DDS and control groups.	Mesalamine	13-23	interleukin 13	Mus musculus	83-88
25612451-9	2014	The glycyrrhizin acid significantly inhibited IL-1beta, IL-3, IL-5, IL-6, IL-10, IL-12 (p40), IL-12 (p70), IL-13, Eotaxin and TNF-alpha secreted by LPS-stimulated RAW264.7 cells (P &lt; 0.05).	glycyrrhizin acid	4-21	interleukin 13	Mus musculus	107-112
24831554-0	2014	Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice.	Oxazolone	75-84	interleukin 13	Mus musculus	41-55
24831554-4	2014	In the current study, the bifunctional IL-4/IL-13 antagonist was evaluated in the murine oxazolone-induced colitis model, which produces disease with features of ulcerative colitis.	Oxazolone	89-98	interleukin 13	Mus musculus	44-49
25172162-0	2014	Glyphosate-rich air samples induce IL-33, TSLP and generate IL-13 dependent airway inflammation.	glyphosate	0-10	interleukin 13	Mus musculus	60-65
25172162-7	2014	Exposure to glyphosate-rich air samples as well as glyphosate alone to the lungs increased: eosinophil and neutrophil counts, mast cell degranulation, and production of IL-33, TSLP, IL-13, and IL-5.	glyphosate	12-22	interleukin 13	Mus musculus	182-187
25172162-7	2014	Exposure to glyphosate-rich air samples as well as glyphosate alone to the lungs increased: eosinophil and neutrophil counts, mast cell degranulation, and production of IL-33, TSLP, IL-13, and IL-5.	glyphosate	51-61	interleukin 13	Mus musculus	182-187
25172162-11	2014	Glyphosate-rich farm air samples as well as glyphosate alone were found to induce pulmonary IL-13-dependent inflammation and promote Th2 type cytokines, but not IL-4 for glyphosate alone.	glyphosate	0-10	interleukin 13	Mus musculus	92-97
25172162-11	2014	Glyphosate-rich farm air samples as well as glyphosate alone were found to induce pulmonary IL-13-dependent inflammation and promote Th2 type cytokines, but not IL-4 for glyphosate alone.	glyphosate	44-54	interleukin 13	Mus musculus	92-97
25170825-9	2014	In addition to reducing the DNCB-induced increase in serum IgE, 7,8,4"-THIF also lowered skin lesion levels of the chemokine thymus and activation regulated chemokine; Th2 cytokines interleukin (IL)-4, IL-5, and IL-13; and Th1 cytokines IL-12 and interferon-gamma.	Dinitrochlorobenzene	28-32	interleukin 13	Mus musculus	212-217
25042746-9	2014	RESULTS: WT mice treated with indomethacin had greater numbers of total cells, eosinophils, and lymphocytes, and increased IL-5 and IL-13 protein expression in BAL fluid compared to vehicle-treated mice.	Indomethacin	30-42	interleukin 13	Mus musculus	132-137
25213768-6	2014	The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P&lt;0.05).	Simvastatin	22-33	interleukin 13	Mus musculus	149-154
24927487-7	2014	The PQ treatment decreased the inflammatory cell count in the bronchoalveolar lavage fluid of the mice and reduced the levels of interleukin (IL)-4, IL-5, IL-13 and immunoglobulin (Ig)E when compared with those in the OVA group.	Primaquine	4-6	interleukin 13	Mus musculus	155-160
24858619-6	2014	Activation of PPAR-gamma by rosiglitazone reduced IL-13-induced collagen expression by suppression of STAT6-driven PDGF production.	Rosiglitazone	28-41	interleukin 13	Mus musculus	50-55
24755955-9	2014	We found that treatments with sesamin after OVA sensitization and challenge significantly decreased expression levels of interleukin-4 (IL-4), IL-5, IL-13, and serum IgE.	sesamin	30-37	interleukin 13	Mus musculus	149-154
24879958-12	2014	In addition, PM014 reduced the levels of Th2 cytokines (IL-4, IL-5 and IL-13) in the BAL fluid and inflammatory mediators such as IgE in the serum, as measured by enzyme-linked immunosorbent assay (ELISA).	pm014	13-18	interleukin 13	Mus musculus	71-76
23914806-3	2014	This study used an isogenic mouse model to examine the influence of perinatal BPA exposure via maternal diet on inflammatory mediators associated with asthma in 6-month-old adult offspring by measuring bone marrow-derived mast cell (BMMC) production of lipid mediators (cysteinyl leukotrienes and prostaglandin D2), cytokines (interleukin [IL]-4, IL-5, IL-6, IL-13, and tumor necrosis factor [TNF]-alpha), and histamine.	bisphenol A	78-81	interleukin 13	Mus musculus	359-364
25074909-9	2014	Unlike aHSCs, aPFs respond to stimulation with taurocholic acid and IL-25 by induction of collagen-alpha1(I) and IL-13, respectively.	Taurocholic Acid	47-63	interleukin 13	Mus musculus	113-118
25132819-5	2014	Loss of LLF GGT activity in the mutant GGT(enu1) mouse causes an increase in baseline LLF glutathione content which is magnified in an IL-13 model of allergic airway inflammation and protective against asthma.	Glutathione	90-101	interleukin 13	Mus musculus	135-140
25132819-11	2014	But mice treated with IL-13 and GGsTop show attenuation of methacholine-stimulated airway hyper-reactivity, inhibition of Muc5ac and Muc5b gene induction, decreased airway epithelial cell mucous accumulation and a fourfold increase in LLF glutathione content compared to mice treated with IL-13 alone.	Methacholine Chloride	59-71	interleukin 13	Mus musculus	22-27
25132819-11	2014	But mice treated with IL-13 and GGsTop show attenuation of methacholine-stimulated airway hyper-reactivity, inhibition of Muc5ac and Muc5b gene induction, decreased airway epithelial cell mucous accumulation and a fourfold increase in LLF glutathione content compared to mice treated with IL-13 alone.	Glutathione	239-250	interleukin 13	Mus musculus	22-27
23914806-6	2014	Following BMMC activation, increases in cysteinyl leukotriene (p &lt; 0.01) and TNFalpha (p &lt; 0.05) production were observed in all BPA-exposure groups, and increases in prostaglandin D2 (p &lt; 0.01) and IL-13 (p &lt; 0.01) production were observed in the high exposure group.	bisphenol A	135-138	interleukin 13	Mus musculus	208-213
24220301-0	2014	Retinoic acid prevents mesenteric lymph node dendritic cells from inducing IL-13-producing inflammatory Th2 cells.	Tretinoin	0-13	interleukin 13	Mus musculus	75-80
24220301-10	2014	These results suggest that RA inhibits allergic responses to oral antigens by preventing MLN-DCs from inducing IL-13-producing inflammatory Th2 cells.	Tretinoin	27-29	interleukin 13	Mus musculus	111-116
24583134-4	2014	Furthermore, both Cyclosporin A (CsA, a specific NFAT inhibitor) and LY294002 (a Phosphoinositide 3-kinase (PI3K) inhibitor) significantly blocked IL-13-induced MUC5AC mRNA and protein production through the inhibition of NFAT3 activity.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	69-77	interleukin 13	Mus musculus	147-152
24397465-6	2014	RESULTS: Kynurenine, but not KA and QA, enhanced IgE-mediated responses, including degranulation, LTC4 release, and IL-13 production in BMMCs through the activation of PLCgamma1, Akt, MAPK p38, and the increase of intracellular calcium.	Kynurenine	9-19	interleukin 13	Mus musculus	116-121
24847698-9	2014	In addition, production of interleukin-13 and interferon-gamma were increased in OVA-stimulated splenocytes recovered from BPA-exposed mice.	bisphenol A	123-126	interleukin 13	Mus musculus	27-41
24587397-8	2014	Combined stimulation with both smoke and RSV synergistically induced cytokine (IL-1alpha, IL-17, IFN-gamma, KC, IL-13, CXCL9, RANTES, MIF and GM-CSF) and protease (MMP-2, -8, -12, -13, -16 and cathepsins E, S, W and Z) expression.	Respiratory Syncytial Virus Vaccines	41-44	interleukin 13	Mus musculus	112-117
24561545-8	2014	In contrast, Dex significantly decreased Th1 and Th2 cytokines in MLNs and also decreased them (except IL-13 and IL-2) in spleen.	Dexamethasone	13-16	interleukin 13	Mus musculus	103-108
24521096-8	2014	The levels of cytokines, such as IL-4, IL-5, IL-10, and IL-13 decreased in the splenocytes of EBT-treated mice.	ebt	94-97	interleukin 13	Mus musculus	56-61
24458645-4	2014	However, vitamin A deprivation paradoxically resulted in dramatic expansion of interleukin-13 (IL-13)-producing ILC2s and resistance to nematode infection in mice, which revealed that ILCs are primary sensors of dietary stress.	Vitamin A	9-18	interleukin 13	Mus musculus	79-93
24374304-4	2014	Oleanolic acid suppressed eosinophil infiltration, allergic airway inflammation, and Penh, which occurred by suppressing the production of IL-5, IL-13, IL-17, and ovalbumin-specific IgE through the upregulation of T-bet and Foxp3, and the downregulation of GATA-3 and RORgammat.	Oleanolic Acid	0-14	interleukin 13	Mus musculus	145-150
24374304-5	2014	The therapeutic effect of oleanolic acid was due to suppression of Th2 cytokines (IL-5 and IL-13), B cell-dependent production of OVA-specific IgE, and Gr-1 expression through the T-bet, GATA-3, retinoic acid-related orphan receptor gamma t (RORgamma t) and forkhead box p3 (Foxp3) transcription pathways.	Oleanolic Acid	26-40	interleukin 13	Mus musculus	91-96
24499286-13	2014	NiNPs also increased IL-13 and eosinophils (p &lt; 0.001) in BALF from T-bet-/- mice after 1 day.	ninps	0-5	interleukin 13	Mus musculus	21-26
24458645-4	2014	However, vitamin A deprivation paradoxically resulted in dramatic expansion of interleukin-13 (IL-13)-producing ILC2s and resistance to nematode infection in mice, which revealed that ILCs are primary sensors of dietary stress.	Vitamin A	9-18	interleukin 13	Mus musculus	95-100
24211923-7	2014	Further, SDG-CUR effectively alleviated airway hyperresponsiveness and levels of T-helper 2 cytokines (interleukin-4, interleukin-5, and interleukin-13) in a murine model of asthma.	secoisolariciresinol diglucoside	9-12	interleukin 13	Mus musculus	137-151
24465497-13	2014	RNA-Seq results showed downregulation of genes in the inducible nitric oxide synthase (iNOS) signaling pathway in PBS-treated DDAH1-transgenic mice versus PBS-treated wild type mice and downregulation of genes in IL-13/FOXA2 signaling pathway in HDM-treated DDAH1-transgenic mice versus HDM-treated wild type mice.	Lead	114-117	interleukin 13	Mus musculus	213-218
24449779-7	2014	Treatment with silymarin also reduced the levels of interleukin-13 (IL-13) in serum and increased the gamma interferon (IFN-gamma)/IL-13 ratio.	Silymarin	15-24	interleukin 13	Mus musculus	52-66
24449779-7	2014	Treatment with silymarin also reduced the levels of interleukin-13 (IL-13) in serum and increased the gamma interferon (IFN-gamma)/IL-13 ratio.	Silymarin	15-24	interleukin 13	Mus musculus	68-73
24449779-7	2014	Treatment with silymarin also reduced the levels of interleukin-13 (IL-13) in serum and increased the gamma interferon (IFN-gamma)/IL-13 ratio.	Silymarin	15-24	interleukin 13	Mus musculus	131-136
24449779-8	2014	There was a linear correlation between IL-13 levels in serum and hydroxyproline hepatic content in both infected untreated and SIL-treated mice, with decreased IL-13 levels corresponding to decreased hydroxyproline hepatic contents.	Hydroxyproline	65-79	interleukin 13	Mus musculus	39-44
24449779-9	2014	Treatment with either SIL or N-acetylcysteine reduced both proliferation of fibroblast cell lines and basal/IL-13-induced production of collagen I, indicating that besides inhibiting IL-13 production during infection, SIL antioxidant properties most likely contribute to inhibition of collagen production downstream of IL-13.	Acetylcysteine	29-45	interleukin 13	Mus musculus	108-113
24449779-9	2014	Treatment with either SIL or N-acetylcysteine reduced both proliferation of fibroblast cell lines and basal/IL-13-induced production of collagen I, indicating that besides inhibiting IL-13 production during infection, SIL antioxidant properties most likely contribute to inhibition of collagen production downstream of IL-13.	Acetylcysteine	29-45	interleukin 13	Mus musculus	183-188
24449779-9	2014	Treatment with either SIL or N-acetylcysteine reduced both proliferation of fibroblast cell lines and basal/IL-13-induced production of collagen I, indicating that besides inhibiting IL-13 production during infection, SIL antioxidant properties most likely contribute to inhibition of collagen production downstream of IL-13.	Acetylcysteine	29-45	interleukin 13	Mus musculus	183-188
24449779-10	2014	These results show that silymarin interferes with fibrogenic cytokines, reduces established fibrosis, and inhibits downstream effects of IL-13 on fibrogenesis, indicating the drug as a safe and cheap treatment to liver fibrotic disease in schistosomiasis.	Silymarin	24-33	interleukin 13	Mus musculus	137-142
25110399-7	2014	Administration of cystamine, an inhibitor of tTG, abrogated the increase in both tTG and IL-13 in infected mice and ameliorated liver fibrogenesis and granuloma development.	Cystamine	18-27	interleukin 13	Mus musculus	89-94
25036132-3	2014	In this study, we found that cyanidin-3-glucoside chloride (C3G), an anthocyanin suppressed IL-4 and IL-13 produced in activated EL-4 T cells but not Th1 cytokines including IL-2, interferon-gamma, or IL-12.	cyanidin-3-o-glucoside	29-58	interleukin 13	Mus musculus	101-106
25036132-3	2014	In this study, we found that cyanidin-3-glucoside chloride (C3G), an anthocyanin suppressed IL-4 and IL-13 produced in activated EL-4 T cells but not Th1 cytokines including IL-2, interferon-gamma, or IL-12.	Anthocyanins	69-80	interleukin 13	Mus musculus	101-106
24770638-9	2014	Measurement of GATA-3-induced cytokines demonstrated that IL-13 was highly expressed in the colon from DSS-induced GATA-3 Tg mice.	Dextran Sulfate	103-106	interleukin 13	Mus musculus	58-63
23413283-9	2013	In TSLPR-deficient mice, bleomycin-induced fibrosis was significantly reduced in parallel with significantly reduced local expression of IL-13.	Bleomycin	25-34	interleukin 13	Mus musculus	137-142
24403255-4	2013	Indeed, IL-13(-/-) mice developed more papillomas after exposure to DMBA/TPA than their heterozygous IL-13-competent littermate controls.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	68-72	interleukin 13	Mus musculus	8-13
24403255-0	2013	IL-13 but not IL-4 signaling via IL-4Ralpha protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis.	dmba/tpa	90-98	interleukin 13	Mus musculus	0-5
24403255-4	2013	Indeed, IL-13(-/-) mice developed more papillomas after exposure to DMBA/TPA than their heterozygous IL-13-competent littermate controls.	Tetradecanoylphorbol Acetate	73-76	interleukin 13	Mus musculus	8-13
24403255-7	2013	Conversely, IL-13 does not affect MCA carcinogenesis but protects mice from DMBA/TPA carcinogenesis.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	76-80	interleukin 13	Mus musculus	12-17
24403255-7	2013	Conversely, IL-13 does not affect MCA carcinogenesis but protects mice from DMBA/TPA carcinogenesis.	Tetradecanoylphorbol Acetate	81-84	interleukin 13	Mus musculus	12-17
24403255-9	2013	Taken together, our results indicate that the course of DMBA/TPA- and MCA-induced carcinogenesis is affected differently by IL-4 versus IL-13-mediated inflammatory cascades.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	56-60	interleukin 13	Mus musculus	136-141
24403255-9	2013	Taken together, our results indicate that the course of DMBA/TPA- and MCA-induced carcinogenesis is affected differently by IL-4 versus IL-13-mediated inflammatory cascades.	Tetradecanoylphorbol Acetate	61-64	interleukin 13	Mus musculus	136-141
24133168-7	2013	Upregulation of TNF-alpha, TGF-beta, and chemokines, as well as increased collagen deposition and airway hyperreactivity to methacholine were all clearly sensitive to IL-13-PE.	Methacholine Chloride	124-136	interleukin 13	Mus musculus	167-172
24140646-9	2013	Interestingly, IL-13 strongly stimulates TRPA1 expression, which is functional in calcium mobilization in mast cells.	Calcium	82-89	interleukin 13	Mus musculus	15-20
24028304-4	2013	RESULTS: Our study demonstrated that Lico A may effectively inhibit the increase in T-helper type 2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13 in bronchoalveolar lavage fluid, and reduced serum levels of OVA-specific IgE and IgG.	licochalcone A	37-43	interleukin 13	Mus musculus	148-153
24133168-0	2013	IL-13 immunotoxin accelerates resolution of lung pathological changes triggered by silica particles in mice.	Silicon Dioxide	83-89	interleukin 13	Mus musculus	0-5
24133168-8	2013	In addition, IL-13-PE inhibited both IL-13-induced proliferation of cultured lung fibroblasts from silicotic mice and silica-induced IL-8 generation from A549 cells.	Silicon Dioxide	118-124	interleukin 13	Mus musculus	13-18
24133168-5	2013	Upregulation of IL-13, its receptor subunits IL-13Ralpha1 and IL-13Ralpha2, and shared receptor IL-4Ralpha were associated with development of granulomatous lung inflammation triggered by silica.	Silicon Dioxide	188-194	interleukin 13	Mus musculus	16-21
24133168-9	2013	In conclusion, our findings show that therapeutic treatment with IL-13-PE can reverse important pathological features caused by inhalation of silica particles, suggesting that this recombinant immunotoxin is a promising molecular template in drug discovery for the treatment of silicosis.	Silicon Dioxide	142-148	interleukin 13	Mus musculus	65-70
24133168-6	2013	IL-13-PE inhibited silica-induced granuloma and fibrotic responses noted at 24 h and 15 d after the last treatment.	Silicon Dioxide	19-25	interleukin 13	Mus musculus	0-5
24112389-11	2013	However, treatment with imatinib and GNF-5 inhibited the ovalbumin-induced increase in IL-13 and CCL2 as well as airway resistance and smooth muscle growth in animals.	Imatinib Mesylate	24-32	interleukin 13	Mus musculus	87-92
24126112-5	2013	The administration of montelukast caused a reduction in elevated interleukin (IL)-4, IL-13, eotaxin, immunoglobulin (Ig), inflammatory cell infiltration into the airways, and mucus production after repeated OVA challenges.	montelukast	22-33	interleukin 13	Mus musculus	85-90
23994558-10	2013	In conclusion, curine showed anti-allergic activity through mechanisms that involve inhibition of IL-13 and eotaxin and of Ca(++) influx, without inducing evident toxicity and as such, has the potential for the development of anti-asthmatic drugs.	curine	15-21	interleukin 13	Mus musculus	98-103
24013845-2	2013	Using IL-4-green fluorescent protein (GFP) reporter mice, we demonstrated that Bavachinin, a single compound isolated from a Chinese herb, significantly inhibited Th2 cytokine production, including IL-4, IL-5 and IL-13.	bavachinin	79-89	interleukin 13	Mus musculus	213-218
22686327-9	2013	Collectively, our data suggest that MWCNT induce epithelial damage that results in release of IL-33, which in turn promotes innate lymphoid cell recruitment and the development of IL-13-dependent inflammatory response.	mwcnt	36-41	interleukin 13	Mus musculus	180-185
24124601-12	2013	GM-IMs showed enhanced expression of M2 macrophage markers such as Arg1 and Retnla following stimulation by Th2 cytokines IL-4 and IL-13.	gm	0-2	interleukin 13	Mus musculus	131-136
23784081-2	2013	Azoxymethane-induced aberrant crypt focus (ACF; 6 weeks) and tumours (32 weeks) were analysed in wild-type (WT) BALB/c mice, as well as in IL-4Ralpha (-) (/-) , IL-13 (-/-) and "double-knockout" (DKO) animals.	Azoxymethane	0-12	interleukin 13	Mus musculus	161-166
23582173-4	2013	Accordingly diarrhoea and DSS-induced colon inflammation were impaired in ST2(-/-) BALB/c mice and exacerbated in wild-type mice by treatment with exogenous recombinant IL-33, associated respectively with reduced and enhanced expression of chemokines (CXCL9 and CXCL10), and inflammatory (IL-4, IL-13, IL-1, IL-6, IL-17) and angiogenic (vascular endothelial growth factor) cytokines in vivo.	dss	26-29	interleukin 13	Mus musculus	295-300
23759184-11	2013	IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA.	Steroids	69-76	interleukin 13	Mus musculus	38-43
24015275-6	2013	PRINCIPAL FINDINGS AND CONCLUSION: Elevated colonic IL-13 levels were observed in WT mice receiving DSS in comparison to control.	Dextran Sulfate	100-103	interleukin 13	Mus musculus	52-57
23165939-7	2013	Chronic treatment with 7, 4"-DHF in a murine model of allergic asthma not only significantly reduced eosinophilic pulmonary inflammation, serum IgE levels, IL-4 and IL-13 levels, but also increased IFN-gamma production in lung cell cultures in response to antigen stimulation.	7,4'-dihydroxyflavone	23-32	interleukin 13	Mus musculus	165-170
23848565-3	2013	We showed that MS and the synthetic peroxisome proliferator-activated receptor (PPAR)-gamma ligand rosiglitazone (RG) significantly inhibited the production of Th2 cytokines, including IL-4, IL-5, and IL-13, in PMA/ionomycin-activated mouse EL-4 T cells.	Rosiglitazone	99-112	interleukin 13	Mus musculus	201-206
24015275-5	2013	METHODOLOGY: Colitis was induced in IL-13 deficient (IL-13-/-) and wild-type (WT) mice with dextran sulfate sodium (DSS) and dinitrobenzene sulfonic acid (DNBS), as well as in IL-13-/- mice given recombinant mouse IL-13 (rmIL-13) and 5-hydroxytryptamine (5-HTP), the direct precursor of 5-HT.	Dextran Sulfate	92-114	interleukin 13	Mus musculus	36-41
24015275-7	2013	IL-13-/- mice administered DSS exhibited significantly reduced severity of colitis compared to WT mice as reflected by macroscopic and histological damage assessments.	Dextran Sulfate	27-30	interleukin 13	Mus musculus	0-5
24015275-8	2013	Following DSS administration, significantly lower pro-inflammatory cytokine production and fewer infiltrating macrophages were observed in IL-13-/- mice compared to WT.	Dextran Sulfate	10-13	interleukin 13	Mus musculus	139-144
24015275-11	2013	IL-13-/- mice also exhibited reduced severity of DNBS-induced colitis.	dinitrobenzenesulfonic acid	49-53	interleukin 13	Mus musculus	0-5
23727181-8	2013	RESULTS: Taraxasterol dramatically decreased the total inflammatory cell and main inflammatory cell counts, reduced the production of Th2 cytokine IL-4, IL-5, IL-13 in BALF and OVA-specific IgE in sera, and suppressed AHR in a dose-dependent manner.	taraxasterol	9-21	interleukin 13	Mus musculus	159-164
23433705-8	2013	PE-pulsed splenic DC from TCDD-treated mice suppressed IL-5, IL-13 and IFN-gamma production by PE-specific T cells, but did not induce CD4+CD25+Foxp3+ T(reg) cells.	Polychlorinated Dibenzodioxins	26-30	interleukin 13	Mus musculus	61-66
23644142-7	2013	In OVA-sensitized and challenged mice, AMPH and MK-801 given alone decreased cellular migration into the lung, reduced IL-13 and IL10 levels in BAL supernatant, reduced ICAM-1 and L-selectin expression in granulocytes in the BAL and decreased mast cell degranulation.	Amphetamine	39-43	interleukin 13	Mus musculus	119-124
23644142-7	2013	In OVA-sensitized and challenged mice, AMPH and MK-801 given alone decreased cellular migration into the lung, reduced IL-13 and IL10 levels in BAL supernatant, reduced ICAM-1 and L-selectin expression in granulocytes in the BAL and decreased mast cell degranulation.	Dizocilpine Maleate	48-54	interleukin 13	Mus musculus	119-124
23644142-9	2013	When both drugs were administered, treatment with MK-801 reversed the decrease in the number of eosinophils and neutrophils induced by AMPH in the BAL of OVA-sensitized and challenged mice as well as the effects on the expression of L-selectin and ICAM-1 in granulocytes, the IL-10, IL-5 and IL-13 levels in BAL supernatants and increased mast cell degranulation.	Dizocilpine Maleate	50-56	interleukin 13	Mus musculus	292-297
23434795-7	2013	Flow cytometry analysis of lung cells indicated greater IL-13-expressing CD(4+) cells in Cpe(fat) versus WT mice after O(3) exposure.	Ozone	119-123	interleukin 13	Mus musculus	56-61
23747851-5	2013	When exposed to ozone, the asthmatic mice expressed more neutrophils, TNF-alpha, IL-13, and hyaluronan in bronchoalveolar lavage than controls.	Ozone	16-21	interleukin 13	Mus musculus	81-86
23632310-6	2013	RESULTS: Our study demonstrated that, compared with model group, GA inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-gamma level in bronchoalveolar lavage fluid; histological studies demonstrated that GA substantially inhibited OVA-induced eosinophilia in lung tissue and airway tissue compared with model group.	Glycyrrhizic Acid	65-67	interleukin 13	Mus musculus	155-160
23454147-4	2013	CG ameliorated DNCB-induced dermatitis severity, serum levels of IgE and TARC, and mRNA expression of TARC, TNF-alpha, IFN-gamma, IL-4, IL-5, and IL-13 in mice.	Dinitrochlorobenzene	15-19	interleukin 13	Mus musculus	146-151
23434795-8	2013	In Cpe(fat) mice, anti-IL-13 treatment attenuated O(3)-induced increases in pulmonary mechanics and inflammatory cell recruitment, but did not affect AHR.	Ozone	50-54	interleukin 13	Mus musculus	23-28
23434795-12	2013	In particular, in obese mice, O(3) induces IL-13 and IL-13 synergizes with TNF via TNFR2 to exacerbate O(3)-induced changes in pulmonary mechanics and inflammatory cell recruitment but not AHR.	Ozone	30-34	interleukin 13	Mus musculus	43-48
23434795-12	2013	In particular, in obese mice, O(3) induces IL-13 and IL-13 synergizes with TNF via TNFR2 to exacerbate O(3)-induced changes in pulmonary mechanics and inflammatory cell recruitment but not AHR.	Ozone	30-34	interleukin 13	Mus musculus	53-58
22902330-7	2013	On the contrary, omega-3 fatty acids had less significant effects on IL-4 and IL-5 and resulted in a slight decrease in IL-13 production in EL-4 T cells.	Fatty Acids, Omega-3	17-36	interleukin 13	Mus musculus	120-125
22902330-2	2013	Alpha-linolenic acid and its metabolites including eicosapentaenoic acid and decosahexaenoic acid induced a dramatic decrease in the production of interleukin (IL)-4, IL-5 and IL-13 in a dose-dependent manner, as well as mRNA expression of their genes, in activated MC/9 mast cells and bone marrow-derived mast cells.	alpha-Linolenic Acid	0-20	interleukin 13	Mus musculus	176-181
22902330-2	2013	Alpha-linolenic acid and its metabolites including eicosapentaenoic acid and decosahexaenoic acid induced a dramatic decrease in the production of interleukin (IL)-4, IL-5 and IL-13 in a dose-dependent manner, as well as mRNA expression of their genes, in activated MC/9 mast cells and bone marrow-derived mast cells.	Eicosapentaenoic Acid	51-72	interleukin 13	Mus musculus	176-181
23661516-7	2013	RESULTS: The results showed that hydrogen-rich saline reduced cell counts and levels of cytokines IL-4, IL-5, IL-13 and TNF-alpha in BALF.	Hydrogen	33-41	interleukin 13	Mus musculus	110-115
22902330-2	2013	Alpha-linolenic acid and its metabolites including eicosapentaenoic acid and decosahexaenoic acid induced a dramatic decrease in the production of interleukin (IL)-4, IL-5 and IL-13 in a dose-dependent manner, as well as mRNA expression of their genes, in activated MC/9 mast cells and bone marrow-derived mast cells.	decosahexaenoic acid	77-97	interleukin 13	Mus musculus	176-181
23646158-0	2013	Baicalein reduces airway injury in allergen and IL-13 induced airway inflammation.	baicalein	0-9	interleukin 13	Mus musculus	48-53
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	interleukin 13	Mus musculus	128-133
23291432-9	2013	Consistent with these findings, IL-13 levels were reduced in bleomycin-challenged murine skin upon PXR activation.	Bleomycin	61-70	interleukin 13	Mus musculus	32-37
26417226-6	2013	NAC significantly decreased neutrophil and eosinophil count in BALF as well as inflammatory cytokines (IL-13 and IL-5).We concluded that addition of NAC to asthma therapy has beneficial preventive effects in an animal model of steroid resistant acute exacerbation of asthma.	Acetylcysteine	149-152	interleukin 13	Mus musculus	103-108
23760007-8	2013	Rutin suppressed DFE/DNCB-induced expression of interleukin (IL)-4, IL-5, IL-13, IL-31, IL-32 and interferon (INF)-gamma in the tissue.	1,1-difluoroethane	17-20	interleukin 13	Mus musculus	74-79
23760007-8	2013	Rutin suppressed DFE/DNCB-induced expression of interleukin (IL)-4, IL-5, IL-13, IL-31, IL-32 and interferon (INF)-gamma in the tissue.	Dinitrochlorobenzene	21-25	interleukin 13	Mus musculus	74-79
23403738-8	2013	EBM84 administration significantly lowered elevated levels of interleukin (IL)-4, IL-13, eotaxin and immunoglobulin (Ig)E in the bronchoalveolar lavage fluid or plasma.	ebm84	0-5	interleukin 13	Mus musculus	82-87
22560858-1	2013	PURPOSE: We administered recombinant interleukin (IL)-4 and recombinant IL-13 locally into the air pouch of mice to improve bone resorption induced by ultra-high-molecular-weight polyethylene (UHMWPE) particles.	Polyethylene	179-191	interleukin 13	Mus musculus	72-77
23298698-10	2013	Local PGE2 administration prevented the increase of airway IL-13 and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.	Dinoprostone	6-10	interleukin 13	Mus musculus	59-64
22849952-8	2013	Ova-activated splenocytes from DHA-fed mice produced less IL-13 (57.2 (se 21.7) pg/ml) and IL-4 (7.33 (SE 3.4) pg/ml) compared with cells from the animals fed the control diet (161.5 (SE 45.0), P&lt; 0.05; 33.2 (SE 11.8), P&lt; 0.05).	dehydroacetic acid	31-34	interleukin 13	Mus musculus	58-63
23180828-10	2013	Indeed, DFO-fed mice had significantly higher plasma IL-5, IL-13, and IL-9 (Th2-biasing cytokines) and cecal IgA compared with CON.	Deferoxamine	8-11	interleukin 13	Mus musculus	59-64
23452625-5	2013	We recently showed that an administration of polyinocinic polycytidilic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13.	polyinocinic polycytidilic acid	45-76	interleukin 13	Mus musculus	232-237
23452625-5	2013	We recently showed that an administration of polyinocinic polycytidilic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13.	poly ic	78-85	interleukin 13	Mus musculus	232-237
23653970-5	2013	RESULTS: After sensitization with aluminum hydroxide and challenge with T putrescentiae in mice, levels of T putrescentiae-specific IgE and IgG1 in sera increased significantly compared to the normal saline group (P &lt; .01): Values for inflammatory leukocytes (neutrophils and eosinophils) and cytokines (interleukin [IL] 4, IL-5, and IL-13) increased significantly after sensitization.	Aluminum Hydroxide	34-52	interleukin 13	Mus musculus	337-342
23378200-11	2013	Baicalin attenuated the effects of ovalbumin significantly.It can be concluded that baicalin has significant anti-remodeling effect on ovalbumin-induced asthmatic airway remodeling mice model by decreasing expression of transforming growth factor-beta1, interleukin-13, and vascular endothelial growth factor and inhibiting the activation of the extracellular signal-regulated kinase pathway.	baicalin	84-92	interleukin 13	Mus musculus	254-268
22915279-2	2013	The treatment with nor-NOHA and prednisolone inhibited the increase in airway hyperresponsiveness, the number of bronchoalveolar lavage fluid cells, protein expression of arginase I and arginase II, messenger RNA (mRNA) expression of nitric oxide synthase (NOS)2 and Th2 cytokines such as interleukin (IL)-4, IL-5, and IL-13, and the pathological inflammatory changes of the lung.	norLeu3-A(1-7)	19-27	interleukin 13	Mus musculus	319-324
22915279-2	2013	The treatment with nor-NOHA and prednisolone inhibited the increase in airway hyperresponsiveness, the number of bronchoalveolar lavage fluid cells, protein expression of arginase I and arginase II, messenger RNA (mRNA) expression of nitric oxide synthase (NOS)2 and Th2 cytokines such as interleukin (IL)-4, IL-5, and IL-13, and the pathological inflammatory changes of the lung.	Prednisolone	32-44	interleukin 13	Mus musculus	319-324
23014334-9	2013	IFNgamma was also the lowest and IL13 highest in mice fed high vitamin A.	Vitamin A	63-72	interleukin 13	Mus musculus	33-37
23184953-2	2013	In an animal model of asthma, a single administration of minocycline conferred excellent protection against ovalbumin-induced airway eosinophilia, mucus hypersecretion, and Th2 cytokine production (IL-4/IL-5/IL-12(p70)/IL-13/GM-CSF) and a partial protection against airway hyperresponsiveness.	Minocycline	57-68	interleukin 13	Mus musculus	219-224
23781267-10	2013	Artepillin C exerted strong antioxidant activity, significantly inhibited the production of ROS, RNS, NO, and cytokine IL-1 beta , IL-3, IL-4, IL-5, IL-9, IL-12p40, IL-13, IL-17, TNF- alpha , G-CSF, GM-CSF, MCP-1, MIP-1 alpha , MIP-1 beta , RANTES, and KC, and markedly blocked NF- kappa B expression in stimulated RAW264.7 macrophages.	artepillin C	0-12	interleukin 13	Mus musculus	165-170
23921222-10	2013	The OVA-induced AHR in response to methacholine was enhanced by IL-13 in WT mice but not ASK1(-/-) mice.	Methacholine Chloride	35-47	interleukin 13	Mus musculus	64-69
23192912-6	2013	Compared with the animals exposed to OVA alone, increased spleen weights, OVA-specific IgE, interleukin-13 cytokine levels, and numbers of lung eosinophils were demonstrated when mice were coexposed to OVA and triclosan.	Triclosan	210-219	interleukin 13	Mus musculus	92-106
23201068-0	2013	Ursolic acid, a potential PPARgamma agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma.	ursolic acid	0-12	interleukin 13	Mus musculus	128-133
23201068-6	2013	In BALB/c mice, ursolic acid had suppressed eosinophil infiltration, allergic airway inflammation, and Penh, which occurred by suppressing the production of IL-5, IL-13, IL-17, and ovalbumin-specific IgE by blocking the GATA-3 and STAT6 pathways.	ursolic acid	16-28	interleukin 13	Mus musculus	163-168
23201068-7	2013	Our data suggest the therapeutic mechanism of ursolic acid in asthma is based on reductions of Th2 cytokines (IL-5 and IL-13), ovalbumin-specific IgE production, and eosinophil infiltration via the Th2-GATA-3, STAT6, and IL-17-NF-kappaB pathways.	ursolic acid	46-58	interleukin 13	Mus musculus	119-124
22763407-0	2013	IL-13-mediated immunological control of enterochromaffin cell hyperplasia and serotonin production in the gut.	Serotonin	78-87	interleukin 13	Mus musculus	0-5
23257358-8	2013	Consequently, the ability of IL-13 to suppress glucose production was abolished in liver cells lacking Stat3 or IL-13 receptor alpha1 (Il-13ralpha1), which suggests that the IL-13Ralpha1/Stat3 axis directs IL-13 signaling toward metabolic responses.	Glucose	47-54	interleukin 13	Mus musculus	29-34
23174390-12	2012	IL-13 and IL-1beta were decreased 6 hours after alcohol exposure, and exposure to alcohol plus NAP plus SAL did not completely ameliorate the decrease.	Alcohols	48-55	interleukin 13	Mus musculus	0-5
23169588-4	2012	IL-13, as well as IL-4, potentiated the cytotoxic effects of t-butyl hydroperoxide and hydrogen peroxide on mouse DA MN9D cells.	tert-Butylhydroperoxide	61-82	interleukin 13	Mus musculus	0-5
23169588-4	2012	IL-13, as well as IL-4, potentiated the cytotoxic effects of t-butyl hydroperoxide and hydrogen peroxide on mouse DA MN9D cells.	Hydrogen Peroxide	87-104	interleukin 13	Mus musculus	0-5
23169588-4	2012	IL-13, as well as IL-4, potentiated the cytotoxic effects of t-butyl hydroperoxide and hydrogen peroxide on mouse DA MN9D cells.	Dopamine	114-116	interleukin 13	Mus musculus	0-5
22871385-9	2012	The levels of IL-4, IL-5, IL-13 and eotaxin in mouse splenocytes increased after treatment with concanavalin A and the increase of the cytokines was decreased by pre-treatment with CSH.	csh	181-184	interleukin 13	Mus musculus	26-31
22974581-9	2012	Compared with the model group, PA suppressed airway inflammation, airway hyperresponsive and remodeling, reduced levels of IL-4 and IL-13 in BALF, and IgE in serum, inhibited expression of TGF-beta1 and pSmad2/3, up-regulated the expression of Smad7 in lung tissue, and also increased the levels of INF-gamma in BALF.	praeruptorin A	31-33	interleukin 13	Mus musculus	132-137
22913509-9	2012	Spontaneous and IL-9-dependent survival and IgE-induced IL-13 secretion, but not degranulation, of BMMCs were reduced by rapamycin.	Sirolimus	121-130	interleukin 13	Mus musculus	56-61
22800928-9	2012	Oral treatment with NSO showed significant decrease in airway hyperresponsiveness, the number of total leukocytes, macrophages and eosinophils, levels of IL-4, IL-5 and IL-13 in BALF, serum levels of total IgE, OVA-specific IgE and IgG1, and significant increase in BALF level of IFN-gamma and serum level of OVA-specific IgG2a, indicating restoration of local Th1/Th2 balance.	caraway oil	20-23	interleukin 13	Mus musculus	169-174
22846675-7	2012	Lidocaine administration also prevented other pathophysiological changes triggered by ovalbumin in lung tissue, including peribronchial eosinophil and neutrophil infiltration, subepithelial fibrosis, increased content of collagen and mucus, matrix metalloproteinase-9 activity, and increased levels of IL-4, IL-5, IL-13, and eotaxin-1.	Lidocaine	0-9	interleukin 13	Mus musculus	314-319
22796441-8	2012	Ethanol induced a 10-fold increase in IL-13, from 84 pg/mL in sensitized mice to 845 pg/mL in ethanol-gavaged sensitized mice.	Ethanol	0-7	interleukin 13	Mus musculus	38-43
22796441-8	2012	Ethanol induced a 10-fold increase in IL-13, from 84 pg/mL in sensitized mice to 845 pg/mL in ethanol-gavaged sensitized mice.	Ethanol	94-101	interleukin 13	Mus musculus	38-43
22939729-7	2012	Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF.	Simvastatin	0-11	interleukin 13	Mus musculus	164-169
22562289-5	2012	RESULTS: In utero nicotine increased interleukin-13 and transforming growth factor-beta1 (TGFbeta1) in the neonatal lung.	Nicotine	18-26	interleukin 13	Mus musculus	37-51
22735668-4	2012	Our results showed that the IL-13 peptide kinoid vaccine could             induce sustained and high titer of IL-13-specific IgG when using aluminum hydroxide             as an adjuvant, and could suppress the accumulation of eosinophils as well as             IL-13 levels in bronchoalveolar lavage fluid (BALF).	Aluminum Hydroxide	140-158	interleukin 13	Mus musculus	28-33
22735668-4	2012	Our results showed that the IL-13 peptide kinoid vaccine could             induce sustained and high titer of IL-13-specific IgG when using aluminum hydroxide             as an adjuvant, and could suppress the accumulation of eosinophils as well as             IL-13 levels in bronchoalveolar lavage fluid (BALF).	Aluminum Hydroxide	140-158	interleukin 13	Mus musculus	110-115
22735668-4	2012	Our results showed that the IL-13 peptide kinoid vaccine could             induce sustained and high titer of IL-13-specific IgG when using aluminum hydroxide             as an adjuvant, and could suppress the accumulation of eosinophils as well as             IL-13 levels in bronchoalveolar lavage fluid (BALF).	Aluminum Hydroxide	140-158	interleukin 13	Mus musculus	110-115
22543031-5	2012	Airway responsiveness to bronchoconstrictor agonists was also examined in precision-cut mouse lung slices pretreated without or with IL-13 for 24 h. Acetylcholine and serotonin dose-response curves indicated that IL-13-treated lung slices had a 40 to 50% larger maximal airway constriction compared with controls.	Serotonin	167-176	interleukin 13	Mus musculus	213-218
22543031-6	2012	Furthermore, acetylcholine induced a larger initial Ca(2+) transient and increased Ca(2+) oscillations in IL-13-treated primary mouse ASM cells compared with control cells, correlating with increased cell contraction.	Acetylcholine	13-26	interleukin 13	Mus musculus	106-111
22613653-11	2012	RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression.	Rosuvastatin Calcium	9-21	interleukin 13	Mus musculus	172-177
21799119-3	2012	We recently showed that a low-dose administration of polyinosinic polycytidylic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13 from T cells.	Poly I-C	53-84	interleukin 13	Mus musculus	240-245
21799119-3	2012	We recently showed that a low-dose administration of polyinosinic polycytidylic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13 from T cells.	Poly C	86-93	interleukin 13	Mus musculus	240-245
22480776-7	2012	Similarly to the pre-treatment, post-treatment with warifteine was effective to inhibit significantly AHR to inhaled methacholine and to reduce IL-13 levels in the BAL.	warifteine	52-62	interleukin 13	Mus musculus	144-149
22709239-7	2012	Treatment with imatinib reduced the incidence of diarrhea, inhibited the development of mastocytosis and jejunal mRNA expression of IL-13, CCL1, CCL17 and CCL22.	Imatinib Mesylate	15-23	interleukin 13	Mus musculus	132-137
22709239-11	2012	Imatinib inhibited the development of intestinal mastocytosis, reduced the incidence of diarrhea, and reduced the expression of IL-13, CCL1, and CCL17.	Imatinib Mesylate	0-8	interleukin 13	Mus musculus	128-133
22583375-0	2012	Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells.	Simvastatin	24-35	interleukin 13	Mus musculus	39-44
22583375-4	2012	OBJECTIVES: In this study, we evaluated whether simvastatin inhibits IL-13-induced pro-inflammatory gene expression of asthma-related cytokines in well-differentiated primary mouse tracheal epithelial (MTE) cell cultures.	Simvastatin	48-59	interleukin 13	Mus musculus	69-74
22583375-5	2012	We hypothesized that simvastatin reduces the expression of IL-13-inducible genes in MTE cells.	Simvastatin	21-32	interleukin 13	Mus musculus	59-64
22583375-7	2012	RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells.	Simvastatin	23-34	interleukin 13	Mus musculus	63-68
22583375-9	2012	CONCLUSIONS: Simvastatin modulates the gene expression of selected IL-13-inducible pro-inflammatory cytokines and chemokines in primary mouse tracheal epithelial cells.	Simvastatin	13-24	interleukin 13	Mus musculus	67-72
22564095-3	2012	Treatment with limonene significantly reduced the levels of IL-5, IL-13, eotaxin, MCP-1, and TGF-beta1 in bronchoalveolar lavage fluid.	Limonene	15-23	interleukin 13	Mus musculus	66-71
22546005-0	2012	Maternal immune activation by poly I:C induces expression of cytokines IL-1beta and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain.	Poly I-C	30-38	interleukin 13	Mus musculus	84-89
22085848-3	2012	TA significantly inhibited increases in IgE, levels of ROS and T helper cytokines, such as interleukin (IL)-4, IL-5, TNF-alpha, and IL-13, in bronchoalveolar lavage fluid (BALF), and effectively suppressed airway hyperresponsiveness, eosinophilia, and mucus hypersecretion in the asthmatic mouse model.	tiarellic acid	0-2	interleukin 13	Mus musculus	132-137
22018693-11	2012	Decreased production of IL-4, IL-5, and IL-13 by colonic lamina propria mononuclear cells of the protected SP(-/-) mice confirms the crucial role of these cytokines in oxazolone colitis.	Oxazolone	168-177	interleukin 13	Mus musculus	40-45
22454678-5	2012	Additionally, IL-4 and IL-13 production in ConA-induced splenocytes was inhibited by Zuonin B.	Zuonin B	85-93	interleukin 13	Mus musculus	23-28
22290391-8	2012	Fisetin dose-dependently inhibited ovalbumin-induced increases in total cell count, eosinophil count, and IL-4, IL-5 and IL-13 levels recovered in bronchoalveolar lavage fluid.	fisetin	0-7	interleukin 13	Mus musculus	121-126
21780211-7	2012	The synthesis of IL-5, IL-13, MCP-1 and eotaxin was also decreased in splenocytes of the DcE-treated group, while IFN-gamma was increased in the Dc-administered group.	ethylene dichloride	89-92	interleukin 13	Mus musculus	23-28
22203879-6	2012	In BALB/c mice, we found that MA and MA128 treatment suppressed eosinophil infiltration into airways and blood, allergic airway inflammation and AHR by suppressing the production of IL-5, IL-13, IL-17, Eotaxin, and OVA-specific IgE, by upregulating the production of OVA-specific Th1 cytokine (IFN-gamma), and by downregulating OVA-specific Th2 cytokine (IL-4) in the culture supernatant of spleen cells.	ma128	37-42	interleukin 13	Mus musculus	188-193
21983080-11	2012	CONCLUSIONS: IL-4 appears to induce CD4(+) Th2 cells to produce IL-13 and B cells to produce IgE, which together mediate oxazolone-induced colitis in mice.	Oxazolone	121-130	interleukin 13	Mus musculus	64-69
22829914-12	2012	IL-4 IL-5 and IL-13 levels decreased significantly (p&lt;0.05) after AEBSF treatment while IL-10 levels increased significantly (p&lt;0.05) in BALF.	4-(2-aminoethyl)benzenesulfonylfluoride	69-74	interleukin 13	Mus musculus	14-19
22119406-7	2012	Surprisingly, this glycolipid-induced AHR pathway required not only IL-13 but also IL-33 and its receptor, ST2, because it was blocked by an anti-ST2 mAb and was greatly reduced in ST2(-/-) mice.	Glycolipids	19-29	interleukin 13	Mus musculus	68-73
22119406-8	2012	When adoptively transferred into IL-13(-/-) mice, both wild-type natural helper cells and NKT cells were sufficient for the development of glycolipid-induced AHR.	Glycolipids	139-149	interleukin 13	Mus musculus	33-38
22774468-5	2012	The diisocyanate-inducedsensitization, is associated with the recruitment of CD4 T lymphocytes to the lungs and the production of Th2-type cytokines, including IL-4, IL-5 and IL-13.	4,4'-diphenylmethane diisocyanate	4-16	interleukin 13	Mus musculus	175-180
22467024-6	2012	PA caused statistically significant increases in Th2 cytokines, IL-4, IL-5 and IL-13, compared with the control.	phthalic anhydride	0-2	interleukin 13	Mus musculus	79-84
22962611-7	2012	We found that mice fed resveratrol showed reduced OVA-specific serum IgE production, anaphylactic reaction, and OVA-induced IL-13 and IFN-a production from the mesenteric lymph nodes (MLNs) and spleens in comparison to the control mice, following oral sensitization with OVA plus CT.	Resveratrol	23-34	interleukin 13	Mus musculus	124-129
22962611-8	2012	In addition, resveratrol inhibited OVA plus CT-induced IL-4, IL-13, and IFN-a production in splenocytes from DO11.10 mice associated with inhibition of GATA-3 and T-bet expression.	Resveratrol	13-24	interleukin 13	Mus musculus	61-66
21815907-13	2012	The secretion of IL-13 was increased in the colon of KO mice after AOM/DSS.	dss	71-74	interleukin 13	Mus musculus	17-22
21616524-9	2011	Exogenous administration of let-7 mimic to lungs of mice with allergic inflammation resulted in a decrease in IL-13 levels, resolution of airway inflammation, reduction in airway hyperresponsiveness, and attenuation of mucus metaplasia and subepithelial fibrosis.	let-7	28-33	interleukin 13	Mus musculus	110-115
22021618-9	2011	Increases in IL-13 and leukotrienes were also blocked by rapamycin, although increases in IL-4 were unaffected.	Sirolimus	57-66	interleukin 13	Mus musculus	13-18
22021618-10	2011	These data demonstrated that rapamycin can inhibit cardinal features of allergic asthma, including increases in AHR, IgE, and goblet cells, most likely as a result of its ability to reduce the production of two key mediators of asthma: IL-13 and leukotrienes.	Sirolimus	29-38	interleukin 13	Mus musculus	236-241
22355204-6	2011	The levels of IL-4, IL-5, and IL-13 cytokines in the BALF increased significantly after treatment with rAs22U and OVA.	ras22u	103-109	interleukin 13	Mus musculus	30-35
21867383-7	2011	The cell counting in cross-sections and [(3)H]thymidine incorporation assays revealed a significant increase in the number of MPAE cells cultured with IL-13 compared with a phosphate-buffered saline (PBS) control.	Thymidine	46-55	interleukin 13	Mus musculus	151-156
21867383-7	2011	The cell counting in cross-sections and [(3)H]thymidine incorporation assays revealed a significant increase in the number of MPAE cells cultured with IL-13 compared with a phosphate-buffered saline (PBS) control.	Phosphate-Buffered Saline	173-198	interleukin 13	Mus musculus	151-156
21867383-8	2011	AG1478 abolished the IL-13-stimulated proliferation of MPAE cells.	RTKI cpd	0-6	interleukin 13	Mus musculus	21-26
21364313-8	2011	TPEN also attenuated the upregulation of TNFalpha, IL-13 and IL-4 in BAL fluids and goblet cell hyperplasia after OVA exposure.	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	0-4	interleukin 13	Mus musculus	51-56
21593451-8	2011	In Teff, A2aR activation (CGS21680) potently inhibited the release of IL-1, IL-2, IL-3, IL-4, IL-12, IL-13, IFN-gamma, TNF-alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), CCL3, and CCL4.	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	26-34	interleukin 13	Mus musculus	101-106
21511060-8	2011	In addition, DA-9601 suppressed DFE/DNCB-induced expression of IL-4, IL-13, IL-31, and TNF-alpha in the ears.	1,1-difluoroethane	32-35	interleukin 13	Mus musculus	69-74
21511060-8	2011	In addition, DA-9601 suppressed DFE/DNCB-induced expression of IL-4, IL-13, IL-31, and TNF-alpha in the ears.	Dinitrochlorobenzene	36-40	interleukin 13	Mus musculus	69-74
21659614-12	2011	Praziquantel significantly reduced lung mRNA expression of IL-13, IL-8, and IL-4, but did not reduce serum cytokine levels.	Praziquantel	0-12	interleukin 13	Mus musculus	59-64
21178983-4	2011	We also observed that IL-13 knockout (KO) and signal transducer and activator of transcription 6 knockout (STAT6KO) mice had a lower number of periodic acid Schiff (PAS)+GCs.	periodic acid schiff	143-163	interleukin 13	Mus musculus	22-27
21567101-11	2011	Following significantly elevated expression of hydroxyproline (P&lt;0.01) at 16 weeks p.i., IL-13 and Arg-1 expression reached maximal values in serum and lung tissue and maintained high levels up to 24 weeks p.i., respectively (P&lt;0.01).	Hydroxyproline	47-61	interleukin 13	Mus musculus	92-97
21951583-5	2011	3 In naive mice, responsiveness to MCh was significantly increased by the combination of IL-1beta and TNF-alpha, IL-13 alone or in combination with IL-1beta, but not by treatment with IL-1beta or TNF-alpha alone.	Methacholine Chloride	35-38	interleukin 13	Mus musculus	113-118
21951583-8	2011	In mice sensitized to OVA, albuterol sensitivity was significantly attenuated by treatment with TNF-alpha, IL-13 or IL-13 in combination with IL-1beta.	Albuterol	27-36	interleukin 13	Mus musculus	107-112
21951583-8	2011	In mice sensitized to OVA, albuterol sensitivity was significantly attenuated by treatment with TNF-alpha, IL-13 or IL-13 in combination with IL-1beta.	Albuterol	27-36	interleukin 13	Mus musculus	116-121
21178983-4	2011	We also observed that IL-13 knockout (KO) and signal transducer and activator of transcription 6 knockout (STAT6KO) mice had a lower number of periodic acid Schiff (PAS)+GCs.	Aminosalicylic Acid	165-168	interleukin 13	Mus musculus	22-27
21178983-6	2011	Cyclosporine A treatment during DS maintained the number of NK/NKT cells in the conjunctiva, increased IL-13 mRNA in NK+ cells, and decreased IFN-gamma and IL-17A mRNA transcripts in NK+ and NK- populations.	Cyclosporine	0-14	interleukin 13	Mus musculus	103-108
21615971-9	2011	Moreover, concomitant CS/SEB exposure induced both IL-13 mRNA expression in lungs and goblet cell hyperplasia in the airway wall.	Cesium	22-24	interleukin 13	Mus musculus	51-56
21321603-6	2011	We further demonstrated that IL-4 and IL-13 induced by cisplatin modulated the phosphorylation of STAT6 by binding with IL-4 receptor alpha and IL-13Ralpha1.	Cisplatin	55-64	interleukin 13	Mus musculus	38-43
21519141-2	2011	To analyze inflammation-associated colonic tumorigenesis, we developed a chronic form of oxazolone-induced colitis in mice that, similar to UC, was distinguished by the presence of IL-13-producing NKT cells.	Oxazolone	89-98	interleukin 13	Mus musculus	181-186
21136283-10	2011	Oxytetracycline treatment caused a marked reduction in IL-4, IL-5, IL-13, immune cells, and the level of ovalbumin-specific IgE.	Oxytetracycline	0-15	interleukin 13	Mus musculus	67-72
21826890-0	2011	[Inhibitory effect of paeoniflorin on the collagen production by fibroblasts through IL-13/STAT6 signaling pathway].	peoniflorin	22-34	interleukin 13	Mus musculus	85-90
21826890-1	2011	OBJECTIVE: To observe the effects of paeoniflorin on 3T3 fibroblast activation, proliferation and collagen production through IL-13/STAT6 signaling pathway.	peoniflorin	37-49	interleukin 13	Mus musculus	126-131
21826890-13	2011	CONCLUSION: Paeoniflorin inhibits activation, proliferation of fibroblasts and production of collagen from fibroblasts through IL-13/STAT6 signaling pathway, which might be one of mechanisms of anti-hepatic fibrosis of paeoniflorin in schistosomiasis japonica.	peoniflorin	12-24	interleukin 13	Mus musculus	127-132
21826890-13	2011	CONCLUSION: Paeoniflorin inhibits activation, proliferation of fibroblasts and production of collagen from fibroblasts through IL-13/STAT6 signaling pathway, which might be one of mechanisms of anti-hepatic fibrosis of paeoniflorin in schistosomiasis japonica.	peoniflorin	219-231	interleukin 13	Mus musculus	127-132
22164245-7	2011	Remarkably, CCI induced TNF (p&lt;0.01), IL-1beta (p&lt;0.05), IL-10 (p&lt;0.05), and IL-13 (p&lt;0.001) gene expression exclusively in the ipsilateral spinal cord of IL-4 ko mice.	CCI	12-15	interleukin 13	Mus musculus	86-91
21074454-9	2011	LY204002 abolished RANTES induced IL-13 release, indicating an Akt cell signaling pathway may be involved in the event.	ly204002	0-8	interleukin 13	Mus musculus	34-39
21034736-7	2011	Montelukast treatment also decreased mRNA levels of IL-6, IL-10, IL-13, and TGF-beta1, all of which were elevated in fibrotic lungs.	montelukast	0-11	interleukin 13	Mus musculus	65-70
21034736-11	2011	These results suggest that montelukast exhibits its beneficial effects by inhibiting the overexpression of IL-6, IL-10, IL-13, and TGF-beta1 and by modulating the homeostatic balance between the cysteinyl-leukotriene type 1 and type 2 receptors.	montelukast	27-38	interleukin 13	Mus musculus	120-125
21168540-5	2011	Astilbic acid inhibited OVA-induced AHR to inhaled methacholine and significantly suppressed the levels of T-helper 2-type cytokines (including IL [interleukin]-4, IL-5, and IL-13) and inflammatory cells (including eosinophils) in bronchoalveolar lavage (BAL) fluid.	3beta,6beta-dihydroxyolean-12-en-27-oic acid	0-13	interleukin 13	Mus musculus	174-179
20827786-6	2010	Our data also show that the increased numbers of inflammatory cells, increased airway hyperresponsiveness, levels of IL-4, IL-5, IL-13, and vascular permeability in the lungs after OVA inhalation were significantly reduced by 2-methoxyestradiol or a VEGF inhibitor, CBO-P11.	2-Methoxyestradiol	226-244	interleukin 13	Mus musculus	129-134
20735407-6	2010	Shikonin-treated BM-DCs were poor stimulators of CD4(+) T lymphocyte and induced lower levels of interleukin (IL)-4, IL-5, IL-13 and tumour necrosis factor (TNF)-alpha release by responding T-cells.	shikonin	0-8	interleukin 13	Mus musculus	123-128
20735407-7	2010	After intratracheal instillation of shikonin in OVA-immunized mice, OVA challenge induced lower IL-4, IL-5, IL-13, TNF-alpha and eotaxin release in bronchial alveolar lavage fluid, lower IL-4 and IL-5 production in lung cells and mediastinal lymph node cells and attenuated OVA-induced lung eosinophilia and airway hyperresponsiveness.	shikonin	36-44	interleukin 13	Mus musculus	108-113
20962901-6	2010	Treatment with paeonol significantly enhanced IFN-gamma levels and decreased interleukin-4 and interleukin-13 levels in bronchoalveolar lavage fluid and total immunoglobulin E levels in serum.	paeonol	15-22	interleukin 13	Mus musculus	95-109
21695271-8	2011	Artesunate dose-dependently inhibited OVA-induced increases in total and eosinophil counts, IL-4, IL-5, IL-13 and eotaxin levels in bronchoalveolar lavage fluid.	Artesunate	0-10	interleukin 13	Mus musculus	104-109
21203431-6	2010	After 48 h of incubation with IL-13 a large number of SAEC were transformed into goblet cells as determined by periodic acid-schiff (PAS)-staining and immunohistochemistry using antibodies against Mucin5AC.	periodic acid-schiff	111-131	interleukin 13	Mus musculus	30-35
21203431-6	2010	After 48 h of incubation with IL-13 a large number of SAEC were transformed into goblet cells as determined by periodic acid-schiff (PAS)-staining and immunohistochemistry using antibodies against Mucin5AC.	Aminosalicylic Acid	133-136	interleukin 13	Mus musculus	30-35
21203431-10	2010	In a mouse model of ragweed pollen extract (RWE)-induced allergic asthma treatment with fidarestat prevented the expression of IL-13, phosphorylation of STAT-6 and transformation of epithelial cells to goblet cells in the lung.	fidarestat	88-98	interleukin 13	Mus musculus	127-132
21203431-12	2010	CONCLUSIONS: The results show that exposure of SAEC to IL-13 caused goblet cell metaplasia, which was significantly prevented by AR inhibition.	saec	47-51	interleukin 13	Mus musculus	55-60
20817778-7	2010	Coexpression in transient assays of wild-type Zta, but not a DNA-binding-defective mutant Zta, activated expression of the IL-13 promoter in lung epithelial cells, and detection of IL-13 in Adv-Zta-treated mice correlated with expression of Zta.	zta	46-49	interleukin 13	Mus musculus	123-128
20885908-8	2010	The levels of INF-r and IL-13 in the supernatants of the lymph node cell cultures stimulated with staphylococcal enterotoxin B (SEB) or ConA were increased in the Cy-treated mice, although the serum levels of total IgE were not.	Cysteine	163-165	interleukin 13	Mus musculus	24-29
20398436-0	2010	Paeoniflorin ameliorates schistosomiasis liver fibrosis through regulating IL-13 and its signalling molecules in mice.	peoniflorin	0-12	interleukin 13	Mus musculus	75-80
20337611-8	2010	Lung inflammation induced by LPS-containing allergen was markedly reduced in IL-13-deficient mice in the context of ASA treatment, but not without ASA.	Aspirin	116-119	interleukin 13	Mus musculus	77-82
20590630-10	2010	Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment.	montelukast	116-127	interleukin 13	Mus musculus	76-81
20398436-4	2010	Upon pathological examination of PAE-treated mice, the size of egg granuloma, fibrosis scores, the concentration of IL-13 and hydroxyproline in liver were significantly reduced compared with the model mice.	peoniflorin	33-36	interleukin 13	Mus musculus	116-121
20398436-6	2010	These results suggested that PAE might alleviate the hepatic granulomas and fibrosis caused by S. japonicum and the inhibitory effect of PAE on hepatic fibrosis might be associated with its ability to decrease the level of IL-13 and to interfere with the IL-13 signalling molecule in HSCs.	peoniflorin	29-32	interleukin 13	Mus musculus	223-228
20463604-4	2010	The experimental data show that activation of alternatively activated macrophages (aaMacs) within type-2 infiltrates by IL-4 or IL-13 can inhibit B16-F1 melanoma cell proliferation through a mechanism that is dependent on arginase-1 depletion of L-arginine within the tumor cell microenvironment.	Arginine	246-256	interleukin 13	Mus musculus	128-133
19834971-9	2010	Moreover, our results clearly demonstrate that IL-19 is required for B-cell infiltration during chronic DSS-induced colitis, which may be mediated by IL-13 and IL-6.	Dextran Sulfate	104-107	interleukin 13	Mus musculus	150-155
20337645-6	2010	The mechanism by which IL-13 up-regulates GABA signalling in airway epithelium is unknown.	gamma-Aminobutyric Acid	42-46	interleukin 13	Mus musculus	23-28
19864008-7	2010	We also showed that the administration of sirtinol reduced significantly the increased numbers of inflammatory cells of the airways; airway hyperresponsiveness; increased levels of IL-4, IL-5, and IL-13; and increased vascular permeability in the lungs after OVA inhalation.	sirtinol	42-50	interleukin 13	Mus musculus	197-202
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	interleukin 13	Mus musculus	51-56
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	7-14	interleukin 13	Mus musculus	51-56
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	ly204002	19-27	interleukin 13	Mus musculus	51-56
19835973-5	2010	N,N-dimethylsphingosine (DMS), a potent SphK inhibitor, decreased MUC5AC expression up-regulated by IL-13 treatment.	N,N-dimethylsphingosine	0-23	interleukin 13	Mus musculus	100-105
19835973-5	2010	N,N-dimethylsphingosine (DMS), a potent SphK inhibitor, decreased MUC5AC expression up-regulated by IL-13 treatment.	N,N-dimethylsphingosine	25-28	interleukin 13	Mus musculus	100-105
19880493-3	2010	In this study, thioglycollate-elicited mouse peritoneal macrophages were treated with interleukin-4 (IL-4) or IL-13 in vitro and challenged with Neisseria meningitidis.	Thioglycolates	15-29	interleukin 13	Mus musculus	110-115
19951958-4	2010	IL-13 pre-treatment inhibits the induction of 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity and delayed-type hypersensitivity (DTH) in antigen-challenged mice, which have been confirmed by neutralizing IL-13 by systemic delivery of non-signaling decoy receptor IL-13Ralpha2.	Dinitrofluorobenzene	46-73	interleukin 13	Mus musculus	0-5
20032720-8	2010	RESULTS: TIMSC accumulated in the spleen of injured mice and were particularly sensitive to IL-4 and IL-13 with large inductions of arginase activity.	timsc	9-14	interleukin 13	Mus musculus	101-106
21197410-4	2010	To investigate the effect of hirsutenone (HIR), a diarylheptanoid compound, on AD-like skin lesions and other factors related to immune response is the aim of this paper Th2-related cytokines (IL-4, IL-5, IL-13), eosinophil, IgE inflammatory factors (COX-2, iNOS) levels were reduced in blood, lymphocytes, and tissue after HIR treatment.	hirsutenone	29-40	interleukin 13	Mus musculus	205-210
21197410-4	2010	To investigate the effect of hirsutenone (HIR), a diarylheptanoid compound, on AD-like skin lesions and other factors related to immune response is the aim of this paper Th2-related cytokines (IL-4, IL-5, IL-13), eosinophil, IgE inflammatory factors (COX-2, iNOS) levels were reduced in blood, lymphocytes, and tissue after HIR treatment.	hirsutenone	42-45	interleukin 13	Mus musculus	205-210
20090941-4	2010	Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t.	pe	56-58	interleukin 13	Mus musculus	51-55
20090941-8	2010	Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE.	Bleomycin	110-119	interleukin 13	Mus musculus	222-226
19786084-5	2010	RESULTS: VM EtOH extract significantly inhibited increases in total immunoglobulin E (IgE) and cytokines IL-4 and IL-13 levels in serum and bronchoalveolar lavage fluid (BALF), and also effectively suppressed airway hyperresponsiveness (AHR), eosinophilia, and mucus hypersecretion, in mice with OVA-induced asthma.	Ethanol	12-16	interleukin 13	Mus musculus	114-119
19822999-11	2010	The IL-13 serum levels were significantly increased by the high-CHO diet (p &lt; 0.05).	CAV protocol	64-67	interleukin 13	Mus musculus	4-9
19951958-4	2010	IL-13 pre-treatment inhibits the induction of 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity and delayed-type hypersensitivity (DTH) in antigen-challenged mice, which have been confirmed by neutralizing IL-13 by systemic delivery of non-signaling decoy receptor IL-13Ralpha2.	Dinitrofluorobenzene	46-73	interleukin 13	Mus musculus	217-222
20391114-9	2010	A similar biphasic response in eosinophil recoveries was observed using daily transnasal methylprednisolone treatments that correlated with a concomitant fall and rise in BAL interleukin-13.	Methylprednisolone	89-107	interleukin 13	Mus musculus	175-189
20706659-9	2010	Melatonin could also decrease the IL-6 and IL-13 production and increase the IL-2 production.	Melatonin	0-9	interleukin 13	Mus musculus	43-48
20953328-2	2010	Interleukin-13 increases expression of the arachidonic acid-metabolizing enzyme, 15-lipoxygenase-1, in a variety of cell types.	Arachidonic Acid	43-59	interleukin 13	Mus musculus	0-14
20062524-3	2010	We also show that the phagocytosis of yeast and the release of reactive oxygen intermediates in response to Candida albicans challenge are impaired in macrophages from Dectin-1 deficient mice treated with PPARgamma ligands or IL-13.	Oxygen	72-78	interleukin 13	Mus musculus	226-231
19386785-6	2009	When evaluated in a BRSV challenge model, mice immunized with DeltaF/CpG/indol/PP developed significantly higher levels of BRSV-neutralizing serum antibodies than mice immunized with the DeltaF protein alone, and displayed significantly less pulmonary IL-4, IL-5, IL-13 and eotaxin and reduced eosinophilia after challenge.	indole	73-78	interleukin 13	Mus musculus	264-269
19202006-9	2009	These findings suggest that the inhibitory effects of STAT6 inhibitory agents, such as AS1517499, both on RhoA and IL-13 up-regulations might be useful for asthma treatment.	4-(benzylamino)-2-((2-(3-chloro-4-hydroxyphenyl)ethyl)amino)pyrimidine-5-carboxamide	87-96	interleukin 13	Mus musculus	115-120
19608720-8	2009	Lung lavage IL-4, IL-13, and tumor necrosis factor-alpha levels were all reduced by treatment with simvastatin (P &lt; 0.05).	Simvastatin	99-110	interleukin 13	Mus musculus	18-56
19735273-6	2009	Mice sensitized to endotoxin(low) OVA at birth in the presence of ssRNA or lipoteichoic acid, but not flagellin, showed an increase in the numbers of airway and tissue eosinophils, mucus producing cells and antigen-specific production of IL-13 as compared with mice exposed only to endotoxin(low) OVA.	lipoteichoic acid	75-92	interleukin 13	Mus musculus	238-243
20079297-15	2009	Application of fasudil resulted in inhibition of the augmented levels of eotaxin, IL-5 and IL-13 in BALF, decreased to (20 +/- 5) ng/L, (57 +/- 14) ng/L and (254 +/- 28) ng/L, respectively (q = 13.119, 17.503, 8.449, respectively, all P &lt; 0.01).	fasudil	15-22	interleukin 13	Mus musculus	91-96
19794524-11	2009	The naringenin-treated mice had lower levels of IL4 and IL13 in the bronchoalveolar lavage fluid and lower serum total IgE.	naringenin	4-14	interleukin 13	Mus musculus	56-60
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	interleukin 13	Mus musculus	77-82
19682371-8	2009	In addition Th2-type cytokines, such as IL-4 and IL-13, and markers of eosinophil chemotaxis, such as CCL11 and CCR3, were increased in OVA-sensitized mice exposed to DEP prior to infection with influenza.	ova	136-139	interleukin 13	Mus musculus	49-54
19556359-9	2009	In contrast, administration of the selective A2AR agonist CGS21680 reversed the counteracting effect of the IL-13 neutralizing antibody on alpha-GalCer preconditioning.	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	58-66	interleukin 13	Mus musculus	108-113
19596983-6	2009	We now show for the first time that, compared with controls, mice exposed prenatally to secondhand CS exhibit increased lung inflammation (predominant infiltration by eosinophils and polymorphs), atopy, and airway resistance, and produce proinflammatory cytokines (IL-4, IL-5, IL-6, and IL-13, but not IL-2 or IFN-gamma).	Cesium	99-101	interleukin 13	Mus musculus	287-292
19592654-2	2009	Skin and cardiac allograft acceptance are readily induced in transgenic mice overexpressing CD200 under control of a doxycycline-inducible promoter, both of which are associated with increased intragraft expression of mRNAs for a number of genes associated with altered T cell subset differentiation, including GATA-3, type 2 cytokines (IL-4, IL-13), GITR, and Foxp3.	Doxycycline	117-128	interleukin 13	Mus musculus	343-348
19450563-4	2009	Moreover, gene expression of the inflammatory cytokines, IL-13, and IL-5 and eotaxin in the lung, and IL-5 in the draining lymph node were significantly decreased in sauchinone-treated mice.	sauchinone	166-176	interleukin 13	Mus musculus	57-62
19582753-11	2009	Furthermore, CCL5 expression in K(d)Gag(197-205)-specific CTL was also regulated by IL-4/IL-13.	Glycosaminoglycans	36-39	interleukin 13	Mus musculus	89-94
19145636-5	2009	Moreover, the expression of Th1/Th2 mRNA cytokines (IL-2, IL-4, IL-5, IL-13) from mouse splenocytes was inhibited severely as was cyclosporine A.	Cyclosporine	130-144	interleukin 13	Mus musculus	70-75
19029019-1	2009	Previous studies have shown that leukotriene B4 (LTB4), a proinflammatory lipid mediator, is linked to the development of airway hyperresponsiveness through the accumulation of IL-13-producing CD8+ T cells, which express a high affinity receptor for LTB4, BLT1 (Miyahara et al., Am J Respir Crit Care Med 2005;172:161-167; J Immunol 2005;174:4979-4984).	Leukotrienes	33-44	interleukin 13	Mus musculus	177-182
18791914-5	2009	The DEP-induced increases in peribronchial eosinophils and mucous goblet cells in the lung tissues, and of IL-5 and IL-13 in the BAL fluid, were significantly attenuated by the antioxidant N-acetylcysteine.	Acetylcysteine	189-205	interleukin 13	Mus musculus	116-121
19289114-5	2009	A reduction of IL-4, IL-5, and IL-13, but not of IFN-gamma, was found in bronchoalveolar lavage fluids of mice treated with umbelliferone, similar to that observed with dexamethasone.	7-hydroxycoumarin	124-137	interleukin 13	Mus musculus	31-36
19428947-5	2009	Lymphocytes from the auricular and mediastinal lymph nodes were cultured to determine the concanavaline A-induced secretion of IL-2, IL-4, IL-10, IL-13, IL-17 and IFN-gamma.	concanavaline a	90-105	interleukin 13	Mus musculus	146-151
19350558-3	2009	In a cytokine chip assay, smDC were characterized by remarkable production of IL-2, IL-3, IL-5, and IL-13 together with well-known Th2 cytokines.	Metam-sodium	26-30	interleukin 13	Mus musculus	100-105
19380786-8	2009	In summary, our results suggest that production of Ym1/2 in response to IL-13 promotes Th2 cytokine production and allergic airways inflammation by inhibiting the production of 12(S)-HETE by 12/15-LOX.	12(S)-HETE	177-187	interleukin 13	Mus musculus	72-77
19342679-2	2009	Using a highly sensitive microarray-based approach, we identified 21 miRNAs with differential expression between doxycycline-induced lung-specific IL-13 transgenic mice (with allergic airway inflammation) and control mice.	Doxycycline	113-124	interleukin 13	Mus musculus	147-152
19288034-9	2009	Serum OVA-specific IgE level and ex vivo IL-4, IL-5 and IL-13, but not IFN-gamma, production by peribronchial lymph node cells was also considerably lower in PPI-treated mice.	ppi	158-161	interleukin 13	Mus musculus	56-61
19237298-5	2009	Pulmonary function tests showed a significant increase in methacholine-induced airway hyperreactivity in OVA/OVA and IL-13-treated mice as compared with controls.	Methacholine Chloride	58-70	interleukin 13	Mus musculus	117-122
19056934-6	2009	In a murine asthma model, aerosolized TG100-115 markedly reduced the pulmonary eosinophilia and the concomitant interleukin-13 and mucin accumulation characteristic of this disease.	tg100	38-43	interleukin 13	Mus musculus	112-126
19065664-0	2009	IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.	Paclitaxel	66-76	interleukin 13	Mus musculus	0-5
18830273-4	2009	The keratin 5 promoter was used with a tetracycline-inducible system to target IL-13 to the skin.	Tetracycline	39-51	interleukin 13	Mus musculus	79-84
19065664-5	2009	IL13-PE38 mediated a synergistic antitumor effect with paclitaxel in OSC-19 in vitro and in vivo in the orthotopic OSCC tongue tumor model.	Paclitaxel	55-65	interleukin 13	Mus musculus	0-4
19354064-4	2009	METHODS: The BHR to methacholine induced by IL-13 or ovalbumin was determined in BALB/c mice, and the provocation concentration of methacholine that caused an increase in enhanced pause in expiration of 200% (PC200) was calculated.	Methacholine Chloride	20-32	interleukin 13	Mus musculus	44-49
19354064-10	2009	CONCLUSIONS: The protective effects of fluticasone, beta-agonists, and fluticasone plus beta-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.	Fluticasone	39-50	interleukin 13	Mus musculus	128-133
19354064-10	2009	CONCLUSIONS: The protective effects of fluticasone, beta-agonists, and fluticasone plus beta-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.	Fluticasone	71-82	interleukin 13	Mus musculus	128-133
19139021-5	2009	Analysis of several proteins involved in new blood vessel formation showed that silibinin decreased the tumor expression of interleukin-13 (47%) and tumor necrosis factor-alpha (47%), and increased tissue inhibitor of metalloproteinase-1 (2-fold) and tissue inhibitor of metalloproteinase-2 (7-fold) expression, without significant changes in vascular endothelial growth factor levels.	Silybin	80-89	interleukin 13	Mus musculus	124-138
19276162-5	2009	injections of 15 mg/kg of doxorubicin encapsulated in IL-13-conjugated liposomes had a 5-fold reduction in the intracranial tumor volume over 6 weeks and four of seven animals survived &gt;200 days after tumor implantation.	Doxorubicin	26-37	interleukin 13	Mus musculus	54-59
19276162-7	2009	The presence of liposomes with doxorubicin in the tumor was shown by taking advantage of the selective expression of IL-13 receptors on the tumor cells and the endogenous fluorescence of doxorubicin.	Doxorubicin	31-42	interleukin 13	Mus musculus	117-122
18688040-8	2009	The IL-13-induced up-regulation of RhoA was inhibited by leflunomide, an inhibitor of signal transducer and activator of transcription 6 (STAT6).	Leflunomide	57-68	interleukin 13	Mus musculus	4-9
19022362-11	2009	Notably, PBDE-exposure resulted in a marked decrease, or even lack, of IL-13, MIP-1beta, RANTES, IFN-gamma and KC levels in non-infected mice.	Halogenated Diphenyl Ethers	9-13	interleukin 13	Mus musculus	71-76
19130938-7	2009	Adoptive transfer of U0126-treated CD8(+) T cells into sensitized mice before secondary allergen challenge resulted in significant decreases in AHR, eosinophilic inflammation, goblet cell metaplasia, and IL-5 and IL-13 levels in bronchoalveolar lavage fluid of recipient mice.	U 0126	21-26	interleukin 13	Mus musculus	213-218
18417511-10	2008	In conclusion, interleukin-13 augments ozone-induced airway hyperresponsiveness and neutrophilic inflammation, possibly through modulation of certain cytokines induced by ozone exposure.	Ozone	39-44	interleukin 13	Mus musculus	15-29
19006098-0	2009	Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis.	Oligonucleotides	45-61	interleukin 13	Mus musculus	20-34
19006098-3	2009	In the present study, IL-13 antisense oligonucleotide (ASO) was designed and formulated with cationic elastic liposome (cEL) to improve transdermal delivery.	Oligonucleotides	38-53	interleukin 13	Mus musculus	22-27
19006098-3	2009	In the present study, IL-13 antisense oligonucleotide (ASO) was designed and formulated with cationic elastic liposome (cEL) to improve transdermal delivery.	Oligonucleotides, Antisense	55-58	interleukin 13	Mus musculus	22-27
19006098-7	2009	The in vivo effect of IL-13 ASO/cEL complex was tested in a murine model of AD.	Oligonucleotides, Antisense	28-31	interleukin 13	Mus musculus	22-27
19006098-7	2009	The in vivo effect of IL-13 ASO/cEL complex was tested in a murine model of AD.	N(6)-(1-carboxyethyl)lysine	32-35	interleukin 13	Mus musculus	22-27
19006098-10	2009	When applied to the ovalbumin-sensitized murine model of AD, topically administered IL-13 ASO/cEL complex dramatically suppressed IL-13 production (by up to 70% of the control) in the affected skin region.	Oligonucleotides, Antisense	90-93	interleukin 13	Mus musculus	84-89
19006098-10	2009	When applied to the ovalbumin-sensitized murine model of AD, topically administered IL-13 ASO/cEL complex dramatically suppressed IL-13 production (by up to 70% of the control) in the affected skin region.	Oligonucleotides, Antisense	90-93	interleukin 13	Mus musculus	130-135
19006098-10	2009	When applied to the ovalbumin-sensitized murine model of AD, topically administered IL-13 ASO/cEL complex dramatically suppressed IL-13 production (by up to 70% of the control) in the affected skin region.	N(6)-(1-carboxyethyl)lysine	94-97	interleukin 13	Mus musculus	84-89
19006098-10	2009	When applied to the ovalbumin-sensitized murine model of AD, topically administered IL-13 ASO/cEL complex dramatically suppressed IL-13 production (by up to 70% of the control) in the affected skin region.	N(6)-(1-carboxyethyl)lysine	94-97	interleukin 13	Mus musculus	130-135
19006098-12	2009	Moreover, IL-13 ASO/cEL-treated AD mice showed reduced infiltration of inflammatory cells into the epidermal and dermal areas, with concomitant reduction of skin thickness.	Oligonucleotides, Antisense	16-19	interleukin 13	Mus musculus	10-15
19006098-12	2009	Moreover, IL-13 ASO/cEL-treated AD mice showed reduced infiltration of inflammatory cells into the epidermal and dermal areas, with concomitant reduction of skin thickness.	N(6)-(1-carboxyethyl)lysine	20-23	interleukin 13	Mus musculus	10-15
18938165-4	2008	Blockade of IL-13 signaling via IL-13R alpha(2) and TGF-beta1 signaling was achieved by the administration of small interfering RNA or decoy oligonucleotides that target promoter sequences of signaling components of these receptors.	Oligonucleotides	141-157	interleukin 13	Mus musculus	12-17
19008643-7	2008	Nafamostat mesilate also dose-dependently inhibited increases in the levels of interleukin-13 and eotaxin in BALF and goblet cell hyperplasia.	nafamostat	0-19	interleukin 13	Mus musculus	79-93
18602067-7	2008	Levels of Type II cytokines IL-4, IL-5 and IL-13 were significantly reduced in mice treated with lupeol, an effect that was similar to that observed in dexamethasone-treated mice.	lupeol	97-103	interleukin 13	Mus musculus	43-48
18976720-9	2009	Furthermore, SU5416 inhibited inflammatory cell numbers and LDH activity in BALF and IL-13 expression in lung tissue at early inflammatory phase of bleomycin-induced pulmonary fibrosis.	Semaxinib	13-19	interleukin 13	Mus musculus	85-90
18817984-2	2008	It was found that acute MPTP treatment induced behavioral dysfunction, activated microglia/astrocytes, and increased the levels of IL-10, IL-12(p40) IL-13, IFN-gamma, and MCP-1 in CSF in B6, but not in BALB.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	24-28	interleukin 13	Mus musculus	149-154
18708131-6	2008	TDI induced marked increases in levels of cytokines (IL-4, IL-10, IL-13, and IFN-gamma) produced by restimulated LN cells.	Toluene 2,4-Diisocyanate	0-3	interleukin 13	Mus musculus	66-71
18641360-2	2008	The Th2 cytokines IL-13 and IL-4 are produced during allergic responses and cause increases in airway epithelial cell mucus and electrolyte and water secretion into the airway surface liquid (ASL).	Water	144-149	interleukin 13	Mus musculus	18-23
18552204-6	2008	Supernatants from PAMP + ATP-treated glia induced the secretion of IL-6, IL-13, and MCP-1 from the MC/9 mast cell line in a manner similar to exogenous recombinant IL-33.	Adenosine Triphosphate	25-28	interleukin 13	Mus musculus	73-78
18571882-6	2008	TMA and TDI induced marked increases in levels of antigen-specific serum IgE and of Th2 cytokines (IL-4, IL-5, IL-10, and IL-13) produced by ex vivo restimulated lymph node cells.	Toluene 2,4-Diisocyanate	8-11	interleukin 13	Mus musculus	122-127
18641694-5	2008	Astragaloside IV treatment resulted in significant reduction of eosinophilic airway inflammation, airway hyperresponsiveness, interleukin (IL)-4 and IL-13 levels in bronchoalveolar lavage fluid, and total immunoglobulin E levels in serum.	astragaloside A	0-16	interleukin 13	Mus musculus	149-154
18258919-6	2008	To identify IL-13-dependent mediators, we performed a limited-scale two-dimensional SDS-PAGE proteomic analysis and identified proteins significantly modulated in this model.	Sodium Dodecyl Sulfate	84-87	interleukin 13	Mus musculus	12-17
18063838-0	2008	Lung lining fluid glutathione attenuates IL-13-induced asthma.	Glutathione	18-29	interleukin 13	Mus musculus	41-46
18442795-10	2008	Mepacrine effectively reduced the rise in IL-4, IL-5, IL-13, and OVA-specific IgE and restored IFN-gamma levels.	Quinacrine	0-9	interleukin 13	Mus musculus	54-59
18490720-6	2008	Adenosine receptor antagonists MRS1706 and DPCPX with known inverse agonist activity at the A(2B) subtype inhibited IL-13 secretion induced by the adenosine analog NECA, but did not mimic the enhanced Ag-induced degranulation observed in A(2B) knockout BMMCs.	N-(4-acetylphenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)acetamide	31-38	interleukin 13	Mus musculus	116-121
18490720-6	2008	Adenosine receptor antagonists MRS1706 and DPCPX with known inverse agonist activity at the A(2B) subtype inhibited IL-13 secretion induced by the adenosine analog NECA, but did not mimic the enhanced Ag-induced degranulation observed in A(2B) knockout BMMCs.	1,3-dipropyl-8-cyclopentylxanthine	43-48	interleukin 13	Mus musculus	116-121
18490720-6	2008	Adenosine receptor antagonists MRS1706 and DPCPX with known inverse agonist activity at the A(2B) subtype inhibited IL-13 secretion induced by the adenosine analog NECA, but did not mimic the enhanced Ag-induced degranulation observed in A(2B) knockout BMMCs.	Adenosine	147-156	interleukin 13	Mus musculus	116-121
18826118-6	2008	RESULTS: With increasing concentrations of SO2, the levels of IL-5 and IL-13 in the peripheral serum, and the density of Eos in sinus mucosa increased simultaneously.	Sulfur Dioxide	43-46	interleukin 13	Mus musculus	71-76
18826118-7	2008	A positive correlation existed between the concentration of inhaled SO2 and the elevation of both IL-5, IL-13 and Eos infiltration in nasal mucosa.	Sulfur Dioxide	68-71	interleukin 13	Mus musculus	104-109
18622847-3	2008	The present study was performed to investigate a potential role of IL-4 and IL-13 in fracture healing and bone induction by demineralized xenogenic bone matrix (DXBM).	dxbm	161-165	interleukin 13	Mus musculus	76-81
18467695-5	2008	Taking advantage of genetically modified ADA-deficient mice, we herein report a direct fibrogenic effect of adenosine on the skin, in which increased collagen deposition is accompanied by increased levels of key mediators of fibrosis, including transforming growth factor beta1, connective tissue growth factor, and interleukin-13.	Adenosine	108-117	interleukin 13	Mus musculus	316-330
18403598-5	2008	Hearts of IL-13 KO mice had increased levels of the proinflammatory and profibrotic cytokines IL-1beta, IL-18, interferon-gamma, transforming growth factor-beta1, and IL-4 as well as histamine.	Histamine	183-192	interleukin 13	Mus musculus	10-15
18276774-4	2008	Tracheal smooth muscle contractility is enhanced by overnight incubation with IL-13, resulting in increased maximal contractions (E(max)) to carbachol (CCh) and KCl.	Carbachol	141-150	interleukin 13	Mus musculus	78-83
18276774-4	2008	Tracheal smooth muscle contractility is enhanced by overnight incubation with IL-13, resulting in increased maximal contractions (E(max)) to carbachol (CCh) and KCl.	Carbachol	152-155	interleukin 13	Mus musculus	78-83
18276774-4	2008	Tracheal smooth muscle contractility is enhanced by overnight incubation with IL-13, resulting in increased maximal contractions (E(max)) to carbachol (CCh) and KCl.	Potassium Chloride	161-164	interleukin 13	Mus musculus	78-83
18382663-9	2008	Lidocaine selectively up-regulated pro-inflammatory proteins including S100A8/9 and CRAMP/LL-37, and down-regulated anti-inflammatory and some pro-resolution peptides and proteins including IL-4, IL-13, TGF-a and Galectin-1.	Lidocaine	0-9	interleukin 13	Mus musculus	196-201
18056481-9	2008	In the in vitro assay, a significant increase in TC activation, as defined by surface markers and cytokines, was observed in the cultures containing the silica-exposed macrophages in wild-type and IL-4Ralpha(-/-) mice, with one exception: IL-4Ralpha(-/-) BMdM were unable to induce an increase in IL-13.	Silicon Dioxide	153-159	interleukin 13	Mus musculus	297-302
18414636-8	2008	Exposure to BPA in adulthood significantly promoted antigen-stimulated production of interleukin (IL)-4, IL-10, and IL-13 but not interferon-gamma (IFN-gamma).	bisphenol A	12-15	interleukin 13	Mus musculus	116-121
18242596-6	2008	Animals dosed with CP-690550 (15 mg/kg/d) during the period of antigen sensitization and boost demonstrated marked reductions in BAL eosinophils and levels of IL-13 and eotaxin following ovalbumin aerosol exposure.	tofacitinib	19-28	interleukin 13	Mus musculus	159-164
18089617-9	2008	Exogenous IL-13 reconstituted airway recruitment of leukocytes in OVA-challenged CD3O(-/-) mice.	Methoxy-d3 radical	81-85	interleukin 13	Mus musculus	10-15
18339016-13	2008	Cycloheximide also diminished activation of p38 MAPK and induction of MUC5AC mRNA expression by IL-13.	Cycloheximide	0-13	interleukin 13	Mus musculus	96-101
18055276-7	2008	Additionally, IL-4, IL-5, and IL-13 levels in the bronchoalveolar lavage fluid were higher in SA group.	sa	94-96	interleukin 13	Mus musculus	30-35
18021768-6	2008	L. pacari reduced IL-4 and IL-13 levels (by 67% and 73%), whereas ellagic acid reduced IL-4, IL-5 and IL-13 (by 67%, 88% and 85%).	Ellagic Acid	66-78	interleukin 13	Mus musculus	102-107
18021768-9	2008	The highest ellagic acid dose reduced neutrophil and eosinophil numbers (by 59% and 82%), inhibited IL-4, IL-5, and IL-13 (by 62%, 61%, and 49%).	Ellagic Acid	12-24	interleukin 13	Mus musculus	116-121
18242212-8	2008	The levels of T helper cell 2 type cytokines such as IL-4 and IL-13 in the LP T cells were significantly higher, but the levels of interferon gamma were lower in OXA- or TNBS-treated CD30LKO mice than in wild-type mice.	Trinitrobenzenesulfonic Acid	170-174	interleukin 13	Mus musculus	62-67
18250429-5	2008	When infected with Chlamydia, BMDC secrete increased TNF-alpha, IL-6, IL-10, IL-12, and IL-13.	bmdc	30-34	interleukin 13	Mus musculus	88-93
18211538-6	2008	Similarly, in vitro study suggested that estrogen treatment, in combination with IL-13, strongly modulates B-cell Ig switching in comparison to testosterone treatment in association with IL-13.	Testosterone	144-156	interleukin 13	Mus musculus	187-192
18501881-0	2008	Interleukin-13 neutralization modulates interleukin-13 induced suppression of reactive oxygen species production in peritoneal macrophages in a murine T-cell lymphoma.	Reactive Oxygen Species	78-101	interleukin 13	Mus musculus	0-14
18501881-0	2008	Interleukin-13 neutralization modulates interleukin-13 induced suppression of reactive oxygen species production in peritoneal macrophages in a murine T-cell lymphoma.	Reactive Oxygen Species	78-101	interleukin 13	Mus musculus	40-54
18501881-6	2008	It has been observed that IL-13 significantly inhibits the ROI generation in all macrophage types while by neutralizing with invivo administration of IL-13R*2 and/or potentiation with Th1 cytokine, the production of reactive oxygen intermediate increases, which indicates that IL-13R*2 and/or potentiation with Th1 cytokine could restore the cytotoxic ability of macrophage in a murine T-cell lymphoma.	reactive oxygen	216-231	interleukin 13	Mus musculus	26-31
18178865-4	2008	Our results showed that the I-Aq/bCII257-270 molecule could systemically reduce proinflammatory IL-17 and IFN-gamma production and significantly increase anti-inflammatory IL-10, IL-13, and FoxP3 gene expression in splenocytes.	bcii257	33-40	interleukin 13	Mus musculus	179-184
17950252-6	2008	In lung tissue, exposure to doxycycline via inhaled route induced a fourfold increase in IL-10 levels, a twofold decrease in IL-5, IL-13 levels and diminished MMP-related proteolysis and the proportion of activated MMP-9 as compared to placebo.	Doxycycline	28-39	interleukin 13	Mus musculus	131-136
18178865-4	2008	Our results showed that the I-Aq/bCII257-270 molecule could systemically reduce proinflammatory IL-17 and IFN-gamma production and significantly increase anti-inflammatory IL-10, IL-13, and FoxP3 gene expression in splenocytes.	i-aq	28-32	interleukin 13	Mus musculus	179-184
17920164-6	2007	Lung IL-13 mRNA levels were particularly elevated in mice administered alpha-galactosylceramide-containing liposomes followed by RSV challenge.	alpha-galactosylceramide	71-95	interleukin 13	Mus musculus	5-10
17568676-2	2008	Reactive nitrogen species are classically induced in Th1 cytokines and/or lipopolysaccharides (LPS) activated macrophages and this response is inhibited by IL-13.	Reactive Nitrogen Species	0-25	interleukin 13	Mus musculus	156-161
17935711-6	2007	Detailed analysis of cytokine gene expression showed that levamisole can decrease IL-4, IL-5 and IL-13 mRNA and increase IL-12, IL-18 and IFN-gamma mRNA.	Levamisole	58-68	interleukin 13	Mus musculus	97-102
17982031-4	2007	Approximately 25% of sIL-13Ralpha2 in serum is complexed to IL-13; this percentage and the absolute quantity of sIL-13Ralpha2 in serum increase considerably during a Th2 response.	sil-13ralpha2	112-125	interleukin 13	Mus musculus	22-27
17982031-7	2007	These observations suggest that sIL-4Ralpha predominantly sustains, increases, and diffuses the effects of IL-4, whereas sIL-13Ralpha2 limits the direct effects of IL-13 to the site of IL-13 production and forms a stable complex with IL-13 that may modify the quality and intensity of an allergic inflammatory response.	sil-13ralpha2	121-134	interleukin 13	Mus musculus	164-169
17982031-7	2007	These observations suggest that sIL-4Ralpha predominantly sustains, increases, and diffuses the effects of IL-4, whereas sIL-13Ralpha2 limits the direct effects of IL-13 to the site of IL-13 production and forms a stable complex with IL-13 that may modify the quality and intensity of an allergic inflammatory response.	sil-13ralpha2	121-134	interleukin 13	Mus musculus	164-169
17458900-9	2007	Furthermore, pretreatment of BMMCs by wortmannin, a specific inhibitor of PI3 kinase, inhibited LPS-stimulated expression of IL-5, IL-10, and IL-13, but not that of TNF-alpha or IL-6.	Wortmannin	38-48	interleukin 13	Mus musculus	142-147
17693426-4	2007	Dermal application of hexylmethane diisocyanate (HMDI), toluene diisocyanate (TDI), or methylene diisocyanate (MDI) significantly increased interleukin-4 (IL-4), IL-5, and IL-13 secretion in parotid lymph node cells.	hexylmethane diisocyanate	22-47	interleukin 13	Mus musculus	172-177
17693426-4	2007	Dermal application of hexylmethane diisocyanate (HMDI), toluene diisocyanate (TDI), or methylene diisocyanate (MDI) significantly increased interleukin-4 (IL-4), IL-5, and IL-13 secretion in parotid lymph node cells.	Toluene 2,4-Diisocyanate	56-76	interleukin 13	Mus musculus	172-177
17693426-4	2007	Dermal application of hexylmethane diisocyanate (HMDI), toluene diisocyanate (TDI), or methylene diisocyanate (MDI) significantly increased interleukin-4 (IL-4), IL-5, and IL-13 secretion in parotid lymph node cells.	methylene diisocyanate	87-109	interleukin 13	Mus musculus	172-177
17693426-5	2007	Isophorone diisocyanate (IPDI) increased IL-4 and IL-13, but not IL-5.	isophorone diisocyanate	0-23	interleukin 13	Mus musculus	50-55
17693426-5	2007	Isophorone diisocyanate (IPDI) increased IL-4 and IL-13, but not IL-5.	isophorone diisocyanate	25-29	interleukin 13	Mus musculus	50-55
17850646-13	2007	Data show that cocultures containing purified CD4+ T DO11.10 cells and APC derived from alcohol-consuming mice show decreased IL-6, IL-12, IL-17A, and IFN-gamma and increased IL-13 cytokine production in response to OVA stimulation.	Alcohols	88-95	interleukin 13	Mus musculus	175-180
17877757-8	2007	Interestingly, AICAR significantly attenuated poly (I:C)-induced airway hyperresponsiveness and airway inflammation, as shown by the attenuation of the influx of total inflammatory cells and soluble products into bronchoalveolar lavage fluid, such as macrophages, eosinophils, IL-5, IL-13, TNF-alpha and IFN-gamma.	Poly I-C	46-56	interleukin 13	Mus musculus	283-288
17883722-4	2007	RESULTS: Bronchial responsiveness measured as the concentration of acetylcholine aerosol needed to increase baseline lung resistance by 100% (PC100) was decreased in IL-13-/-, but increased in IL-4/5/9/13-/- mice.	Acetylcholine	67-80	interleukin 13	Mus musculus	166-171
17458900-0	2007	Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells.	Ceramides	0-8	interleukin 13	Mus musculus	61-66
17458900-10	2007	Thus, ceramide appeared to down-regulate LPS-stimulated production of IL-5, IL-10, and IL-13 from mast cells by inhibiting PI3 kinase-Akt pathway in a cell type-specific manner.	Ceramides	6-14	interleukin 13	Mus musculus	87-92
17458900-5	2007	Administration of cell-permeable C8 ceramide reduced production of IL-5, IL-10, and IL-13 from LPS-stimulated mouse bone marrow-derived mast cells (BMMCs) apparently through transcriptional inhibition, but did not affect IL-6 or TNF-alpha production.	2,3-N-octanoylsphingosine	33-44	interleukin 13	Mus musculus	84-89
17384531-5	2007	Flavonoids inhibit histamine release, synthesis of IL-4 and IL-13 and CD40 ligand expression by basophils.	Flavonoids	0-10	interleukin 13	Mus musculus	60-65
17458900-6	2007	Consistently, LPS-stimulated production of IL-5, IL-10, and IL-13 from BMMCs is significantly enhanced in the presence of fumonisin B1, a de novo ceramide synthesis inhibitor.	fumonisin B1	122-134	interleukin 13	Mus musculus	60-65
17458900-6	2007	Consistently, LPS-stimulated production of IL-5, IL-10, and IL-13 from BMMCs is significantly enhanced in the presence of fumonisin B1, a de novo ceramide synthesis inhibitor.	Ceramides	146-154	interleukin 13	Mus musculus	60-65
17318628-11	2007	Combined exposure to NQ and OVA elevated the levels of IL-13 and MUC5AC in the lung as compared with exposure to NQ or OVA alone.	Naphthoquinones	21-23	interleukin 13	Mus musculus	55-60
17603291-6	2007	Pretreatment with gefitinib reduced the inflammatory cell counts and released cytokine concentrations (IL-4 and IL-13) in BALF, as well as eosinophil recruitment in the lungs and AHR, in a dose-dependent manner.	Gefitinib	18-27	interleukin 13	Mus musculus	112-117
17556716-9	2007	MEASUREMENTS AND MAIN RESULTS: Intravenous administration of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a selective glycogen synthase kinase-3beta inhibitor, significantly inhibited ovalbumin-induced increases in total cell counts, eosinophil counts, and IL-5, IL-13, and eotaxin levels recovered in bronchoalveolar lavage fluid in a dose-dependent manner.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	61-110	interleukin 13	Mus musculus	278-283
17582479-7	2007	In the treatment model IMO-treated mice showed decreased IgE, IL-5, and IL-13 levels and increased IgG2a and IFN-gamma levels in the serum, intestines, and spleen cells compared with PBS-treated mice.	6-o-phosphoryl inosine monophosphate	23-26	interleukin 13	Mus musculus	72-77
17641053-6	2007	TDI exposure elevated IL-4, IL-5, IL-13, and IFN-gamma mRNA expression in the nasal mucosa, suggesting a mixed Th1/Th2 immune response.	Toluene 2,4-Diisocyanate	0-3	interleukin 13	Mus musculus	34-39
17313488-0	2007	Impact of T-cell receptor Vbeta haplotypes on the development of dermatitis in DS-Nh mice: synergistic production of interleukin-13 caused by staphylococcal enterotoxin C and peptide glycans from Staphylococcus aureus.	Polysaccharides	183-190	interleukin 13	Mus musculus	117-131
17439248-0	2007	Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.	Acetaminophen	72-85	interleukin 13	Mus musculus	36-50
17439248-2	2007	In the present study, we investigated the role of interleukin (IL)-13 in acetaminophen (APAP)-induced liver disease (AILD).	Acetaminophen	73-86	interleukin 13	Mus musculus	50-69
17439248-2	2007	In the present study, we investigated the role of interleukin (IL)-13 in acetaminophen (APAP)-induced liver disease (AILD).	Acetaminophen	88-92	interleukin 13	Mus musculus	50-69
17439248-3	2007	Following APAP (200 mg/kg) administration to male C57BL/6 wild-type (WT) mice, hepatotoxicity developed up to 24 h post-APAP, with a concomitant increase in serum IL-13 concentration.	Acetaminophen	10-14	interleukin 13	Mus musculus	163-168
17439248-4	2007	Pretreatment of these mice with an IL-13-neutralizing antibody exacerbated liver injury, as did APAP administration to IL-13 knockout (KO) mice in comparison to WT mice.	Acetaminophen	96-100	interleukin 13	Mus musculus	119-124
17439248-6	2007	In this regard, multiplex antibody arrays were used to identify potential IL-13-regulated biomarkers, including various cytokines and chemokines, as well as nitric oxide (NO), associated with AILD that were present at higher concentrations in the sera of APAP-treated IL-13 KO mice than in WT mice.	Acetaminophen	255-259	interleukin 13	Mus musculus	74-79
17430358-11	2007	Fasudil caused a dose-dependent inhibition in increased levels of IL-5, IL-13, and eotaxin in BAL fluid by OVA challenges.	fasudil	0-7	interleukin 13	Mus musculus	72-77
16624819-8	2006	The splenocytes from the mice fed with CS produced less interleukin (IL)-5, IL-10, and IL-13 than those from the control group.	Chondroitin Sulfates	39-41	interleukin 13	Mus musculus	87-92
16990616-8	2007	These data support the potential utility of a dual IL-4 and IL-13 oligonucleotide inhibitor in allergy/asthma, and suggest that local inhibition of IL-4Ralpha in the lung is sufficient to suppress allergen-induced pulmonary inflammation and AHR.	Oligonucleotides	66-81	interleukin 13	Mus musculus	60-65
17135575-4	2007	We found that PGI(2) analogs (cicaprost and iloprost) inhibited the production of Th1 cytokines (IFN-gamma) and Th2 cytokines (IL-4, IL-10, and IL-13) in a dose-dependent pattern.	Iloprost	44-52	interleukin 13	Mus musculus	144-149
17276885-12	2007	The effects of histamine on the STAT6 phosphorylation were indirect since they were blocked either by the antibodies to IL-4 and IL-13 or in IL-4 knock out mice in the presence of IL-13 antibody.	Histamine	15-24	interleukin 13	Mus musculus	129-134
17276885-12	2007	The effects of histamine on the STAT6 phosphorylation were indirect since they were blocked either by the antibodies to IL-4 and IL-13 or in IL-4 knock out mice in the presence of IL-13 antibody.	Histamine	15-24	interleukin 13	Mus musculus	180-185
17135575-4	2007	We found that PGI(2) analogs (cicaprost and iloprost) inhibited the production of Th1 cytokines (IFN-gamma) and Th2 cytokines (IL-4, IL-10, and IL-13) in a dose-dependent pattern.	Epoprostenol	14-20	interleukin 13	Mus musculus	144-149
17135575-4	2007	We found that PGI(2) analogs (cicaprost and iloprost) inhibited the production of Th1 cytokines (IFN-gamma) and Th2 cytokines (IL-4, IL-10, and IL-13) in a dose-dependent pattern.	cicaprost	30-39	interleukin 13	Mus musculus	144-149
17202330-7	2007	Iloprost and cicaprost also suppressed LPS-induced expression of CD86, CD40, and MHC class II molecules by BMDCs and inhibited the ability of BMDCs to stimulate Ag-specific CD4 T cell proliferation and production of IL-5 and IL-13.	Iloprost	0-8	interleukin 13	Mus musculus	225-230
17202330-7	2007	Iloprost and cicaprost also suppressed LPS-induced expression of CD86, CD40, and MHC class II molecules by BMDCs and inhibited the ability of BMDCs to stimulate Ag-specific CD4 T cell proliferation and production of IL-5 and IL-13.	cicaprost	13-22	interleukin 13	Mus musculus	225-230
16902192-8	2007	However, TNF-alpha, IL-13, monocyte chemotactic protein-1, protease activity, and production of ROS were dose-dependently increased after silica exposure, and production was enhanced after Fc epsilon RI stimulation.	Silicon Dioxide	138-144	interleukin 13	Mus musculus	20-25
16891391-6	2006	Changes in methacholine-induced R(L) were significantly greater in the WT than in the CD38KO mice following intranasal IL-13 challenges.	Methacholine Chloride	11-23	interleukin 13	Mus musculus	119-124
16891391-7	2006	Airway reactivity after IL-13 exposure, as measured by the slope of the methacholine dose-response curve, was significantly higher in the WT than in the CD38KO mice.	Methacholine Chloride	72-84	interleukin 13	Mus musculus	24-29
16891391-9	2006	IL-13 treatment reduced isoproterenol-induced relaxations to similar magnitudes in tracheal segments obtained from WT and CD38KO mice.	Isoproterenol	24-37	interleukin 13	Mus musculus	0-5
17172420-8	2006	The therapeutic potential and targeting efficacy of the IL-13-conjugated liposomes carrying doxorubicin was tested in vivo using a s.c. glioma tumor mouse model.	Doxorubicin	92-103	interleukin 13	Mus musculus	56-61
17082623-5	2006	Analysis of MoPn-driven cytokine production by immune cells revealed that mice that were treated with DPDC produced significantly higher levels of Th1 (TNF-alpha, IFN-gamma, and IL-12) but lower levels of Th2 (IL-4, IL-5, and IL-13)-related cytokines than the recipients of SPDC following infection challenge.	dpdc	102-106	interleukin 13	Mus musculus	226-231
17015710-6	2006	This study with the TDI-induced model of asthma revealed the following typical pathophysiological features: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased levels of Th2 cytokines (IL-4, IL-5, and IL-13), adhesion molecules (ICAM-1 and VCAM-1), chemokines (RANTES and eotaxin), TGF-beta1, and NF-kappaB in nuclear protein extracts.	Toluene 2,4-Diisocyanate	20-23	interleukin 13	Mus musculus	243-248
16792687-9	2006	Inhibition of p38 MAPK, ERK and JAK-2 activities by pretreating the cells with their corresponding inhibitors SB203580, PD98059 and AG490, respectively, significantly suppressed IL-4- and IL-13-induced MCP-1 production in BEAS-2B cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	120-127	interleukin 13	Mus musculus	188-193
16792687-9	2006	Inhibition of p38 MAPK, ERK and JAK-2 activities by pretreating the cells with their corresponding inhibitors SB203580, PD98059 and AG490, respectively, significantly suppressed IL-4- and IL-13-induced MCP-1 production in BEAS-2B cells.	SB 203580	110-118	interleukin 13	Mus musculus	188-193
16792687-9	2006	Inhibition of p38 MAPK, ERK and JAK-2 activities by pretreating the cells with their corresponding inhibitors SB203580, PD98059 and AG490, respectively, significantly suppressed IL-4- and IL-13-induced MCP-1 production in BEAS-2B cells.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	132-137	interleukin 13	Mus musculus	188-193
16831597-1	2006	BACKGROUND &amp; AIMS: The cytokines interleukin (IL)-4 and IL-13 have pleiotropic effects on a variety of cell types and impact both pathologic changes and tissue remodeling.	Adenosine Monophosphate	12-15	interleukin 13	Mus musculus	60-65
17075244-3	2006	Recent studies in allergen-induced airway hyperresponsiveness and inflammation using mice lacking BLT1 have shown crucial new roles for leukotriene B4 and BLT1 in Th2 cytokine IL-13 production from lung T cells and recruitment of antigen-specific effector CD8+ T cells, suggesting novel mechanisms for their actions.	Leukotriene B4	136-150	interleukin 13	Mus musculus	176-181
16723093-9	2006	RESULTS: Oral administration of amurensin H significantly inhibited OVA-induced increases in total cell counts, eosinophil counts, and TNF- alpha, IL-4, IL-5 and IL-13 levels in BALF.	amurensin H	32-43	interleukin 13	Mus musculus	162-167
16528019-0	2006	Niflumic acid suppresses interleukin-13-induced asthma phenotypes.	Niflumic Acid	0-13	interleukin 13	Mus musculus	25-39
16489117-9	2006	This hyperresponsiveness was inhibited by 5-lipoxygenase inhibitor and IL-13 neutralization, suggesting that airway responses were induced through IL-13 and leukotriene pathway.	Leukotrienes	157-168	interleukin 13	Mus musculus	71-76
16630940-7	2006	RESULTS: In sensitized mice, inhalation of ultrafine particles 24 hours before allergen challenge caused a significant increase of bronchoalveolar lavage inflammatory cell infiltrate, protein, IL-4, IL-5, and IL-13 compared with relevant controls.	ultrafine	43-52	interleukin 13	Mus musculus	209-214
16644484-3	2006	Verproside significantly inhibited the increase of total IgE and the cytokines IL-4 and IL-13 in plasma and bronchoalveolar lavage fluid, and also effectively suppressed airway hyperresponsiveness, eosinophilia and mucus hypersecretion in OVA-induced asthmatic mice.	verproside	0-10	interleukin 13	Mus musculus	88-93
16361354-6	2006	Treatment with S-28463 also abolished both the elevation in serum IgE level as well as the induction of IL-4, IL-5, and IL-13 by OVA challenge.	S 28463	15-22	interleukin 13	Mus musculus	120-125
16339999-3	2006	The Syk inhibitor R406 (30 mg/kg, administered orally, twice daily) prevented the development of AHR, increases in eosinophils and lymphocytes and IL-13 levels in bronchoalveolar lavage (BAL) fluid, and goblet cell metaplasia when administered after sensitization and before challenge with OVA.	R406	18-22	interleukin 13	Mus musculus	147-152
16339999-6	2006	Co-culture of BMDC with immune complexes of OVA and IgG anti-OVA together with OVA-sensitized spleen mononuclear cells resulted in increases in IL-13 production.	bmdc	14-18	interleukin 13	Mus musculus	144-149
16594735-6	2006	Interleukin 13 treatment reduced levels of Cys-LTs in bronchoalveolar lavage fluid.	Cysteine	43-46	interleukin 13	Mus musculus	0-14
16594735-8	2006	Interleukin 13 treatment also increased transcript levels of the Cys-LT 1 and Cys-LT 2 receptors, while LTC4 increased transcript levels of the alpha1 chain of the IL-13 receptor.	Cysteine	65-68	interleukin 13	Mus musculus	0-14
16594735-8	2006	Interleukin 13 treatment also increased transcript levels of the Cys-LT 1 and Cys-LT 2 receptors, while LTC4 increased transcript levels of the alpha1 chain of the IL-13 receptor.	Cysteine	78-81	interleukin 13	Mus musculus	0-14
16504965-13	2006	Incubation of lung slices without serum but with IL-13 increased BAT as well as airway responsiveness to acetylcholine and both effects were more pronounced in small compared to large airways.	Acetylcholine	105-118	interleukin 13	Mus musculus	49-54
16364441-9	2006	The most potent inhibitory antibody identified, GM1E7, inhibited IL-13-driven gene activation and cell proliferation in immune cell lines with IC(50) values in the low nanomolar range.	gm1e7	48-53	interleukin 13	Mus musculus	65-70
16251181-8	2006	In the present study, release of 45Ca from cultured mouse calvarial bones stimulated by different cytokines, peptides, and steroid hormones was inhibited by IL-4 and IL-13.	Steroids	123-139	interleukin 13	Mus musculus	166-171
16251181-11	2006	In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13.	Cholecalciferol	122-132	interleukin 13	Mus musculus	159-164
16940745-10	2006	A decrease in IFN-gamma production and an increase in IL-5 and IL-13 production were observed in the mice fed the TBT diet and treated with TNCB.	tributyltin	114-117	interleukin 13	Mus musculus	63-68
16423038-7	2006	Promoter deletion analysis localized a phorbol 12-myristate 13-acetate (PMA)-sensitive element to a proximal promoter region between -109 and -79 base pairs upstream from the IL-13 transcription start site.	Tetradecanoylphorbol Acetate	39-70	interleukin 13	Mus musculus	175-180
16423038-7	2006	Promoter deletion analysis localized a phorbol 12-myristate 13-acetate (PMA)-sensitive element to a proximal promoter region between -109 and -79 base pairs upstream from the IL-13 transcription start site.	Tetradecanoylphorbol Acetate	72-75	interleukin 13	Mus musculus	175-180
16940745-10	2006	A decrease in IFN-gamma production and an increase in IL-5 and IL-13 production were observed in the mice fed the TBT diet and treated with TNCB.	Picryl Chloride	140-144	interleukin 13	Mus musculus	63-68
16374521-7	2006	Systemic administration of the MAPK/ERK kinase 1 (MEK1) inhibitor PD98059 or use of Tg mice in which a dominant-negative MEK1 construct was expressed inhibited IL-13-induced inflammation and alveolar remodeling.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	66-73	interleukin 13	Mus musculus	160-165
16357187-4	2005	In contrast, CD1(-/-) mice, which are deficient for IL-13 because they lack IL-13-producting NKT cells, generate M1 macrophages that are cytotoxic for 4T1 via the production of nitric oxide.	Nitric Oxide	177-189	interleukin 13	Mus musculus	52-57